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ABSTRACT 
This research work focuses on the design, the synthesis, interaction studies and 
biological evaluation of new aromatic heterocyclic small molecules addressed either 
towards the B-DNA as well as the G4-DNA isoforms as targets.  
The synthesis and the biological evaluation of a new benzo[b]thiophene and 
benzo[b]furan series were reported. Generally, all tested compounds in the first series 
showed a good antiproliferative effect on HeLa tumor cell line with GI50 values in a low 
micromolar range. These findings could be in accordance with biological assays that 
highlight a possible antimitotic mechanism or a potential inhibition of the topoisomerase 
II enzyme, thus affecting and modulating some of the B-DNA functions. This could 
justify the cell cycle arrest at G2/M checkpoint. 
The synthesis and the biological evaluation of the new benzo[b]furan were accomplished. 
In this series, the thiophene central core of the benzo[b]thiophene derivatives above 
mentioned has been replaced with a furan ring, in order to evaluate the isosteric influence 
on the biological activity, affording significant  growth inhibition effect when 
antiproliferative screening on HeLa and MCF7 tumor cell lines were carried out, 
producing cell cycle arrest with proapoptotic effects. 
The design, synthesis and biological studies of some new potential ligands of G-
quadruplex have attracted further interest.  
Synthesis of bis-isoquinoline derivatives and double-chained naphthalenes were carried 
out. Unfortunately spectroscopic tests on G4-DNA isoforms gave any expected result 
previously observed through in silico assessments.  
Besides, linear and annellated naphthaleno-pyridazinone derivatives were synthesized via 
nucleophilic substitution reaction and intramolecular Heck-type arylation, exploiting as 
starting material the 2-benzyl-4,5-dibromopyridazin-3(2H)-one, because its controllable 
regiochemistry. Noteworthy, antiproliferative tests on Hela cell tumor lines over 48 hours 
treatment have shown interesting GI50 values both in micromolar and nanomolar range.  
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1. Introduction 
 
It has long been known that the deoxyribonucleic acid (DNA) is the main bio-target for 
anticancer drugs currently used in the clinical field, both if they are able to bind the 
polynucleotide covalently or reversibly. However, the side effects on normal cells from 
the classical DNA-interactive drugs, such as alkylators, intercalators, and strandbrakers 
are so relevant as to limit their therapeutic use (1).  
The current anticancer treatments have several limitations, including drug resistance and 
side-effects of toxicity (2), due to the correspondence in shape and chemical structure of 
DNA both in healthy and tumor cells. The rapid, abnormal, and uncontrolled cell 
division characterizes cancer cells, which are continuously undergoing mitosis. Because 
this rapid cell division, tumor cells do not have sufficient triggering time for repair 
mechanisms. Indeed, when a DNA damage is sensed in a cell, mechanisms involving 
proteins such as p53 are activated. Particularly, activation of p53 in normal cells can 
result in several cellular responses namely upregulation of DNA repair systems, 
programmed cell death (apoptosis) or cell cycle arrest, which allows time to DNA to be 
repaired. Differently, tumor cells are defective in their ability to undergo cell cycle arrest 
or apoptosis in response of DNA damage, thus resulting more sensitive to DNA-
damaging agents (3,4). Although targeted therapies in anticancer drug discovery are 
being developed, the lack of selectivity remains a major issue for current anticancer 
therapeutics. Therefore, the development of synthetic molecules that alter or halt with 
lower side effects the cell proliferation processes giving rise to tumors, is still a topic 
highly studied by many research groups. 
 
1.1 DNA-Interactive Drugs Limitations 
1.1.1 Side effects of Toxicity  
Most of the side effects of toxicity of the current DNA-interactive drugs are observed in 
the bone marrow, the mucosa, the gastrointestinal tract (GI) and the hair, namely where 
rapid cell proliferation occurs.  
Doses in the toxic range ensure the effectiveness of a cancer drug itself thus to kill tumor 
cells but allowing healthy cells of bone marrow and GI tract to survive, although there 
are some evidences according which nausea and vomiting, for instance, are not 
depending on the destruction of GI cells rather on the DNA-interactive agents effect on 
the central nervous system (CNS) (5). According to the fractional cell kill hypothesis (6), 
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a given drug concentration administered over a defined time period will kill a constant 
fraction of cells, regardless of the absolute number of cells. Therefore, since each cycle 
of treatment will kill a specific amount of the remaining cells, the effectiveness of the 
treatment is a direct function of the dose and the frequency of the cycle repetition. 
Besides, in anticancer drug therapies single-drug treatments are not completely effective, 
have short duration, and complete remission is only short lived. Furthermore, relapse is 
associated with resistance to the original drug.  
 
1.1.2 Combination Chemotherapy: a Drug Interactions and Resistance issue   
In order to overcome anticancer drugs resistance, in the late 1950s combination 
chemotherapy has been introduced. Indeed, whether single-drug treatment may increase 
the rate of mutation cells into resistant forms, multiple drugs therapies show many 
advantages and improved effectiveness, acting through different mechanisms of action 
that allow independent cell killing by each drugs. Moreover, cells resistant to one drug 
may be sensitive to another and if drugs do not have overlapping toxicities, each of them 
can be used at full dosage ensuring their effectiveness in combination. On the other hand, 
drugs that cause for instance renal toxicity must not used in combination with drugs 
whose primary mechanism of excretion depends on renal elimination. Indeed, the most 
relevant issue associated with the use if combination chemotherapy, is still drug 
interaction (7). 
 
1.2 DNA Structure and Properties 
The three dimensional structure of B-DNA consists of two complementary strands of 
antiparallel poly-deoxyribonucleotide, wrapped around one another to form a double 
helix. 
The two strands are held together by specific hydrogen bonds of Watson-Crick, which 
are established between purine and pyrimidine nucleotides. The two purine bases, 
adenine (A) and guanine (G) and the two pyrimidine bases, cytosine (C) and thymine (T) 
form stable 3,5’- phosphodiester bonds, through the linkages between the 5’-phosphate 
group of one nucleotide and a 3’-hydroxyl group on the sugar of the adjacent nucleotide 
(fig.1). 
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Figure 1. 3',5'-Phosphodiester linkages between A(adenine)/G(guanine) and C(cytosine)/T(thymine)  of the 
DNA. 
 
The different spacing between the two sugar phosphate backbones of the double helix 
along the helical axis is due to the two glycosidic bonds joining the base pair to its sugar 
rings that are not directly opposite to each other. As a consequence, the grooves between 
the backbones result larger, in the case of the major groove, and smaller if it deals with 
the minor groove (fig.2).  
 
 
 
Figure 2. Features of DNA base pairs A-T, C-G responsible for the formation of major and minor grooves. 
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In the major groove the base pair nitrogen and oxygen atoms project inward from their 
sugar phosphate backbones towards the centre of the DNA, while in the minor groove 
nitrogen and oxygen atoms of base pairs project outward from their sugar-phosphate 
backbones towards the outer side of the DNA. Therefore, electrostatic interactions with 
B-DNA are historically classified into minor and major groove and interactions of 
intercalation (2,3). For intercalation is meant the insertion of planar molecules, in 
particular those containing aromatic heterocyclic rings, between two adjacent base pairs 
of DNA, perpendicular to the axis of the double helix, causing a vertical separation of the 
pairs of complementary bases with deformation and elongation of the sugar-phosphate 
backbone (10).  
Thus, in the B-DNA, the backbone of the paired strands provides a shallow-wide major 
groove and a deep-narrow minor grove (11,12), with different chemical features that 
form the basis for molecular recognition by small molecules and proteins.  
 
1.2.1 The Importance of the DNA base pairing  
Base pairing plays a key role in maintaining the integrity of the DNA.  The specificity of 
base pairing is depending on several factors: hydrogen bonding and shape represent two 
significant aspects in this regard. 
 
1.2.1.1 Hydrogen Bonding and Tautomerism 
Due to the tautomerism of the different heterocyclic bases, largely depending on the 
dielectric constant of the medium and on the pK of the respective heteroatoms (13), at 
physiological pH, the more stable tautomeric form for the bases having amino 
substituents as A, C, and G is, by far (>99.9%), the amino form not the imino form and 
the oxygen atoms of G and T also strongly prefer (>99.9%) being in the keto form rather 
than the enol one (14). Apparently, these four bases in the appropriate tautomeric forms 
are the only requirement for complementary base recognition.  
Donor and acceptor groups are complementary for C and G and for A and T, but not for 
C and A or G and T (fig. 3).  
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Figure 3.  Complementary base recognition by hydrogen bonding sites of the DNA bases. D, hydrogen bond 
donor; A, hydrogen bond acceptor. 
 
Modifications of the bases, such as replacement of the carbonyl group in purines by a 
thiocarbonyl group, would increase the enol population to about 7% (15), resulting in a 
significant effect on base pairing. 
 
1.2.1.2 Base-pairs Isosters to Determine Important DNA Features 
Hydrogen bonding is not the only factor that controls the specificity of base pairing; 
shape may also play an important role. As demonstrated by Kool in its studies (16-18), in 
the synthesis of several nonpolar nucleoside isosteres, thus lacking hydrogen bonding 
functionality, complementarity of size and shape is as important as the hydrogen bond 
ability in controlling the DNA base pairing (19,20). 
In order to determine the importance of hydrogen bonding for DNA, a thymidine 
isostere, the difluorotoluene isostere nucleoside 1 (log P= +1.39) has been synthezized, 
resulting in a nearly perfect mimic of thymidine (log P = −1.27) in the crystalline state 
and in solution (21).  
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Figure 4. Nonpolar nucleoside isosters (1 and 2) of thymidine and adenosine (7) 
 
Indeed, the isostere 1, incorporated and substituted in a template strand of DNA where it 
is paired opposite to adenine, adopts a structure identical to that of a T–A base pair (22) 
and common polymerases is able to selectively insert adenosine opposite it (23) with a 
similar efficiency to that of a natural base pair. The benzimidazole isostere of 
deoxyadenosine, 2 is less similar in shape but it still base pairs by non-hydrogen-bond 
interactions by mimicking adenosine in DNAs (22) even as a substrate for polymerases. 
This suggests that Watson–Crick hydrogen bonds are not necessary to replicate a base 
pair with high efficiency and selectivity and that steric and geometric factors may be at 
least as important in the polymerase active site (24,25).  
 
1.3 G4s-DNA  
Unlike the well known double–helical B-DNA that, as above mentioned, consists of two 
complementary antiparallel, sugar-phosphate poly-deoxyribonucleotide strands, held 
together with specific Watson-Crick hydrogen bonds between purine and pyrimidine 
nucleotides, G-quadruplexes (G4s) are higher-order DNA and RNA secondary structures. 
G-quadruplexes show a considerable polymorphism, important in the carcinogenic 
processes. These structures are characterized by a core of at least two overlapping G-
tetrads. 
The G-tetrads are formed by a pseudo planar quartet of guanines, adopting either anti or 
syn alignements respect to the glycosidic bonds, stabilized by Hoogsteen-hydrogen bonds 
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and a positively charged monovalent metal ion (mainly K + or Na+) located within the 
central channel of stacked G-tetrads, which allows the neutralization of the strong 
electrostatic potential associated with the guanine carbonilic oxygenes, fostering the 
stabilization of G4-structures (10,26). 
In detail, each tetrad is overlapped parallel to another of the same strand through π-π 
stacking interactions, thereby forming a polymer with helical structure (fig.5). 
 
 
Figure 5. Tetrad consists of 4 guanines stabilized by Hoogsteen hydrogen bonds and the presence of monovalent 
metal ion (left side). Schematic representation of a structure given by the intramolecular bonds of G-quadruplex 
tetrads (right side). 
 
Structurally, there are different topologies of G-quadruplex depending on the orientation 
of the filaments, the length of the loops and the nucleotide sequence thereof. In addition, 
the G-quadruplex structures can be both of intramolecular and intermolecular nature.  
In the latter case, the secondary structure is given by the union of multiple strands that 
can arrange in all possible combinations of parallel and anti-parallel orientation (26). The 
filaments of connection (fig. 6), called loops, can be classified into: edgewise, lateral, 
linking two adjacent antiparallel strands; double chain reversal, that combine two 
adjacent parallel filaments, and diagonal loops, which bind two antiparallel strands but 
opposite (27), and finally V-shaped loops that connect the corners of two stacked guanine 
tetrads, which lack a connection (28). 
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Figure 6. G4-DNA: loops 
 
From a different perspective, G4s are higher-order DNA and RNA secondary structures 
located in key areas of the eukaryotic genome, including telomeres and regulatory 
regions of many genes among which oncogenes (29). 
Bioinformatical analyses combined with biophysical and structural investigations have 
highlighted the relative abundance of putative G-Quadruplex forming sequences in 
promoter regions of oncogenes close to transcriptions start sites, which include also the 
c-myc gene (30). 
The MYC gene promoter was one of the most studied system for the G-quadruplex 
formation, especially because its dysregulation is one of the hallmarks of many cancers 
(30). Unlike telomeric G-Quadruplexes, which can be formed from the single-stranded 
DNA, G-Quadruplexes in gene promoter regions are constrained by the duplex nature of 
genomic DNA. Each of single stranded elements in gene promoter double stranded DNA 
could be a precursor of the formation of secondary DNA structures like G-Quadruplexes 
and protruding structures that keep the two DNA strands separated and prevent the 
formation of the basal transcriptional complex. 
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G4 structures are over-expressed not only in telomeres, about which it will discuss 
hereinafter, but also in gene promoter regions, making them even more attractive as 
therapeutic targets in oncology (10). The first study about it reported that the proto-
oncogene c-myc, is upregulated in up to 80% of solid tumors, and it has a putative G4 in 
the nuclease hypersensitive element (NHE) targeted with a small molecule. Since then, 
the folding patterns of several promoter G-quadruplexes have been proposed, such as the 
genes encoding MYC, B cell lymphoma 2 (BCL-2) (31), vascular endothelial growth 
factor (VEGF)(32), hypoxia-inducible factor 1a (HIF1a) (33), the transcription factor 
MYB(34), and KRAS (35,36). 
Therefore, the transcriptional repression can be achieved by induction of putative G-
quadruplex formation, that can inhibit the MYC transcription thus suppress oncogenic 
expression (30). 
 
1.3.1 The Important Presence of G4-DNAs in Telomeres  
Telomeres are repetitive hexanucleotide non-coding sequences, placed at each end of a 
chromatid, with the function to protect chromosomes from erosion or from fusion with 
adjacent chromosomes, during gene duplication. 
Human telomere consists of a double stranded DNA sequence 5-10 kilobases long. It is 
characterized by tandem repeats of the hexanucleotide d(TTAGGG)n (37,38), ending up 
in a single-stranded G-rich 3’ overhang of 35-600 bases (38-40), (fig. 7). 
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Figure 7. Schematic representation of the DNA overhang region (26). 
 
In order to protect the otherwise exposed telomeric overhangs, the telomere ending is 
folded in a higher-order conformation known as telomeric loop or “T-loop” (41), (fig. 8). 
 
 
 
Figure 8. Schematic representation of the chromosome end, folded in T-loop, including members of the shelterin 
proteins complex (26). TRF1, telomere-repeat-binding factor 1; TRF2, telomere-repeat-binding factor 2; POT1, 
protection of telomeres protein; TPP1, tripeptidyl pepti-dase; TIN2, interacting nuclear factor; RAP1, 
repressor activator protein 1. 
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This structural organization, which provides the maintenance and capping of telomeric 
DNA, is achieved through a smaller displacement loop (D-loop) of the G-rich strand, 
which is mediated by six shelterin proteins: telomere-repeat-binding factors (TRF1, 
TRF2), protection of telomeres protein (POT1), interacting nuclear factor (TIN2), 
repressor activator protein 1 (RAP1), and tripeptidyl peptidase 1 (TPP1) (26).  
Telomeres are essential for genome integrity. The double stranded terminates with a 
single-stranded 3’ extension of a G-rich sequence that can fold into G-quadruplex 
structures. Such single-stranded 3’ overhang is the substrate for the telomerase. 
Telomeres shorten with each cell replication and, when they reach a critically short 
length, such shortening leads normal cells to arrest proliferation, undergo senescence, by 
acquiring a variety of altered functions up to a DNA damage response that culminates in 
cell cycle arrest or cell death.  
 
1.3.2 Telomerase Enzyme and the G-Rich Telomeric DNA 
Telomerase is a RNA-dependent DNA polymerase almost universally conserved in 
eukaryotes. It is made up of a minimal catalytic core including two subunits: the TERT 
protein (Telomerase Reverse Transcriptases) and the RNA component known as TERC 
(Telomerase RNA Component) or simply TR (Telomerase RNA) (42,43). 
The active site of the enzyme catalytic subunit, mainly characterized by aspartic acid 
triplets, acts as a reverse transcriptase likewise the viral ones (44,45). 
The human proteic subunit hTERT is a heterodimer, made up of the proteins p123 and 
p43, which binds the RNA component TR with a ratio of 1:1:1 (46). The human 
ribonucleic subunit (hTERC) is a large RNA made up of 451 nucleotides in humans and 
between 148 and 209 nucleotides in ciliates (47). It contains a small portion of eleven 
nucleotides (5’-CUAACCCUAAC in human), located at the 5’ end, which encodes the 
related telomere repeat and works as a template for the additions of nucleotides at the end 
of the chromosome (42). The elongation of telomere occurs in several steps that can be 
summarized as shown in (fig. 9). 
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Figure 9. The elongation of telomere: (I): initial annealing; (II): first extention cycle; (III): dissociation and 
reannealing; (IV): extension cycles and DNA polymerase complementing the laggins strand  
 
Telomerase, a unique reverse transcriptase, plays a key role in maintaining telomere 
length and integrity: it binds to the G-rich 3’ end of telomeric DNA and fosters the 
addition of telomeric DNA onto the chromosome ends using its own integral RNA 
template. Likewise, telomeres of tumor cells do not shorten during proliferation but 
instead tend to have short but yet stable telomeres. This is the reason why telomerase, 
which has been found upregulated in 85-90% of human tumors, ensures cellular 
immortality, hence the proliferation of cancer cells. 
Noteworthy, the G4-DNA formation in a telomeric primer obstructs telomerase 
association and inhibits primer extension.  
Nevertheless, it is worth to notice that telomerase is inactive in few tumors in which 
other pathways are responsible for the telomere maintenance (48). This recombination-
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dependent telomere lengthening mechanism, named Alternative Lengthening of 
Telomeres, or “ALT” pathway, replaces telomerase activity in about 10-15% of human 
cancers. Therefore, therapeutics directed only against telomerase in cancer cells might 
not be able to interact with those using ALT pathway that, for this reason, will be 
resistant to therapy (49). 
On the other hand, targeting telomeres might be a new solution for resistant tumor cell 
lines. In this context, G-rich 3’ overhangs play a key role. The latter is the natural 
substrate for telomerase, which uses it as its primer, and it is probably the necessary 
structural motif for the recombination-based mechanism of telomere maintenance ALT 
(50). Interestingly, it has been shown that the guanine-rich 3' overhangs of telomeres, 
with TTAGGG repeats, can equilibrate between single-stranded and G4 structures by 
means of hPOT1 protein (51). G4 folding of the G-overhang is a structural motif for 
telomere protection, alternative or in addition to the T-loop conformation. As a matter of 
fact, when the telomere tail is in a G4 conformation, the activity of telomerase, and 
probably of ALT, is inhibited (50,52,53). 
This interesting finding suggests that ligand-induced stabilization of telomeric G4 
scaffold is a promising strategy for anticancer drug development (44,54-56). 
Furthermore, this telomerase inhibition pathway represents a useful approach to bypass 
the occurrence of ALT. 
Thus, G-quadruplexes are considered effective targets for novel anticancer drugs 
development, although telomere-targeting G-quadruplex ligands, known hitherto, have 
not yet been successful in clinical phase, due in part to poor tumor penetrating ability and 
lack of target selectivity (57). 
 
1.4 Heterocyclic Aromatic Compounds in Anticancer Drug Discovery 
Heterocycles are heavily involved in life processes. DNA, RNA, proteins, and 
coenzymes are classical examples of fundamental biological macromolecules structured 
by heterocyclic moieties. The biomolecular standpoint of drug action confirms the broad 
biocompatibility and the versatile aptitude of heterocycles to mimic endogenous 
molecules and consequently to interact with biological entities (58). These features make 
heterocyclic chemistry one of the major pivots for the development of new drugs, 
justifying the intense attention of the scientific community on this field. 
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1.4.1 Isosterism and Bioisosterism in Medicinal Chemistry 
The discovery of more potent, clinically safe, and commercially attractive new targeted 
drugs is the driving force at the base of medicinal chemistry research. To reach this goal, 
different approaches might be followed. On this purpose, the study of structure-activity 
relationship (SAR), between molecular structures and their biological activity, is a 
valuable and rational approach in the lead compounds identification and optimization. 
The SAR analysis enables the identification of chemical moieties, responsible for the 
interactions with a biological target and, therefore, for their therapeutic effects in an 
organism (59). Structural modifications may be conducted on lead compound in order to 
get more suitable the pharmacodynamic properties and/or to improve the 
pharmacokinetic ones. More often the lead optimization process is based on the isosteric 
replacements of functional groups to systematically understand the contribution of each 
modification of the lead compounds on the biological activity. 
The concept of isosterism, was introduced for the first time by Irving Langmuir (1919). 
He defined isosteres those atoms or groups of atoms or molecules or compounds (organic 
or inorganic) having the same electronic and steric arrangements (60,61). Later, the 
isosteric concept was extended to the biological field in the therapeutic search of new 
drugs, defining the concept of bioisosterism. Friedman (1951) identified bioisosteres 
those molecules or atoms, which fulfill the electronic and steric criteria of isosterism, 
retaining the same biological effects of their correspondent isosters  (61). 
 
Table 1. Ring Equivalents producing biososteric structural modifications. 
RING EQUIVALENTS 
    
Benzene Thiophene Furan Pyrrole 
 
  
 
 Benzene Pyridine  
 
  
 
 Pyrrole Imidazole  
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H
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N
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In medicinal chemistry field, the approach to bioisosteric structural modifications, like 
ring equivalents (table 1) or ring-to-ring transformations, are widely investigated in lead 
compounds optimization, producing a notable number of clinically drugs (62). Indeed, 
the substitution of –CH= by –N= or –CH=CH- by –S- within aromatic rings has been one 
of the most successful application of classical isosterism (e.g. H1-blockers) (63). 
 
 
Figure 10. Successful  bioisosters: Sildenafil (3) and Vardenafil (4); Levofloxacin (5) and Ciprofloxacin (6); 
Gefitinib (7) and Erlotinib (8). 
  
In figure 10 are reported some examples of successful application of bioisosterism in the 
drug structural optimization process: Sildenafil (3) (Viagra) >> Vardenafil (4) (Levitra), 
Levofloxacin (5) (Tavanic) >> Ciprofloxacin (6) (Cipro) and Gefitinib (7) (Iressa) >> 
Erlotinib (8) (Tarceva). 
 
1.4.2 From The Canonical B-DNA to the Modern G4-DNA Interactive Agents 
The main goal of anticancer research is to develop targeted therapeutic strategies in order 
to find new agents with selective biological activity against tumor cells. Regulation of 
duplication and transcription machinery is a crucial way to achieve gene expression 
control in human cells. Therefore, deoxyribonucleic acid (DNA) is an elective target for 
anticancer therapy. Classical DNA-binding drugs, such as intercalators, alkylators, and 
strand breakers, exert their biological activity in an unselective way, producing serious 
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side effects on normal cells (1). Accordingly, an intriguing challenge is to design DNA-
interactive molecules showing maximum specificity in DNA-binding, without interfering 
with the functions of healthy cells. 
In the last few decades, the design of small molecules able to bind non-canonical DNA 
secondary structures, such as G-quadruplexes (G4s), has aroused considerable interest. 
Several compounds described in literature have already shown to be good candidates as 
powerful sequence-specific G4s binders, stabilizing the non canonical DNA structures 
mainly through top/end stacking interactions (64). 
In this regard, many research groups have worked to identify or design small-molecule 
ligands, which specifically bind to the G4s. Thus, several ligands, which have high 
affinity for G4s and inhibit cell proliferation, have been proposed. Some of these 
compounds have shown to inhibit telomerase or to affect telomere lengthening 
(54,65,66). 
Evidence that G4 structures may occur at the telomeres and in gene promoter regions, 
has undoubtedly provided further impetus to the development of drugs that interact with 
or promote the formation of the G-quadruplexes. 
 
1.4.2.1 Classical DNA-Interactive Drugs 
DNA-interactive drugs can be classified into three clinically important major classes: 
! reversible binders, which interact with DNA through the reversible formation of 
non-covalent interactions;  
! alkylators, which react covalently with DNA bases;  
! DNA strand breakers, which generate reactive radicals producing cleavage of the 
polynucleotide strands.  
The primary DNA sequence recognition by proteins results from complementary 
hydrogen bonding between amino acid residues on the protein and nucleic acid bases in 
the major and minor grooves of DNA (7,67). In detail, proteins and large molecules, for 
example oligonucleotides, bind B-DNA preferentially through the major groove, because 
it is a good receptor in terms of size, flexibility, and possibility to form H-bonds through 
donor and acceptor sites, which are more abundant than those present in the minor 
groove (1,68,69). Small molecules typically bind B-DNA through the minor groove, 
where sequence recognition is limited compared to the major groove, in large part due to 
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less varied H-bonding patterns and more limited shape variations with sequence 
(1,68,69). 
However, it is not yet clear what DNA sequences (genes) should be targeted.  
 
1.4.2.1.1  Reversible DNA Binders 
DNA functions can be altered by three important ways of reversible interaction of small 
molecules binding to duplex DNA:  
1. electrostatic binding along the exterior of the helix;  
2. interaction with the edges of the base pairs in either the major or minor groove;  
3. intercalation between the base pairs. 
Indeed, since nucleic acids inside the cell interact with small molecules as water, metal 
cations, small organic molecules, and proteins, important for stabilization of the nucleic 
acid structure, interference with these interactions can disrupt the DNA structure (7).  
 
1.4.2.1.1.1 External Electrostatic Binding 
The interactions hereinafter described are generally not dependent upon DNA sequence. 
The polyanionic nature of duplex DNA, containing a negatively charged sugar-phosphate 
backbone, strongly affects both the structure and function of DNA. Cations and water 
molecules bind to DNA and allow it to exist in various secondary structures. Release of 
bound cationic counter ions of the negative phosphate groups upon binding of specific 
cation ligands can lead to disruption of the DNA structure, providing both favourable 
(increased entropy) and unfavourable (decreased enthalpy because of loss of specific 
ionic interactions) contributions to the overall free energy (7). 
 
1.4.2.1.1.2 Groove Binding 
The major and minor grooves differ in their electrostatic potentials, hydrogen bonding 
features, steric effects, and degree of hydration. As above mentioned, proteins exhibit 
binding specificity interacting primarily with major groove, but small molecules prefer 
minor groove binding. Minor groove binding molecules generally have aromatic rings 
connected by single bonds that allow for torsional rotation in order to fit into the helical 
curvature of the groove with displacement of water molecules (70). The minor groove 
turns out more suitable to flat aromatic molecule binding with its narrow A-T regions 
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respect to the G–C regions, binding to such molecules through van der Waals 
interactions and interactions with the edges of the base pairs on the floor of the groove.  
Furthermore, a higher selectivity for cationic molecules in A–T regions can be achieved, 
because of greater negative electrostatic potential in these regions of the minor groove 
relative to the G–C regions (71). 
 
 
Figure 11. Netropsin, a typical  minor groove binder. 	
A typical minor groove binder is the antitumor, antibacterial, and antiviral agent 
netropsin (fig.11). This agent causes a widening of the minor groove (0.5–2.0 Å) in the 
AATT region and a bending of the helix axis (8°) away from the site of bindin (72), thus 
interferring with the interaction of topoisomerase II and leading to DNA damage. 
 
1.4.2.1.1.3 Intercalation and Topoisomerase-Induced DNA Damage 
Intercalation was firstly described in 1961 by Lerman (73), as a noncovalent interaction 
through which the drug is held rigidly perpendicular to the helix axis. This causes the 
vertical separation of the base pairs, distorting the sugar-phosphate backbone. 
Intercalation occurs without disruption of the Watson–Crick hydrogen bonding: the 
regular helical structure is destroyed, the DNA at the site of binding is unwinded and, as 
a result, interferences with the action of DNA-binding enzymes such as DNA 
topoisomerases and DNA polymerases occur. In detail, interference with topoisomerases 
alters the degree of supercoiling of DNA; interference with DNA polymerases inhibits 
the elongation of the DNA chain in the 5′ to 3′ direction and also prevents the correction 
of mistakes in the DNA by inhibiting the hydrolysis of the phosphodiester bond of 
mismatched residues at the terminus.  
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Intercalation of a drug into DNA represents only the first step before that DNA damage 
occurs. Other mechanisms are involved. For instance, simple cationic intercalators 
initially interact with the negatively charged DNA sugar-phosphate backbone; then the 
intercalator diffuses along the surface of the helix until it encounters gaps between base 
pairs, thereby creating a cavity for intercalation. 
Many classes of antitumor agents involve the DNA topoisomerases subsequent to 
intercalation (74). In this regard, a variety of examples are reported in the literature:  
mammalian DNA topoisomerase I is involved in the action of the antitumor agent 
topotecan hydrochloride (fig.12), (75) whereas DNA topoisomerase II is involved in the 
action of a variety of classes of antitumor drugs, such as anthracyclines, 
anthracenediones, acridines, actinomycins, and ellipticines (76). 
 
 
Figure 12. Topotecan hydrochloride. 	
Flat, generally aromatic or heteroaromatic molecules bind to DNA by intercalating and 
stacking between the base pairs of the double helix. The main driving forces for 
intercalation are stacking and charge-transfer interactions, but hydrogen bonding and 
electrostatic forces also play a role in stabilization. Furthermore, the van der Waals 
forces that hold the molecules intercalated into the base pairs, are stronger than those 
between the stacked base pairs.  
Three classes of drug molecules are ranked as DNA intercalators: the acridines (e.g. 
amsacrine), the actinomicines (e.g. dactinomycin), and the anthracyclines (e.g. 
doxorubicin and daunorubicin), (fig.13). 
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Figure 13. DNA-interactive drugs acting as intercalators between the base pairs.  	
In 1952, Dactinomycin and its parent Actinomycin analog, were found active as 
antitumor agents and were used clinically. Dactinomycin acts through the binding to 
double-stranded DNA, and inhibits DNA-directed RNA synthesis or DNA synthesis in a 
concentration-dependent manner.  The peptide substituents, lying in the minor grove, 
may halt the progression of RNA polymerase along the DNA thus to block the chain 
elongation (77). Therefore it is evident that intercalators cytotoxicity is due to the 
interference with the normal cellular processes of DNA, such as replication and 
transcription. 
In the 1960s and early 1970s, among a variety of anilino-substituted acridine derivatives 
tested as antitumor agents, Amsacrine turned out as the most potent with mode of action 
of intercalators of double-stranded (duplex) DNA, so as to be still used in the treatment 
of leukemia (78).  
The antracycline class of antitumor anibiotics is well represented by Doxorubicin (fig. 
13). It is not yet clear the mechanism of action of these compounds: they may act either 
intercalating into the DNA double helix by forming a ternary complex with DNA 
topoisomerase II, causing topoisomerase II-induced DNA damage with consequent 
inhibition of replication and transcription processes, or through radical-induced DNA 
strand breakage (79).  
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In general, groove binders exhibit significantly greater binding selectivty than 
intercalators. Groove binders interact with more base pairs than intercalators as they lie 
along the groove and display A-T binding preference; differently, most intercalators 
show no sequence preferences in their binding unless a slight G–C preference (7).  
 
 1.4.2.1.2 DNA Alkylators 
As Ross described (80), a biological alkylating agent is a compound that can replace a 
hydrogen atom with an alkyl group under physiological conditions (pH 7.4, 37 °C, 
acqueous solution). DNA alkylators differ from DNA intercalators by the nature of their 
respective interactions; indeed the former are reversible-type and the latter are covalent 
bonds, namely irreversible-type. 
The lead compound of DNA alkylators was the sulphur mustard, a highly cytotoxic 
chemical warfare agent used in World Wars I and II. This chemical caused leukopenia 
(low white blood cell count), bone marrow aplasia, dissolution of lymphoid tissues, and 
ulceration of GI tract (81). These potent effects suggested the use of the sulphur mustard 
as antitumor agents. The high toxicity of this agent led Gilman and others to asses the 
antitumor effects of the isosteric nitrogen mustard (82), (fig.14), the Mechloretamine, 
still used in the treatment of advanced Hodgkin’s disease. 
 
 
Figure 14. Successful bioisosteric substitution: sulphur mustard and its bioisoster mechloretamine. 
 
Nitrosoureas are a metabolically activated alkylating agents type. They were developed 
from the lead compound N-methylnitrosourea (Fig.15, R=CH3, R’=H), which displayed 
modest antitumor activity than its analogues carmustatine and lomustatine (fig.15). The 
lipophilic features of the 2-chloroethyl analogues allowed their use in the treatment of 
brain tumors. 
 
Cl S Cl Cl N Cl
R
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Figure 15. Nitrosoureas analogues used in the treatment of brain tumors. 
 
 
1.4.2.1.3 DNA Strand breakers 
DNA strand breakers are metabolically activated radical generators. The mechanism of 
action of strand breakers includes the initial intercalation into DNA and the subsequent 
generation of radicals that abstract hydrogen atoms from the DNA sugar-phosphate 
backbone or from DNA bases, leading to DNA strand breakage. Examples of these 
compounds are anthracycline antitumor antibiotics, bleomycin, tirapazamine (7). The 
anthracyclines Doxorubicine and Daunorubicine (fig.13), as mentioned above, can act 
either via the topoisomerase-induced mechanism or as radical-induced DNA strand 
breakage. In this latter mechanism of action, DNA damage occurs through a one-electron 
reduction of anthracyclines, presumably catalized by flavoenzymes such as NADPH 
cytocrome P-450 reductase, which produce the anthracycline semiquinone radical 
(scheme 1).  
 
 
 
             Scheme 1. Mechanism of DNA strand breakage by anthracyclines (7). 
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1.4.2.2 G4-DNA Binders 
Several compounds have already described in literature as good G4s DNA binders. Such 
molecules are able to stabilize the non canonical DNA structures manly through top/end 
stacking interactions. 
In order to obtain the stabilization of the G4s-DNA, the following structural features are 
requiered: the ligand has to display a delocalized π-system, giving rise to top-stacking 
interaction with the quartet of guanine and some side chains, positively charged, which 
would be useful either to increase the solubility and possibly the bioavailability of the 
G4-interacting agent, and to allow interactions with the skeleton of the sugar phosphate, 
negatively charged. Furthermore, the presence of a positive charge into a central channel 
formed by guanine would improve the interactions with G4s. A further characteristic 
never investigated hitherto (26), is the symmetry. BRACO-19 (fig.16), is one of the most 
representative symmetrical compounds able to interact with G4-DNA, showing in vivo 
anticancer activity in tumor xenografts, in a significant shorter time exposure (83). 
 
 
 
 
Figure 16. BRACO-19 	
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2. Aim of the Work 
This PhD work focuses on the design, the synthesis, and the biological evaluation of 
novel heterocyclic small molecules able to halt tumor cell proliferation, both reproducing 
the mechanisms of the classical DNA-interactive drugs, namely the reversible binding to 
DNA through the formation of non-covalent interactions, and interacting with secondary 
structures of the DNA (G-quadruplexes), recently turned out as more appealing targets in 
anticancer drug discovery.  
In particular, these objectives are summarized as follows: 
- in silico studies, as approach to rationalize upstream the proposed synthetic 
pathways concerning both some new old-fashioned DNA-interactive drugs and 
novel modern G-quadruplex DNA binders;  
- synthesis of heterocyclic symmetrical and unsymmetrical small molecules 
selected in silico, in detail of: 
. benzo[b]thiophene and benzo[b]furan series; 
. bis-isoquinoline derivatives;   
. double-chained naphthalene-derivatives; 
. linear and annellated, symmetrical and unsymmetrical, naphthaleno-
pyridazinone derivatives. 
- Interaction studies between the synthesized compounds and B and G4s DNA 
isoforms through UV-vis spectroscopy; 
- Evaluation of cytotoxic activity in vitro on tumor cell lines. 
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3. Experimental part  
3.1 Results And Discussion 
This research work focuses on the design, the synthesis, and the biological evaluation of 
novel heterocyclic ring systems able to halt tumor cell proliferation. 
The access points to the B-DNA, as reported above, are the minor and major grooves, 
while the G4-DNA interact with its ligands through top/end stacking interactions with 
the G-tetrads and interactions with the grooves. Thus, it is easy asserting that the features 
for the interaction with the two targets seem to be roughly similar. 
However, some ligands prefer one structure to another. Looking back through the 
classical binders of B-DNA (fig.17a-b) and the G4-DNA (fig.18), some similarities can 
be observed. At first glance, all the structures display planar aromatic rings, 
heterogeneous chains or both. But a difference in symmetry can be easily detected (26). 
Indeed, intercalators (fig.18a) and the structures binding the grooves (figure 18b) appear 
to be devoid of symmetry elements. In contrast, the classical G4-DNA binders show at 
least the element of symmetry Cnv (26). 
 
 
 
Figure 17. Chemical structures of the most representative B-DNA binders: a) intercalators; b) groove binders. 
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     Figure 18. G4- DNA binders known in the literature. 	
Our symmetry considerations reported by Lauria and co-workers (26) were useful to 
address this research work to the discovery of both new DNA-interactive drugs and new 
potential G-quadruplex binders and stabilizers. It is worth noting that molecules without 
symmetry are not necessarily less effective DNA binding drug, but as shown hereinafter, 
they exploit a different mechanism of action than that observed in G4-DNA binding. 
 
3.1.1 Synthesis, Biological Evaluation and In Silico Insights of Novel Heterocyclic 
Ring System as Potential Classical DNA-Interactive Drugs 
This section focuses on the design, the synthesis, and the biological evaluation of novel 
heterocyclic ring systems able to halt tumor cell proliferation, reproducing the 
mechanisms of the classical DNA-interactive drugs, namely the reversible binding to 
DNA through the formation of non-covalent interactions. 
 
3.1.1.1 New 3-Benzoylamino-benzo[b]thiophene Derivatives as Potential Antimitotic 
Agents or Topoisomerase II Inhibitors 
A new series of 3-benzoylamino-5-imidazol-5-yl-benzo[b]thiophenes of type 1 and the 
parent amino derivatives were synthesized and screened as antitumor agents.  
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Figure 19. Ethyl 3-benzoylamino-5-[(1H-imidazol-4-yl-methyl)-amino]-benzo[b]thiophene-2-carboxylates (1), 2-
(alkoxycarbonyl)-3-anilino-benzo[b]thiophenes and thieno[2,3-b]pyridines (2), (84). 	
Several published works assigned to scaffold 1 a peculiar biological activity, suggesting 
the proposed molecules as potential bioisosteres of major microtubules assembly 
inhibitors. Indeed, in the past few years, an ever increasing number of thieno derivatives 
as potent tubulin polymerization inhibitors have been proposed (85-87). In this contest, 
Romagnoli and co-workers reported an interesting series of 2- (alkoxycarbonyl)-3-
anilinobenzo[b]thiophenes of type 2. These compounds, acting on the colchicine binding 
site of tubulin, showed an excellent antiproliferative activity, interfering with 
microtubules dynamics during cancer cell division processes (88,89). 
All tested compounds of type 1 showed concentration-dependent antiproliferative 
activity profile against HeLa cell line, exhibiting GI50 values in the low micromolar 
range. The most active compounds were tested in cell cycle perturbation experiments. A 
rapid accumulation of cells in the G2/M phase, with a concomitant reduction of cells in 
both the S and G0/G1 phases, was observed, suggesting that cell exposure to selected 
derivatives produces mitotic failure. To rationalize the biological results, the 3-
benzoylamino-benzo[b]thiophenes were analyzed through the in silico VLAK protocol. 
Compounds having the 3,4,5-trimethoxy-benzoyl moiety were in silico classified as 
potential antimitotic agents or topoisomerase II inhibitors, in good agreement with the 
biological studies. 
 
3.1.1.1.1 Chemistry 
As shown in scheme 2, the general synthetic route for the preparation of 3-
benzoylamino-benzo[b]thiophene derivatives 10 a-l involved five steps, starting from the 
commercially available 2-fluorobenzonitrile 3.  
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Scheme 2. Synthesis of ethyl 3-benzoylamino-5-[(1H-imidazol-4-yl-methyl)-amino]-benzo[b]thiophene-2-
carboxylates 10 a-l. Reagents and conditions: (i): HNO3 : H2SO4 (1:1), N2, 0 °C, 2h; (ii): ethylthioglicolate/NaH 
60%, anydrous DMSO; (iii): pyridine, rt, 12 h; (iv): 10% Pd/C, ethanol, rt 2h; (v): NaCNBH3, ethanol/AcOH, 
2h (84). 
 
Pale yellow needles of 2-fluoro-5- nitrobenzonitrile 4 were obtained, in quantitative 
yield, by nitration of 3, using a mixture of concentrated nitric and sulfuric acids, under 
inert atmosphere (90). The presence of both cyano and nitro substituents on substrate 4 
enhanced the reactivity of the ortho-fluorine atom, which readily underwent nucleophilic 
displacement by ethyl thioglycolate, in the presence of NaH (60% in oil dispersion) and 
dimethyl sulfoxide (DMSO). Subsequent intramolecular cyclization in situ led to the 
formation of the central core, and the isolation of the key intermediate 3-amino-
benzo[b]thiophene 5. 
To introduce the benzoyl moiety, amino derivative 5 was treated with substituted benzoyl 
chlorides 6 a-f. The nucleophilic acyl substitution was carried out employing pyridine 
both as base and solvent. The use of other reaction media gave a significant decrease of 
the yields. Reduction of nitro group on compounds 7 a-f was achieved through 
F
CN
F
CNO2N
S
O
O
NH2
O2N
Cl
O
R3
R2
R1
3 4 5
6 a-f
iiii ii
S O
O
NHO
R1
R2
R3
S O
O
NHO
HN
N
HN
R1
R2
R3
R4
O2N
7 a-f
iv
S O
O
NHO
R1
R2
R3
H2N
8 a-f
9 a-b
N
N
H
H
O
R4
       9       
a R4=H
b R4=CH3
               6-7-8              
a R1=R2=R3= H
 
b R1=R3= H; R2= OCH3 
c R1=R3= H; R2= CH3
d R1=R3=R2= OCH3
e R1=R3= H; R2= CF3
f R1= Cl; R2= F; R3= H
                        10             
a R1=R2=R3=R4= H
 
b R1=R3= H; R2= OCH3; R4= H 
c R1=R3= H; R2= CH3; R4= H
d R1=R3=R2= OCH3; R4= H
e R1=R3= H; R2= CF3; R4= H
f R1= Cl; R2= F; R3= H; R4= H
g R1=R2=R3= H; R4= CH3
h R1=R3= H; R2=OCH3; R4= CH3
i R1=R3= H; R2=CH3; R4= CH3
j R1=R3=R2= OCH3; R4=CH3
k R1=R3= H; R2= CF3; R4= CH3
l R1=Cl; R2= F; R3= H; R4= CH3 10 a-l
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hydrogenation with 10% Pd/C in ethanol. After removal of the catalyst, amino 
derivatives 8 a-f were easily isolated as pure needles, in good yields. The last synthetic 
step provided the imidazole moiety insertion via a reductive amination in the presence of 
imidazole-4-carbaldehydes 9 a, b. 
The reaction of the amino group with the aldehydes led to the formation of the 
corresponding imines, which, by mean of sodium cyanoborohydride addition, provided 
to a tightly selective reduction affording ethyl 3-benzoylamino-5-[(1H-imidazol-4-yl- 
methyl)-amino]-benzo[b]thiophene-2-carboxylates 10 a-l. 
 
3.1.1.1.2 Biology: Antiproliferative Activity 
The antiproliferative activity of 3-benzoylamino-5-imidazol- 4yl-benzo[b]thiophene 
derivatives 10 a-l and their corresponding precursors 8 a-f was evaluated on HeLa tumor 
cell line for 48 h using MTT based cell viability assay.  
 
Table 2. Cytotoxicity over 48 h of 3-benzoylamino-benzo[b]thiophene derivatives 8 a-f, 10 a-f, 10 g-l against 
Hela cell line expressed as GI50 values [GI50+ SE (µM)]. 
 
   
R1=R2=R3=H 
R1=R3=H; R2= OCH3    
R1=R3=H; R2= CH3 
R1=R2=R3= OCH3 
R1=R3=H; R2= CF3 
R1= Cl; R2= F; R3= H 
 
a >50 
b >50 
c 24.44 + 0.31 
d 4.66 + 0.31 
e 6.68+ 0.57 
f 12.29 + 1.69 
 
a 17.89 + 2.03 
b 12.92 + 0.94  
c 11.72+ 1.17 
d 6.79 + 0.33 
 e 16.84 + 0.98  
 f 10.65 + 1.32 
g 23.32 + 2.91 
h 8.22 + 0.75 
i 11.42 + 1.03 
j 2.23 + 0.04 
k 12.82 + 1.09 
l 2.91 + 0.24 
 
 
All tested compounds showed concentration-dependent antiproliferative activity, but they 
did not affect the cell membrane integrity in the concentration range 1-20 µM, as 
determined preliminary by the Trypan Blue exclusion method. For an easier analysis of 
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the biological results, the tested molecules have been divided into three main subgroups: 
5-amino- benzo[b]thiophenes 8 a-f, imidazole side-chain compounds 10 a-f, and methyl-
imidazole side-chain derivatives 10 g-l (table 2).  
The majority of our benzo[b]thiophene compounds proved a good growth inhibition 
effect, exhibiting GI50 values in the low micromolar range. As a general trend, 5-amino-
benzo[b]thiophenes 8 a-f showed lower activity than the corresponding compounds with 
the imidazole side-chain 10. Only when the benzoyl moiety was functionalized with 4-
CF3, the activity of the amino intermediate 8e was more potent than imidazole 
derivatives 10e and 10k. The presence of the methyl moiety on the imidazole ring 
resulted in a significant increase of activity for the 3,4,5-trimethoxy (10d vs 10j) and the 
3-chloro-4-fluoro-benzoylamino-benzo[b]thiophene derivatives (10f vs 10l), while it was 
irrelevant in the other cases. Relatively to the influence of the substituents on the benzoyl 
moiety there is no clear difference on activity between electron-withdrawing and 
electron-releasing substituents. Anyway, 3,4,5-trimethoxy benzoyl (TMB) derivatives 
8d, 10d, and 10j stand out as the most active of each subgroup. 
 
3.1.1.1.2.1 Cell cycle analysis 
The derivatives 8d, 10j, and 10l, which showed the highest antiproliferative effect, were 
tested in cell cycle perturbation experiments to evaluate their potential influence on cell-
cycle distribution. The flow cytometric analysis was performed after 24 and 48 h of 
incubation in order to detect the shifts in cell cycle distribution before a significant 
amount of cells underwent apoptosis. The working concentrations were fixed taking into 
account the GI50 values measured at 48 h. The histograms show the percentage of cells 
in the respective cell cycle phase (G1, S, and G2/M), along with the percentage of cells 
in the sub-G0/G1 (apoptotic cells) obtained by flow cytometry (fig.20). Untreated HeLa 
cells revealed a normal diploid distribution, presenting fast proliferation features, with S 
+ G2/M phase cells accounting for about 40% of the total cells (ctrl). After cell exposure 
to selected 3-benzoylamino-benzo[b]thiophene derivatives 8d, 10j, and 10l, a rapid 
accumulation of cells in the G2/M phase, with a concomitant reduction of cells in both 
the S and G0/G1 phases, was observed. These changes occurred in a concentration-
dependent manner. In fact, while in the experimental conditions a treatment with 1xGI50 
produced only slight variations, a concentration of about 2xGI50 induced significant 
effects on cell cycle distribution. The time-dependent tendency of benzo[b]thiophenes 
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effects was confirmed, after 48 h of treatment, by the deep alterations in the cell cycle 
distribution profile, with significant reduction of the cells number in all phases, and by 
the simultaneous increase of the cells population in subG0/G1, which is indicative of 
apoptotic cells (data not shown). 
 
 
 
Figure 20. Effects of compounds 8d, 10j, and 10l on the cell cycle distribution of Hela cells following 24 h treatment. The 
cells were cultured without any compound (ctrl) or with compound used at the indicated concentrations. Cell cycles 
distribution was analysed by the standard propidium iodide procedure as described in Methods. The histograms 
represent the percentage of cells in the respective cell cycle phase (G0/G1, S, and G2/M), along with the percentage of 
cells in the subG1 (dead cells) obtained by flow cytometry. Results are expressed as the mean of two independent 
experiments, performed in duplicate + SE. Statistical analyses were performed using the Student’s test to determine the 
differences between the datasets. *p < 0.05 denotes significant differences from untreated control cells (84). 
 
3.1.1.1.3 In Silico Insights 
In attempt to rationalize biological results of selected hits on cell-cycle distribution and 
considering the structural features of the proposed derivatives of type 8 and 10, similar to 
known antimitotic agents, the benzothiophenes were analyzed through the in silico 
VLAK protocol (91). Mostly developed in the last years, as well as the recent protocol 
BIOTA (92), this protocol was employed in the design and optimization of lead 
compounds as anticancer drugs. The interesting results, concerning a wide set of 
heterocyclic derivatives, confirmed this in silico methodology as powerful approach in 
prediction capability of biological activities (93-95). The VLAK protocol is focused on 
the search of molecular descriptors, which could be considered as the “pins of the lock”. 
The lock represents the biological target, or a specific mechanism of action (MA), which 
need a key (the molecule) to be tuned (95). 
The first step of the VLAK protocol is the conversion of the biological targets, or the 
MAs, in “lock models” in which the keys (designed ligands) fit to modulate the 
biological activity (91). In this study, the VLAK protocol was applied to predict the MA 
of 3- benzoylamino-benzo[b]thiophene derivatives by using the National Cancer Institute 
(NCI) Anticancer Agent Mechanism (ACAM) database as training set. Drug screening 
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data are available for each structure as measurement of their growth inhibition ability 
over a panel of about 60 human tumor cell lines, and all tested molecules are explicitly 
designed as training set for neural network and multivariate analysis (96-98). In 
particular, this database is constituted by 114 antitumor drugs ranked according to their 
MA that can be considered as the locks in this protocol (99). Therefore, for each class of 
drugs (Alkylating Agents, Antimitotic Agents, Topoisomerase I Inhibitors, 
Topoisomerase II Inhibitors, RNA/DNA Antimetabolites, and DNA Antimetabolites), a 
“lock model” was generated starting from available known compounds. A set of 2D and 
3D molecular descriptors was selected in order to best differentiate ACAM drugs 
database by MA. Once defined the lock model for each MA, compounds have been 
classified in terms of structure affinity to lock models. In table 3 the percentages of 
affinity (A%) for the screened derivatives are reported. 
 																										
	 34	
Table 3. Percentage of affinity (A%) calculated for the tested compounds. In bold, the highest A% values for the 
most active compounds (8d, 10d and 10j) as antimitotic and topoisomerase II inhibitors classes (84). 
Compound Alkylating 
agents 
Antimitotic 
agents 
DNA 
antimetabolites 
Topoisomerase 
I inhibitors 
Topoisomerase 
II inhibitors 
RNA-DNA 
antimetabolites 
8a 
8b 
8c 
8d 
8e 
8f 
10b 
10c 
10d 
10e 
10f 
10g 
10h 
10i 
10j 
10k 
10l 
66.27 
64.59 
66.37 
46.27 
53.87 
60.85 
41.37 
43.16 
35.25 
40.22 
42.25 
44.48 
41.62 
43.40 
35.20 
41.46 
42.23 
44.94 
53.90 
47.50 
60.57 
40.77 
40.22 
55.29 
48.52 
56.39 
38.92 
41.95 
45.58 
54.88 
49.57 
56.74 
42.30 
42.98 
41.35  
38.99  
38.31  
23.35  
33.44  
43.58  
31.03  
29.74  
22.62  
31.11  
34.67  
30.19  
28.07  
26.70  
20.07  
28.77  
32.02 
 
38.57 
53.55 
45.36 
56.25 
43.74 
45.92 
52.66 
48.83 
33.77 
38.89 
51.70 
46.60 
50.26 
47.40 
31.21 
41.64 
53.42 
26.95 
36.60 
29.59 
56.32 
34.65 
30.79 
60.69 
52.80 
62.67 
45.41 
46.64 
47.89 
61.26 
54.34 
61.32 
44.37 
48.74 
 
46.99  
50.29  
47.35  
45.25  
57.40  
54.95  
42.63  
40.57  
35.61 
 49.06 
48.70  
40.24  
37.03  
38.56  
33.64  
44.63  
44.10 
 
Analyzing the results for compounds that showed the most significant biological effect 
(8d, 10j, and 10l) it is noteworthy that TMB derivatives 8d, 10j represent the most 
significant compounds in terms of affinity for the class of antimitotic agents (B), 
showing good values of A%. The structural features of these compounds, similar to the 
well known antimitotic agents such as colchicine and combretastatin A-4, could justify 
these results (fig.21). 
	 35	
 
Figure 21. TMB derivatives (8d and 10j) showing good percentage of affinity (A%) and well-known antimitotic 
agents (Colchicine and Combrestatine A-4) 	
Molecule 10l did not show high affinity percentage towards the antimitotic mechanism 
of action group (42.98), maybe because of the structural modifications involving the 
benzoyl moiety. Thus, in terms of structural analogies with known antimitotic 
compounds, these results highlight the importance of the TMB moiety and underline that 
the presence of the imidazole ring as substituent, essential for the biological activity, 
does not affect the structural analogy with known antimitotic agents. The difference in 
the affinity toward antimitotic agents for compound 10l could be justified by the different 
functionalization of the benzoyl moiety rather than the presence of the methyl group on 
the imidazole ring. Another important aspect to be underlined is the good affinity 
percentage for topoisomerase II inhibitors showed by 3-benzoylamino-
benzo[b]thiophene derivatives 10 b, d, h, j. It is worth noting that these findings are in 
agreement with the biological insights. In particular, the in silico studies make possible to 
hypothesize that observed arrest in the G2/M phase, after cell exposure to selected 
derivatives, involving mitotic failure can be associated, with both an antimitotic 
mechanism by interference with mitotic spindle formation and the DNA-Topoisomerase-
II inhibition. 
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3.1.1.2 New Class of Benzo[b]furan Derivatives with Antiproliferative Activity 
A new series of 3-benzoylamino-5-imidazol-benzo[b]furans and the parent amino 
derivatives were synthesized and screened as antitumor agents, in order to investigate the 
influence of isosteric replacements and to optimize the antiproliferative activity with 
respect to the previous benzo[b]thiophene series. As a general trend, tested 3-
benzoylamino-5-imidazol-benzo[b]furans showed concentration-dependent 
antiproliferative activity against HeLa and MCF-7 cell lines and some of these exhibited 
GI50 values in the low micromolar range. In most cases the insertion of a methyl 
substituent on the imidazole moiety improved the antiproliferative activity. Therefore the 
methyl-imidazol-benzo[b]furans compounds were tested in cell cycle perturbation 
experiments, producing cell cycle arrest with proapoptotic effects. 
Focusing the attention on the thieno heterocyclic ring systems 8 and 10, (fig.22) 
previously reported as a novel series of benzo[b]thiophene derivatives showing 
concentration-dependent antiproliferative profile, with GI50 values in the low micromolar 
range against HeLa cells (84), a few studies were carried out on the basis of the isosteric 
concept, suggesting useful aromatic ring replacements, in order to optimize the 
antiproliferative effects of our lead compounds. 
Analyzing the benzo[b]thiophenes series, from a structural point of view, only a few 
derivatives exhibited notable antiproliferative effect, when functionalized with a methyl-
imidazole side chain; instead no significant differences were observed by changing the 
substituents on the benzoyl moiety (both electron-withdrawing and electron-releasing 
substituents). These findings led this research work to further study these type of 
molecules and to investigate the isosteric replacement of benzo[b]thiophene skeleton by 
a benzo[b]furan one, in order to optimize the antiproliferative activity. In detail, 
hereinafter, is described the synthesis, and the biological screening of a new series of 
benzo[b]furan derivatives 11, 12, and 13 (fig.22). 
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Figure 22. General chemical structures of  benzo[b]thiophene derivatives (84) and their related benzo[b]furan 
isosters. 
The interest on these new molecules is also supported by several experimental data, 
which assigned to the benzo[b]furan scaffold peculiar biological activities. Romagnoli 
and co-workers reported interesting series of 3-arylaminobenzo[b]furans 15 as result of 
accurate bioisosteric replacements and SAR studies (84,89). These compounds, acting on 
the colchicine binding site of tubulin, showed highly antiproliferative activity, 
comparable to the thiophene derivatives 14a,b (fig.23). 
 
 
Figure 23. Chemical structures of 2-(alkoxycarbonyl)-3-(3,4,5-trimethoxyanilino)benzo[b]thiophene 14a, 2-
(alkoxycarbonyl)-3-(3,4,5-trimethoxyanilino)thieno[2,3-b]pyridine 14 b (89), 2-(alkoxycarbonyl)-3-(3,4,5-
trimethoxyanilino)benzo[b]furan 15 and respectively IC50 ranges against a panel of seven cancer cell lines  (100). 
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3.1.1.2.1 Chemistry 
As shown in scheme 3, the general synthetic route for the preparation of 3-
benzoylamino-benzo[b]furan derivatives 11-13 started from the commercially available 
2-fluorobenzonitrile (3). Pale yellow needles of 2-fluoro-5-nitrobenzonitrile (4) were 
obtained, in quantitative yield, by nitration of (3), using a mixture of concentrated nitric 
and sulfuric acids, under inert atmosphere (90). The presence of both cyano and nitro 
substituents on substrate (4) enhanced the reactivity of the ortho-fluorine atom, which 
readily underwent nucleophilic displacement by ethyl glycolate, in the presence of 
K2CO3 and N,N-dimethyl-formamide (DMF). Subsequent intramolecular cyclization in 
situ led to the benzo[b]furan central core, allowing the isolation of the 3-amino-
benzo[b]furan derivate 16.  
To introduce the benzoyl moiety, the key intermediate 3-amino-benzo[b]furan 16 was 
treated with benzoyl chlorides 6a-f, variously substituted with electron-withdrawing and 
electron-releasing groups. The nucleophilic acyl substitution was carried out employing 
pyridine both as base and solvent. In the same way to what observed in the 
benzo[b]thiophene series, the use of other reaction media gave a significant decrease of 
the yields. Reduction of nitro group of 17a-f was realized through hydrogenation with 
10% Pd/C in ethanol. After removal of the catalyst, amino derivatives 11a-f were easily 
isolated as pure needles, in good yields. The last synthetic step provided the imidazole 
moiety insertion via a reductive amination in the presence of imidazole-4-carbaldehydes 
9a,b. The reaction of the amino group with the aldehydes led to the formation of the 
corresponding imines; therefore, the subsequent addition of sodium cyanoborohydride 
performed a tightly selective reduction and the final formation of ethyl 3-benzoylamino-
5-[(1H-imidazol-4-yl-methyl)-amino]-benzo[b]furan-2-carboxylates 12a-f and 13a-f. In 
this synthetic step, when is employed the carbaldehyde 9b, it was possible to isolate the 
methyl-imidazole side-chain derivative 18, where the hydrolysis of the amide function 
releases the 3-amino group from the benzoyl moiety. 
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Scheme 3. Synthesis of ethyl 3-benzoylamino-benzo[b]furan-2-carboxylates 11 a-f, 12 a-f and 13 a-f. Reagents 
and conditions: (i) HNO3: H2SO4 (1:1), N2, 0 °C, 2h; (ii) ethylglycolate, K2CO3, anydrous DMF, 12h; (iii) 
pyridine, rt, 12 h; (iv) 10% Pd/C, H2, ethanol, rt, 2 h; (v) NaCNBH3, ethanol/AcOH, 2h. 
 
3.1.1.2.2 Biology: Antiproliferative Activity  
The antiproliferative activity of the synthesised 3-benzoylamino-benzo[b]furan 
derivatives 11a-f, 12a-f, and 13a-f was evaluated on HeLa and MCF-7 tumour cell lines 
for 48h, using MTT based cell viability assay. In table 1 were displayed the GI50 values 
of all tested compounds, which, for an easier analysis, were divided into three main 
subgroups: 5-amino-benzo[b]furans 11a-f, imidazole side-chain compounds 12a-f, and 
methyl-imidazole side-chain derivatives 13a-f. 
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Table 4. Antiproliferative activity over 48h of 3-benzoylamino-benzo[b]furan derivatives 11 a-f, 12 a-f and 13 a-f 
against Hela and MCF-7 cell lines expresses as GI50 values [GI50 + SE (mM)]. 
 
 
11 a-f 
 
12 a-f 
 
13 a-f 
Hela MCF-7 Hela MCF-7 Hela MCF-7 
a R1=R2=R3= H 35.09 ± 3.52 >50 41.59 ± 3.08 49.65± 4.91 7.69 ± 0.46 12.27 ± 1.46 
b R1=R3= H; R2= 
OCH3 
>50 >50 7.98 ± 0.67 13.36 ± 1.94 14.31 ± 1.97 17.35 ± 1.78 
c R1=R3= H; R2= CH3 35.32 ± 3.92 30.84 ± 4.09 13.65 ± 1.02 18.22 ± 1.28 9.20 ± 0.34 15.53 ± 0.98 
d R1=R3=R2= OCH3 >50 >50 12.18 ± 1.19 3.88 ± 0.40 12.19 ± 1.59 9.21 ± 1.02 
e R1=R3= H; R2= CF3 >50 >50 >50 >50 2.01 ± 0.13 14.16 ± 2.02 
f  R1= Cl; R2= F; R3= 
H 
42.05 ± 5.08 35.63 ± 4.30 13.61 ± 0.86 11.25 ± 1.11 2.14 ± 0.35 1.55 ± 0.14 
 
 
As a general trend, the screened 5-amino-benzo[b]furan derivatives 11a-f showed poor 
antiproliferative effects on both tumor cell lines. Only in few cases, it was possible to 
observe low activity, with GI50 values greater than 30 µM. 
As clearly highlighted by the data reported in table 3, the insertion of the imidazole side 
chain moiety exerted a weighty influence on the antiproliferative activity. Indeed, with 
the exception of derivatives 12a and 12e, where the benzoyl moiety was respectively not 
functionalized or brings a 4-trifluoromethyl substituent, the inhibition growth effects of 
benzo[b]furan compounds of type 12 were promising, showing GI50 values in the low 
micromolar range. Within this subgroup, remarkable was the selective antiproliferative 
effect of the 3,4,5-trimethoxy-benzoyl-benzo[b]furan 12d on MCF-7 cell line, with a 
GI50 value of 3.88 µM. 
The insertion of methyl group on the imidazole ring further increased the biological 
activity, especially in the cases of 13a, e, f, where the benzoyl moiety was respectively 
unsubstituted (13a vs 12a), or functionalized with 4-trifluoromethyl- (13e vs 12e) and 3-
chloro-4-fluoro- (13f vs 12f) substituents. The cytotoxic activity was worthily interesting 
in the case of derivative 13f, the most active of the benzo[b]furan series, where GI50 
values on HeLa and MCF-7 tumour cell lines were respectively at 2.14 and 1.55 µM. 
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Generally, the biological activity of tested benzo[b]furan derivatives was less influenced 
by the substituents (both with electron-withdrawing and electron-releasing effects) 
located on the benzoyl moiety than by the imidazole side chains insertion. However, it 
was evident that the biological activity of the not substituted (11a, 12a, and 13a) and of 
the 4-trifluoromethyl- (11e, 12e, and 13e) derivatives, with respect to the other cases, 
varied in peculiar ways along the progression of the synthesis, from the 5-amino-
benzo[b]furans to the methyl-imidazole side-chain derivatives. 
Finally, the biological screening of derivative 18, where the 3-amino group is free from 
the benzoyl moiety, certified the crucial importance of this molecular portion on the 
antiproliferative activity. The analysis of the cytotoxic data obtained for both tumor cell 
lines evidenced GI50 values up to 50 µM. 
 
3.1.1.2.2.1 Cell Cycle Analysis 
The methyl-imidazole side-chain compounds 13a-f were also tested on HeLa cells, in 
cell cycle perturbation experiments, to evaluate their potential influence on cell-cycle 
distribution. The flow cytometric analysis was performed after 24h of incubation, in 
order to detect the shifts in cell cycle distribution before a significant amount of cells 
underwent apoptosis. The working concentrations were chosen taking into account the 
GI50 values measured at 48h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 42	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In figure 24 the percentage of cells in the respective cell cycle phase (G1, S, and G2/M) 
were shown, along with the percentage of cells in the sub-G0/G1 (dead cells) obtained by 
flow cytometry. Untreated HeLa cells showed a normal diploid distribution presenting 
fast proliferation characteristics, with S + G2/M cell phases accounting for about 40% of 
the total cells (ctrl). Significant suppression of the G0/G1 phase with accumulation of 
cells in the G2/M was observed after cell exposure to 1xGI50 µM of methyl-imidazole 
side-chain derivatives 13b-d,f. The antiproliferative effect was concentration-dependent 
and, in our experimental conditions, treatment with a concentration of about 2xGI50 
produced deep alterations in the distribution profile. Indeed, it was possible to observe a 
significant reduction of the cell number in all phases and a simultaneous increase of the 
cell population in sub G0/G1, which was indicative of apoptotic cells. Interestingly, the 
not substituted 13a and the 4-trifluoromethyl- 13e derivatives, assayed at 1x and 2xGI50, 
failed to produce significant cell cycle alterations. On the contrary, cell exposure to 
Figure	24.	Effects	of	compounds	13	a-f	on	the	cell	cycle	distribution	of	Hela	cells	following	24h	treatment.	
The	 cells	 were	 cultured	 without	 any	 compound	 (ctrl)	 or	 with	 compound	 used	 at	 the	 indicated	
concentrations.	 Cell	 cycles	 distribution	 was	 analysed	 by	 the	 standard	 propidium	 iodide	 procedure	 as	
described	in	Methods.	The	histograms	represent	the	percentage	of	cells	in	the	respective	cell	cycle	phase	
(G0/G1,	 S,	 and	 G2/M),	 along	 with	 the	 percentage	 of	 cells	 in	 the	 subG1	 (dead	 cells)	 obtained	 by	 flow	
cytometry.	Results	are	expressed	as	the	mean	of	two	independent	experiments,	performed	in	duplicate	+	
SE.	Statistical	analyses	were	performed	using	the	Student’s	test	to	determine	the	differences	between	the	
datasets.	*p	<	0.05	denotes	significant	differences	from	untreated	control	cells.	
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2.5xGI50 and 5xGI50 µM of derivatives 13a,e, induced G0/G1 arrest associated with 
reduction of the cell number in other phases. 
 
3.1.1.3 Synthesis, Biological Evaluation and In Silico Insights of New Potential G4-
DNA Binders and Stabilizers 
Although the interest in molecules able to interact through the mechanism of 
intercalation has not changed over the years, the lack of selectivity together with the 
discovery of more specific targets have made the B-DNA a less attractive target in the 
search for new anticancer drugs. 
The current appealing challenge is to design DNA-interactive molecules showing higher 
specifity in DNA binding, without interfering with the functions of healthy cells.  
In this regards, we focused our attention on the design, the synthesis, and the biological 
evaluation of novel heterocyclic ring systems potentially able to halt tumor cell 
proliferation through the binding to DNA when it assumes secondary structures known 
as G-quadruplexes (G4s), preferring them over the B form. Indeed, as already pointed 
out, the stabilization of such DNA secondary structures can modulate and control various 
processes in the carcinogenic pathways. On the basis of our considerations (26), 
symmetry could be an interesting feature to investigate in order to understand which 
structural feature affects more the G4 arrangement, hard to figure out due to the structure 
heterogeneity of both G4 stabilizers and the DNA G4s isoforms (26). 
 
3.1.1.3.1 In silico Insight, Synthesis and Spectroscopic Assays of Bis Isoquinoline 
Derivatives  
Molecular modelling studies made possible the identification of structures potentially 
related to telomeric G4s (h-telo) and the proto-oncogenes c-kit and c-myc, taken from the 
PDB database. 
From the virtual screening of the database DRUG-LIKE (ZINK), a series of structures 
that share a common π-delocalized system core have been selected. These scaffolds, 
when functionalized with proper positively charged side chains, affect more the G4 
arrangment, both stacking at the top/end of a G-tetrad and interacting with the groves. All 
the molecules screened display symmetry features, noteworthy, as the most interesting 
already known G4- stabilizers. 
A series of these molecules have been submitted to a retrosynthetic study when not 
commercially available. 
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Indeed, the virtual screening of diversity set selected the structure 19, shown in figure 25, 
commercially available.  
 
 
Figure 25. (19) 2,2'-(butane-1,4-diyl)bis(isoquinolin-2-ium) bromide  
 
3.1.1.3.1.1 Chemistry  
The two bis-isoquinolino derivatives 22a and 22b (scheme 4) were accomplished 
respectively from compounds 20a and 20b (Scheme 4). They were allowed to react with 
1,3-dichloro-2-propanol, 21, at 140 °C within a Shlenk flask for 10-20 hours. 
 
 
 
3.1.1.3.1.2 Spectroscopic Assays 
Spectroscopic studies were carried out between the synthesized derivatives, obtained 
according to the scheme 4, and both the G4-DNA and B-DNA isoforms. 
Although molecular modeling studies showed interesting interactions between the 
isoquinoline structures and the grooves of the promoter c-kit, unfortunately the 
spectroscopic tests on G4-DNA did not give the expected results. No interesting 
interactions with the B form of the DNA have been found.  
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Scheme	 4.	 Synthesis	 of	 bis	 isoquinoline	 derivatives:	 (22	 a),	 2,2'-(2-hydroxypropane-1,3-
diyl)bis(isoquinolin-2-ium)	and	(22	b),	2,2'-(2-hydroxypropane-1,3-diyl)bis(3-methylisoquinolin-2-
ium).	Reagents	and	conditions:	20	a:	 Isoquinoline;	20	b:	2-methyl	 isoquinoline;	21:	1,3-dichloro-2-
propanol;	i:	140	°C,	10.20	h.	
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3.1.1.3.2 In silico Insight, Synthesis and Spectroscopic Assays of Double Chained 
Naphthalenes as G4 Binders  
The presence of G-quadruplexes in promoter regions of a number of oncogenes with 
functions in transcriptional regulation led our interest in  designing and developing 
binders to specific G-rich sequences in oncogenes promoters able to modulate their 
expression. The first approached target was the human proto-oncogene c-Kit, which 
presents a G4 sequence (c-Kit1) with a large irregular cleft, not present in any other G4s. 
Computational studies were used to drive synthetic work, employing large databases of 
heterocyclic molecules and G4 isoforms as templates in the molecular modelling 
strategies. The designed binder (fig. 26) display a π-delocalized system able to stack at 
the top/end of the G4 and side arms able to fit specific binding pockets. These two 
fragments are connected by a proper linker. The selectivity of the synthesized binder was 
assessed by competitive binding experiment with other G4s from telomeric and gene 
promoter sequences, mainly using spectroscopic techniques. 
 
3.1.1.3.2.1 Chemistry 
The 2,7-bis(4-morpholinobut-1-yn-1-yl)naphthalene,  26  (fig.26 ), a symmetrical 
compound featured by a naphthalene core and two bromo-ethyl side chains in 2,9 
positions, has been synthesized according to the scheme 5.  
 
 
Figura 26. 2,7-bis(4-morpholinobut-1-yn-1-yl)naphthalene. 
 
Substrate, 23, a 2,7-dihydroxynaphthalene commercially available, underwent a 
nucleophilic substitution base-catalysed (I) by trifluoromethansulfonic anhydride to give 
compound 24, achieved in order to improve the reactivity of leaving groups of this 
substrate in the next step. Thus, in presence of 2,6-lutidine and DMAP, after adding a 
solution in THF of the trifluoromethansulfonic anhydride to the reaction mixture, either 
at -78 °C or 0 °C to 0 °C, in the former case, and to room temperature in the latter case, 
the best yield obtained was about 30%. A better yield (60%) was achieved after using 
NN
OO
26
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pyridine as a base, and carrying out the reaction at room temperature after the addition at 
0 °C of trifluoromethansulfonic anhydride.  
 
 
 
Scheme 5. Synthetisis of 2,7-bis(4-morpholinobut-1-yn-1-yl)naphthalene derivative (26). Reaction conditions: 
(i): Pyridine, DCM, N2; addiction of Tf2O at 0 °C -> r.t., over night; 60% yield. (ii): 4-Bromo-1-butyne, CuI, 
DIPEA, DMF dry, Pd(PPh3)2Cl2, N2, 3h, r.t.; 40% yield. (iii): Morpholine, DCM dry, r.t. -> reflux, 3h; 40% 
yield. 
 
The following cross-coupling Sonogashira reaction (II) between 24 and 4-bromo-1-
butyne, gave the formation of the C-C bond, catalyzed by CuI and triphenyl phosphine 
palladium di-chloride. 
The cross-coupling reaction must be carry out under inert atmosphere because as a result 
of the presence of copper iodide, the Glaser coupling between two alkynes may occur, 
giving some side products. 
This reaction was carried out at room temperature and DIPEA was used as a base, 
yielding the 2,7-bis(4-bromobut-1-yn-1-yl)naphthalene derivative (40% yield).  
In the next step, to a solution of DCM anhydrous, a solution of morpholine (2 
equivalents) in DCM anhydrous was added dropwise at room temperature over 1 hour. 
After that, the reaction mixture was refluxed over 3 hours, yielding compound 26 in a 
good yield. 
 
3.1.1.3.2.2 Spectroscopic Analysis Results 
Even in this case, although molecular modelling studies showed interesting interactions 
between compound 26 and G4-structures, spectroscopic tests on G4-DNA did not turn 
out the expected interactions.  
 
BrBrNN
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3.1.1.4 In Silico Insight, Synthesis and Biological Evaluation of New Pyridazyne-
Based Small Molecules as G-quadruplex  Binders  
In the effort to find new G4-DNA binders showing better tumor penetrating ability and 
target selectivity than the G4-stabilizers known hitherto (101), this section focused on the 
design and synthesis of new potential G4-DNA binders and stabilizers.  
During my PhD visiting at the Department of Organic Chemistry (Semmelweis 
University, Budapest), the interest on development of symmetrical G4-binders met the 
great experience on the chemistry of 3-(2H)–pyridazinones of Prof. Péter Mátyus, giving 
rise the input to the implementation of some interesting symmetrical pyridazinone 
derivatives as potential new G4-DNA binders and stabilizers. 
Since the early eighties, the considerable interest on the pyridazinone system was due to 
its synthetic versatility, well-balanced physic-chemical properties, and the presence of 
possible binding sites for interactions with various receptors. Among several new 
pyridazinone derivatives, identified as lead compounds, the most advanced a 3-(2H)–
pyridazinone derivative, GYKY-16084, has been developed for the treatment of benign 
prostatic hyperplasia (102). Recently, GYKY-16084, entered Phase II clinical trials 
(102). 
 
 
Figure 27.  GYKI 16084 (102) 
 
3.1.1.4.1 Chemistry and Biological Assays 
Linear and annellated naphthaleno-pyridazinone derivatives were synthesized via 
nucleophilic substitution reaction and intramolecular Heck-type arylation (schemes  6-7).  
O
O N
H
N
N
O
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Scheme 6. Synthesis of 5,5'-((3,6-dibromonaphthalene-2,7-diyl)bis(oxy))bis(2-benzylpyridazin-3(2H)-one) (31) 
and (32). (i) : K+(CH3)3CO-, dry DMF, r.t., 3hrs, 95% yield; (ii): Pd(PPh3)2Cl2; NaOAcx3H2O, DMA, 130 °C; (iii): 
Pd(PPh3)2Cl2; NaOAcx3H2O, DMA, 130 °C; (iv): K2CO3, CH3CN, 3h MW, 60%.  
 
 
Scheme 7.  Synthesis of 5,5'-(naphthalene-2,7-diylbis(oxy))bis(2-benzyl-4-bromopyridazin-3(2H)-one) (28) and 
(33): (i): K+(CH3)3CO-, dry DMF, r.t., 3hrs, 95% yield; (ii): Pd(PPh3)2Cl2; NaOAcx3H2O, DMA, 130 °C, 100% 
yield. 
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Noteworthy, in the synthetic pathway A) the nucleophilic substitution by 2,7-dihydroxy 
naphthalene 23 occurs on C-5 of 4,5-dibromo-2-N-benzylpyridazinone, ruling out any 
SN2 on C-4 of 4,5-dihalo-2-N-benzylpyridazinone, which would result in the synthesis of 
a linear asymmetric molecule, if 2,7-dihydroxynaphthalene was differently substituted. 
This has been proven by the 1H-NMR analysis reported hereinafter (fig.28). The relative 
HPLC chromatogram and elemental analysis (here not reported) fully support the NMR 
results (fig.28). 
 
 
 
 
Figure 28. Compound 28: HPLC chromatogram  and 1H-NMR  spectrum. 	Compound	28	was	synthesized	under	different	conditions	in	order	to	improve	both	the	yield	and	the	reaction	time.	Therefore,	as	first	attempt	the	reaction	between	23	
OO
N
NN
N
OO
Br Br
7.31 m
7.34 m
7.47 m
5.36 s
7.43 s
7.27 dd
7.94 d
7.38 d
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and	27	was	 carried	 out	 in	 dry	 aceto	 nitrile,	 by	 using	 dry	 potassium	 carbonate	 as	base	 and	 refluxing,	 affording	 30%	 white	 chrystals.	 Then	 the	 yield	 was	 doubled	when	the	same	reaction	was	conducted	in	a	microwave	reactor	over	2.30	hours,	at	130	 °C,	 200	 psi	 and	 200	 watt.	 Although	 a	 better	 reaction	 time	 and	 yield	 were	accomplished,	 some	 2-benzyl-4,5-dibromopyridazin-3(2H)-one	 resulted	 still	unreacted.	 Thus,	 a	 new	method	was	 developed,	 using	 potassium	 tert	 butoxide	 as	base,	in	dry	DMF,	at	room	temperature,	over	3	hours,	which	afforded	95%	yield.		Through	 this	 procedure	 all	 the	 starting	 materials	 disappeared	 over	 the	 reaction	time	 above	 indicated.	This	 result	was	 important	 to	 achieve	 since	 it	 represented	 a	great	 limit	 approached	 so	 far	 by	 any	 researcher	 who	 has	 had	 to	 face	 to	 the	nucleophilic	substitution	reaction	by	a	4,5-dihalo-2-N-benzylpyridazinone. 	
The choice of both starting materials 23 and 29 and the entries 27 and 30, together with 
the synthetic versatility of the pyridazinone compounds were crucial in order to get 
symmetrical or unsymmetrical final products after the ring closure reactions. Linear 
derivative 32 resulted from the strategic choise of 3,6-dibromo-2,7-dihydroxynaphthalene 
29 as starting and 5-iodo-2-N-benzylpyridazinone 30 as entry. Compound 29 was 
synthesized according to the literature (103). The reaction between 29 and 30 was carried 
out under three different parallel conditions: a first	attempt	in	dry	aceto	nitrile,	using	dry	potassium	carbonate	as	base	and	 refluxing	over	19	hours,	 yielded	60%	white	chrystals.	A	parallel	reaction	conducted	in	the	microwave	reactor	over	2.30	hours,	at	100	°C,	200	psi	and	50	watt	afforded	the	same	yield.		The	last	reaction	conditions,	which	 foresaw	 the	 use	 of	 potassium	 tert	 butoxide	 as	 base,	 in	 dry	 DMF,	 at	 room	temperature,	over	3	hours	resulted	too	strong,	hence	unsuccessful. 
The Heck-type intramolecular arylation of 28 linear derivative, gave the ring closure in 
C-3 and C-8 of the naphthalene ring (instead of C-3 and C-6 as it was expected), yielding 
the unsymmetrical derivative 33. When the synthesis starts from 3,6-dibromo-2,7-
dihydroxynaphthalene, only the symmetrical anellated naphthaleno-pyridazinone 
derivative 32 can be achieved. Unless 33, all the above described derivatives show a C2v 
symmetry feature (table 5). 
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Table	5.	Symmetry features of naphthaleno-pyridazine based derivatives.	
STARTING ENTRY LINEAR NAPHTHALENO- PYRIDAZINE-BASED DERIVATIVE 
POINT 
GROUP 
SYMMETRY 
ANELLATED 
NAPHTHALENO- 
PYRIDAZINE-BASED 
DERIVATIVE 
POINT 
GROUP 
SYMMETRY 
 
   
C2V 
 
E 
23 27 28  33  
   
C2V 
 
C2V 
29 30 31  32  
 
 
The synthesized compounds 28 and 31 were subjected to antiproliferative tests on HeLa 
cells, over 48 hours treatment. Noteworthy, the different position of the two bromo in 28 
and 31 significantly affected the antiproliferative activity. Indeed, 28 and 31 respectively 
show >50 µM and 10.34 µM GI50 values. Even the di- and monohalo-2-N-benzyl 
pyridazinone compounds, 27 and 30 underwent the same antiproliferative assay. 
Interestingly 27 shows a 0.0027 µM GI50 value vs  >50 µM shown by compound 30. 
Derivatives 32 and 33 could not be assayed since these products were not soluble neither 
in DMSO nor in Ethanol as we could expected since their molecular structure. 
In order to evaluate a potential effect of the substituent in compound 28, derivative 40 
was accomplished, as shown in the following reaction scheme: 
 
	
Scheme	8.	(i): K2CO3, CH3CN, 8 h, refluxing, 20% yield. 	
Table	6.	GI50(mM)	values,	(HeLa	cells,	over	48	hrs	treatment)	related	to	compounds	28	and	40.	
	
																																																							 	
					
COMPOUND R=R1 GI50(µM) values, (HeLa cells, over 48 hrs treatment) 
28 -Bn >50 
40 -CH3 3.18 	
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The growth inhibition of 50% resulted dramatically increased when the naphthaleno 
pyridazine-based derivative displayed in table 6, is symmetrically substituted by a methyl 
group instead of a benzyl one.  
  
Due to its controllable regiochemistry, 2-Benzyl-4,5-dibromopyridazin-3(2H)-one 27 
was chosen again as starting material for the synthesis of new other pyridazine-based 
derivatives. Compounds 34 and 35 were initially designed to be synthesized via 
nucleophilic substitution reaction and intramolecular Heck-type arylation, as previously 
above described. 
 
 
Figure	29. 1,2-Dihydroxy benzeno-pyridazinone anellated derivative (34); 1,8- dihydroxy naphthaleno 
pyridazinone derivative (35). 
 
The nucleophlic substitution reaction afforded both symmetrical dihydroxy benzeno- and 
naphthaleno-pyridazinone angular derivatives (fig.29), since the substitution occurs on 
C5 of 4,5-dibromo-2-N-benzylpyridazinone in the case of both hydroxyl groups, giving 
the best yield when the reactions were carried out using a microwave reactor. 
 
 
Scheme	 9. (i): K2CO3, CH3CN, 30 h, refluxing, 50% yield; (ii): K2CO3, CH3CN, 3h MW, 60%; (iv): 
Pd(PPH3)2Cl2, NaOAcx3H2O, DMA, 100 °C, 100 WATT, Ar, MW. 
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Unfortunately Heck type intramolecular arylation in both case of 37 and 38 did not occur 
at the conditions used and derivatives 34 and 35 could not be accomplished.  
 
 
Scheme	 10. (i): K2CO3, CH3CN, 8 h, refluxing, 20% yield; (ii): K2CO3, CH3CN, 4h MW, 40%; (iv): 
Pd(PPH3)2Cl2, NaOAcx3H2O, DMA, 130 °C, 1h, Ar, MW. 
 
Compounds 37 and 38 were subjected to antiproliferative tests on HeLa cells, over 48 
hours treatment. Interestingly, in this case a difference in dimension of the two cores, 
benzene in 37 and naphthalene in 38, significantly affected the antiproliferative activity. 
Indeed, 37 shows 16.84 µM and 38 >50 µM GI50 values.  
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4. Conclusions And Perspectives 
This PhD work aimed to the design, the synthesis, and the biological evaluation of novel 
heterocyclic small molecules able to halt tumor cell proliferation, both reproducing the 
mecanisms of action of the classical DNA-interactive drugs, namely the reversible 
binding to DNA through the formation of non-covalent interactions, and interacting with 
secondary structures of the DNA (G-quadruplexes), recently turned out as more 
appealing targets in anticancer drug discovery.  
In the former work, the synthesis and the biological evaluation of the new 
benzo[b]thiophene series of type 10 and the related amino precursors 8 a-f are reported. 
Generally, all tested compounds showed a good antiproliferative effect with GI50 values 
in a low micromolar range. Antiproliferative screening on HeLa tumor cell line 
underlined a significant growth inhibition effect of final imidazole-side chain compounds 
10 a-l. Methyl insertion on the imidazole ring resulted in a notable increase of activity 
for the TMB (10d vs 10j) and the 3-chloro-4-fluoro-benzoylamino-benzo[b]thiophene 
derivatives (10e vs 10k), while it was irrelevant in the other cases. 
No differences were observed in the biological activity by changing the substituents on 
the benzoyl moiety (both electron-withdrawing and electron-releasing substituents), and 
the TMB derivatives 8d, 10d, and 10j resulted the most active of each subgroup. To 
evaluate their potential influence on cell-cycle distribution, derivatives 8d, 10j, and 10l 
were also tested in cell cycle perturbation experiments. After cell exposure to 
benzo[b]thiophene derivatives, a rapid accumulation of cells in the G2/M phase, with a 
concomitant reduction of cells in both the S and G0/G1 phases, was observed. 
To rationalize biological results of selected hits on cell-cycle distribution, considering the 
structural features of the proposed derivatives of type 6 and 13, similar to known 
antimitotic agents, the benzothiophenes were analyzed through the in silico VLAK 
protocol. Compounds presenting the TMB moiety were classified as potential antimitotic 
agents, showing high affinity percentage for this mechanism of action class. The 
presence of the imidazole ring does not seem to affect the mechanism of action as 
previously observed by biological assays. This is also underlined by the presence of 
several imidazole derivatives as the best ranked antimitotic agents in table 2. Another 
important aspect to be underlined is the good percentage of affinity for topoisomerase II 
inhibitors showed by some other 3-benzoylamino-benzo[b]thiophene derivatives as 
10b,d,h,j. These findings could be in accordance with biological assays where a possible 
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antimitotic mechanism or a potential inhibition of the topoisomerase II enzyme could 
justify the cell cycle arrest at G2/M checkpoint. 
In the latter work, the synthesis and the biological evaluation of the new benzo[b]furan 
series of type 11, 12, and 13 were reported. With respect to the previous issued 
benzo[b]thiophene series (8 and 10) and their antiproliferative activity, we replaced the 
thiophene central core with a furan ring, in order to evaluate the isosteric influence on the 
biological activity. As a general trend, the antiproliferative screening on HeLa and MCF7 
tumor cell lines underlined a significant growth inhibition effect of final imidazole-side 
chain compounds 12a-f and 13a-f. Methyl insertion on the imidazole ring resulted in a 
notable increase of activity. The cytotoxic effect is remarkably interesting in the case of 
derivative 13f, where GI50 values on both HeLa and MCF-7 tumour cell lines are 
respectively at 2.14 and 1.55 µM. No differences were observed in the biological activity 
by changing the substituents on the benzoyl portion, even though the presence of this 
moiety was crucial for the antiproliferative effects. Indeed the lack of activity observed in 
the biological screening of derivative 18 confirmed the importance of this moiety present 
in the whole benzo[b]furan series. To evaluate their potential influence on cell-cycle 
distribution, the methyl-imidazole side-chain compounds 13a-f were also tested on HeLa 
cells, in cell cycle perturbation experiments, producing cell cycle arrest with proapoptotic 
effects. 
As last, the design, the synthesis, and the biological evaluation on new potential G-
quadruplex binders were reported.  
Synthesis of bis-isoquinoline derivatives and double-chained naphthalenes were carried 
out. Spectroscopic tests on G4-DNA isoforms did not turn out the expected interaction, 
previously observed through molecular modelling studies.  
Linear and annellated naphthaleno-pyridazinone derivatives were synthesized via 
nucleophilic substitution reaction and intramolecular Heck-type arylation exploiting as 
starting material, as in many of our synthetic pathways, the 2-benzyl-4,5-
dibromopyridazin-3(2H)-one, because its controllable regiochemistry.  
As shown in schemes 6-7, the strategical choise of starting materials 23 and 29, and 27 
and 30, afforded respectively symmetrical and unsymmetrical anellated compounds 32 
and 33. In schemes 9-10 was important to accomplish linear, and eventually anellated 
compounds, showing two cores differently sized to evidence any difference in 
antiproliferative activity and/or in interaction with B-DNA and G4-DNA. Considerably 
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results were achieved. Indeed, the antiproliferative screening on HeLa tumor cell lines 
underlined a significant growth inhibition effect concerning compounds 31, highlighting 
the importance of the different position of two bromo placed in C3 and C6, over the 
naphthalene core in 31 and on C4, over the pyridazinone in compound 28; besides, the 
benzene core in 37 improved the GI50 value than that of the naphthalene one in 
compound 38. Furthermore, a significant growth inhibition effect was provided by 
changing the benzyl group with a methyl one in compound 28. Derivative 40 resulted the 
most active on HeLa tumor cell lines besides the commercially available 27 starting 
material. The anellated derivatives 34 and 35 above proposed to be achieved via Heck-
type arylation, were assumed unable to C-C bond formation maybe due to both distance 
and strain issues.   
The final aim was to evaluate any interaction of the anellated derivatives with B-DNA 
and G4-DNA, through UV-vis spectroscopy, circular dichroism (CD), fluorescence, 
viscosity, electrophoresis gel determination of binding constants studies. Unfortunately, 
due to some solubility issues, the anellated compounds achieved could not undergone 
any spectroscopic assays and antiproliferative screenings.  Since some flat pyridazine-
based compounds herein proposed, seems to be still promising as new potential G4-
binders and stabilizers, in the near future might be interesting properly functionalize 32 
and 33 derivatives, through the removal of the N-benzyl protective group, yielding the 
unsubstituted fused pyridazinone compounds to be decorated with proper side chains 
expected to bind the grooves of G4s.  
The functionalization of these derivatives would afford interesting symmetrical and 
unsymmetrical disubstituted compounds, with improved chemical-physical features, 
useful to assess any interaction with B-DNA and G4-DNA. 
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5. Experimental Part 
Chemistry 
Materials and Methods 
Unless otherwise indicated, all reagents and solvents were purchased from commercial 
sources and used without further purification. All melting points (°C) were determined 
on a Büchi Tottoli capillary apparatus and are uncorrected; IR spectra were determined in 
bromoform with a Jasco FT/IR 5300 spectrophotometer. 1H NMR, 13C NMR spectra 
were recorded, at 200 and 50.3 MHz respectively, in CDCl3 or DMSO-d6 solution, using 
a Bruker AC-E series 200 MHz spectrometer. Chemical shifts values are given in ppm 
and referred as the internal standard to tetramethylsilane (TMS). The following 
abbreviations are used: br s= broad signal, s= singlet, d= doublet, t= triplet, q= quartet, m 
= multiplet, rt= room temperature. The purity of all compounds screened in biological 
assays was determined to be >95% by HPLC/MS analysis. Mass spectra were performed 
using a GC and MS Shimadzu QP5050 with EI (75 ev). Microanalyses were in 
agreement with theoretical values ±0.4%. Thin layer chromatography was performed on 
precoated (0.25 mm) silica gel GF254 plates, compounds were detected with 254 nm UV 
lamp. Column chromatography was performed with Merck silica gel ASTM (230 and 
400 mesh), or with a Biotage FLASH40i chromatography module (prepacked cartridge 
system). 2-fluorobenzonitrile (3) is commercially available. 2-fluoro-5-nitro-benzonitrile 
(4) was obtained following the procedure reported in literature (90). 
 
Benzo[b]thiophene series. Synthesis of ethyl 3-amino-5-nitro-benzo[b]thiophene-2- 
carboxylate (5) 
According to the literature procedure (93), ethyl thioglycolate (1.2 mL, 11 mmol) was 
added to a stirred mixture of NaH 60% dispersion in mineral oil (0.36 g, 15 mmol) in dry 
DMSO (10 mL). After stirring at room temperature for 20 min, a solution of 2- fluoro-5-
nitrobenzonitrile (4) (1.66 g, 10 mmol) in dry DMSO (20 mL) was added dropwise. The 
reaction was stirred at room temperature for further 3 h and then was poured onto stirred 
water/ice. The precipitate was collected by filtration and dried to give orange-red needles 
of 5, 2.48 g.  
(5). Yield 93%. Mp 207-208 °C. IR nmax: 3491, 3367 (NH2), 1657 (CO) cm_1. 1H 
NMR (CDCl3) d: 1.41 (t, 3H, J = 8.0Hz, CH3), 4.42 (q, 2H, J = 8.0 Hz, CH2), 6.03 (br s, 
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2H, exchange with D2O, NH2), 7.84 (d, 1H, J = 8.8 Hz, H-7), 8.29 (dd, 1H, J = 2.0, 8.8 
Hz, H-6), 8.59 (d, 1H, J = 2.0 Hz, H-4); 13C NMR (DMSO- d6) d: 14.3 (q), 60.2 (t), 96.9 
(s), 119.4 (d), 122.0 (d), 124.3 (d), 131.4 (s), 144.5 (s), 144.9 (s), 149.7 (s), 163.9 (s). 
Anal. Calcd. (%) for C11H10N2O4S: C, 49.62; H, 3.79; N, 10.52; found: C, 49.64; H, 
3.81; N, 10.48. 
General procedure for the synthesis of ethyl 3-benzoylamino-5-nitro-
benzo[b]thiophene-2-carboxylates 7a-f 
To a suspension of amine 5 (0.37 mmol) and pyridine (0.56 mmol) was added the 
appropriate benzoyl chloride 11 (0.56 mmol). The reaction mixture was stirred at room 
temperature for about 12 h, and then poured onto stirred water/ice. The precipitate was 
collected by filtration, dried over night. The crude was crystallized from ethyl acetate. 
Ethyl 3-benzoylamino-5-nitro-benzo[b]thiophene-2-carboxylate (7a). Yield 95%. Mp 
200-201 _C. IR nmax: 3606 (NH), 1687, 1679 (CO) cm_1. 1H NMR (CDCl3) d: 1.43 (t, 
3H, J = 8.0 Hz, CH3), 4.44 (q, 2H, J = 8.0 Hz, CH2), 7.48-7.69 (m, 3H, H-3’, H-4’, H-
5’), 7.89 (d, 1H, J = 8.8 Hz, H-7), 8.11 (dd, 2H, J = 2.0, 8.0 Hz, H-2’, H-6’), 8.32 (dd, 
1H, J = 2.0, 8.8 Hz, H-6), 9.24 (d, 1H, J = 2.0 Hz, H-4), 10.69 (s, 1H, NH). 13C NMR 
(CDCl3) d: 14.2 (q), 62.3 (t), 117.3 (s), 121.7 (d), 123.3 (d), 124.2 (d), 127.9 (d), 128.6 
(s), 129.0 (d), 132.8 (d), 132.9 (s), 141.0 (s), 144.5 (s), 145.1 (s), 164.1 (s), 165.3 (s). 
Anal. Calcd. (%) for C18H14N2O5S: C, 58.37; H, 3.81; N, 7.56; found: C, 58.34; H, 
3.84; N, 7.53. 
Ethyl  3-(4-methoxy-benzoylamino)-5-nitro-benzo[b]thiophene-2-carboxylate (7b). 
Yield 82%. Mp 191-192 _C. IR nmax: 3601 (NH), 1696, 1672 (CO) cm_1. 1H NMR 
(CDCl3) d: 1.43 (t, 3H, J = 8.0 Hz, CH3), 3.91 (s, 3H, OCH3), 4.44 (q, 2H, J = 8.0 Hz, 
CH2), 7.05 (d, 2H, J 1⁄4 8.0 Hz, H-3’ ,H-5’ ), 7.89 (d, 1H, J = 9.0 Hz, H-7), 8.07 (d, 2H, J 
= 8.0 Hz, H-2’, H-6’), 8.32 (dd, 1H, J = 2.0, 9.0 Hz, H-6), 9.25 (d, 1H, J = 2.0 Hz, H-4), 
10.64 (s, 1H, NH). 13C NMR (CDCl3) d: 14.2 (q), 55.6 (q), 62.3 (t), 114.1 (d), 114.2 (d), 
121.2 (d), 121.6 (s), 121.8 (s), 126.8 (s), 132.3 (d), 132.8 (d), 141.3 (s), 141.8 (s), 144.5 
(s), 145.0 (s), 164.2 (s), 164.8 (s). Anal. Calcd. (%) for C19H16N2O6S: C, 56.99; H, 
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4.03; N, 7.00; found: C, 56.95; H, 4.07; N, 7.03. 
Ethyl 3-(4-methyl-benzoylamino)-5-nitro-benzo[b]thiophene-2-carboxylate (7c). 
Yield 98%. Mp 231-232 _C. IR nmax: 3607 (NH), 1700, 1677 (CO) cm_1. 1H NMR 
(CDCl3) d: 1.43 (t, 3H, J = 8.0 Hz, CH3), 2.47 (s, 3H, CH3), 4.44 (q, 2H, J = 8.0 Hz, 
CH2), 7.37 (d, 2H, J 1⁄4 8.8 Hz, H-3’,H-5’), 7.90 (d, 1H, J = 8.0 Hz, H-7), 8.00 (d, 2H, J 
1⁄4 8.8 Hz, H-2’, H-6’), 8.33 (dd, 1H, J = 2.0, 8.0 Hz, H-6), 9.25 (d, 1H, J = 2.0 Hz, H-4), 
10.66 (s, 1H, NH). 13C NMR (CDCl3) d: 14.2 (q), 21.6 (q), 62.3 (t), 118.5 (s), 121.7 (d), 
123.3 (d), 124.2 (d), 128.0 (d), 129.7 (d), 130.3 (s), 132.9 (s), 141.2 (s), 143.6 (s), 144.5 
(s), 145.1 (s), 164.1 (s), 165.3 (s). Anal. Calcd. (%) for C19H16N2O5S: C, 59.37; H, 
4.20; N, 7.29; found: C, 59.40; H, 4.17; N, 7.32. 
Ethyl 3-(3,4,5-trimethoxy-benzoylamino)-5-nitro-benzo[b]thiophene-2-carboxylate 
(7d).  Yield 99%. Mp 211-213 _C. IR nmax: 3607 (NH), 1680, 1668 (CO) cm_1. 1H 
NMR (CDCl3) d: 1.46 (t, 3H, J = 8.0 Hz, CH3), 3.98 (s, 3H, OCH3), 4.02 (s, 6H, 2 
OCH3), 4.45 (q, 2H, J = 8.0 Hz, CH2), 7.38 (s, 2H, H-2’,H-6’), 7.93 (d, 1H, J = 8.0 Hz, 
H-7), 8.36 (dd, 1H, J = 2.0, 8.0 Hz, H-6), 9.32 (d, 1H, J = 2.0 Hz, H-4), 10.72 (s, 1H, 
NH). 13C NMR (CDCl3) d: 14.2 (q), 56.4 (q), 61.0 (t), 62.3 (q), 105.3 (d), 117.0 (s), 
117.5 (d), 121.7 (d), 121.9 (d), 128.4 (s), 131.3 (s), 132.8 (s), 141.1 (s), 145.1 (s), 145.6 
(s), 153.4 (s), 164.2 (s), 165.0 (s). Anal. Calcd. (%) for C21H20N2O8S: C, 54.78; H, 
4.38; N, 6.08; found: C, 54.76; H, 4.40; N, 6.10. 
Ethyl 3-(4-trifluoromethyl-benzoylamino)-5-nitro-benzo[b]thiophene-2-carboxylate 
(7e). Yield 74%. Mp 236-237 _C. IR nmax: 3616 (NH), 1695, 1684 (CO) cm_1. 1H 
NMR (CDCl3) d: 1.44 (t, 3H, J = 8.0Hz, CH3), 4.46(q,2H, J = 8.0Hz, CH2), 7.85 (d, 2H, 
J = 8.0Hz, H-3’, H-5’), 7.92 (d, 1H, J = 8.0 Hz, H-7), 8.23 (d, 2H, J = 8.0 Hz, H-2’, H-6’ 
), 8.36 (dd, 1H, J = 2.0, 8.0 Hz, H-6), 9.27 (d, 1H, J = 2.0 Hz, H-4), 10.83 (s, 1H, NH). 
13C NMR (CDCl3) d: 14.2 (q), 62.5 (t), 117.7 (s), 120.9 (s), 121.9 (d), 123.5 (s), 124.1 
(d), 125.0 (s), 126.1 (d), 128.4 (d), 130.6 (d), 132.7 (s), 140.5 (s), 144.4 (s), 151.5 (s), 
164.0 (s), 164.2 (s). Anal. Calcd. (%) for C19H13F3N2O5S: C, 52.06; H, 2.99; N, 6.39; 
found: C, 52.10; H, 2.93; N, 6.42. 
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Ethyl 3-(3-chloro-4-fluoro-benzoylamino)-5-nitro-benzo[b]thiophene-2-carboxylate 
(7f). Yield 57.4%. Mp 218-219 _C. IR nmax: 3620 (NH), 1693, 1684 (CO) cm_1. 1H 
NMR (CDCl3) d: 1.47 (t, 3H, J = 8.0 Hz, CH3), 4.49 (q, 2H, J = 8.0 Hz, CH2), 7.36 (t, 
1H, J = 10.0 Hz, H-5’), 7.94 (d, 1H, J = 8.0 Hz, H-7), 8.03 (dq, 1H, J = 2.0, 10.0 Hz, H- 
6’ ), 8.23 (dd, 1H, J =  2.0, 8.0 Hz, H-6), 8.37 (dd, 1H, J = 2.0, 10.0 Hz, H- 2’ ), 9.24 (d, 
1H, J = 2.0 Hz, H-4), 10.83 (s, 1H, NH). 13C NMR (CDCl3) d: 14.2 (q), 62.5 (t), 117.3 
(d, J = 5 Hz), 117.4 (s), 121.8 (d), 122.5 (s), 123.4 (s), 123.9 (d), 128.1 (d), 130.3 (s), 
131.4 (s), 132.6 (d), 140.5 (s), 144.4 (s), 145.2 (s), 161.0 (d, J = 30 Hz), 163.2 (s), 164.2 
(s). Anal. Calcd. (%) for C18H12ClFN2O5S: C, 51.13; H, 2.86; N, 6.63; found: C, 
51.16; H, 2.90; N, 6.65. 
General procedure for the synthesis of ethyl 5-amino-3 
benzoylaminobenzo[b]thiophene-2-carboxylates  8 a-f 
A suspension of 5-nitro compound 7 a-f (1 mmol), 10% Pd/C (0.05 g) in ethanol was 
subjected to hydrogenation using a Parr Hydrogenation apparatus at 500 psi for 2 h. After 
then, the catalyst was removed by filtration and the filtrate was concentrated under 
reduced pressure. The crude was recrystallized from ethanol. 
Ethyl 5-amino-3-benzoylamino-benzo[b]thiophene-2-carboxylate (8a). Yield 91%. 
Mp 184-185 _C. IR nmax: 3612, 3356 (NH2), 3293 (NH), 1688, 1664 (CO) cm_1. 1H 
NMR (CDCl3) d: 1.42 (t, 3H, J = 8.0 Hz, CH3), 4.41 (q, 2H, J = 8.0 Hz, CH2), 4.83 (br 
s, 2H, NH2) 6.96 (dd, 1H, J = 2.0, 8.0 Hz, H-6), 7.49 (d, 1H, J = 2.0 Hz, H-4), 7.52-7.63 
(m, 5H, C6H5), 8.10 (d, 1H, J = 8.0 Hz, H-7), 10.48 (s, 1H, NH). 13C NMR (CDCl3) d: 
14.3 (q), 61.6 (t), 111.0 (d), 119.0 (d), 123.2 (d), 127.8 (d), 128.9 (d), 130.4 (s), 131.1 (s), 
132.4 (d), 133.9 (s), 139.1 (s), 143.6 (s), 146.6 (s), 161.2 (s), 165.9 (s). Anal. Calcd. (%) 
for C18H16N2O3S: C, 63.51; H, 4.74; N, 8.23; found: C, 63.53; H, 4.72; N, 8.21. 
Ethyl 5-amino-3-(4-methoxy-benzoylamino)-benzo[b]thio- phene-2-carboxylate 
(8b). Yield 98%. Mp 160-161 _C. IR nmax: 3613, 3360 (NH2), 3296 (NH), 1683, 1660 
(CO) cm_1. 1H NMR (DMSO-d6) d: 1.19 (t, 3H, J = 8.0 Hz, CH3), 3.91 (s, 3H, OCH3), 
4.24 (q, 2H, J = 8.0 Hz, CH2), 5.08 (br s, 2H, NH2) 6.94 (d, 1H, J = 2.0 Hz, H-4), 7.09-
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7.17 (m, 3H, H-6, H-3’, H-5’), 7.50 (d, 1H, J = 8.0 Hz, H-7), 8.07 (d, 2H, J = 8.8 Hz, H-
2’, H-6’), 10.04 (s, 1H, NH). 13C NMR (DMSO-d6) d: 13.9 (q), 55.6 (q), 60.8 (t), 113.5 
(d), 113.7 (d), 118.8 (d), 119.2 (d), 126.3 (s), 127.2 (s), 129.6 (d), 130.2 (s), 134.2 (s), 
138.8 (s), 139.7 (s), 161.7 (s), 161.9 (s), 164.9 (s). Anal. Calcd. (%) for C19H18N2O4S: 
C, 61.61; H, 4.90; N, 7.56; found: C, 61.59; H, 4.93; N, 7.52. 
Ethyl 5-amino-3-(4-methyl-benzoylamino)-benzo[b]thiophene-2-carboxylate (8c). 
Yield 70%. Mp 208-209 _C. IR nmax: 3613, 3360 (NH2), 3297 (NH), 1682, 1665 (CO) 
cm_1. 1H NMR (DMSO-d6): d 1.18 (t, 3H, J = 8.0 Hz, CH3), 2.42 (s, 3H, CH3), 4.23 (q, 
2H, J = 8.0 Hz, CH2), 5.32 (br s, 2H, NH2) 6.90-6.95 (m, 2H, H-4, H- 6), 7.38 (d, 2H, J 
1⁄4 8.0 Hz, H-3’, H-5’), 7.64 (d, 1H, J = 8.0 Hz, H-7), 7.97 (d, 2H, J = 8.8 Hz, H-2’, H-
6’), 10.20 (s, 1H, NH). 13C NMR (DMSO-d6) d: 14.5 (q), 21.5 (q), 61.3 (t), 105.8 (d), 
118.3 (d), 123.0 (d), 125.9 (s), 127.8 (d), 129.0 (d), 131.0 (s), 135.5 (s), 137.1 (s), 141.9 
(s), 146.5 (s), 161.9 (s), 163.0 (s), 165.2 (s). Anal. Calcd. (%) for C19H18N2O3S: C, 
64.39; H, 5.12; N, 7,90; found: C, 64.42; H, 5.15; N, 7.93. 
Ethyl 5-amino-3-(3,4,5-trimethoxy-benzoylamino)-benzo[b]thiophene-2-carboxylate 
(8d). Yield 93%. Mp 182-183 _C. IR nmax: 3404, 3316 (NH2), 3213 (NH), 1696, 1655 
(CO) cm_1. 1H NMR (DMSO-d6) d: 1.20 (t, 3H, J = 8.0 Hz, CH3), 3.76 (s, 3H, OCH3), 
3.88 (s, 6H, 2 OCH3), 4.22 (q, 2H, J = 8.0 Hz, CH2), 5.34 (br s, 2H, NH2) 6.87 (d, 1H, J 
= 2.0 Hz, H-4), 6.93 (dd, 1H, J = 2.0, 8.0 Hz, H-6), 7.41 (s, 2H, H-2’, H-6’), 7.65 (d, 1H, 
J = 8.0 Hz, H-7), 10.22 (s, 1H, NH). 13C NMR (DMSO-d6) d: 14.0 (q), 56.1 (q), 60.1 
(q), 60.8 (t), 99.5 (s), 105.3 (d), 105.7 (d), 118.3 (s), 123.0 (d), 125.8 (d), 128.9 (s), 135.2 
(s), 137.1 (s), 140.5 (s), 146.5 (s), 152.7 (s), 161.8 (s), 164.6 (s). Anal. Calcd. (%) for 
C21H22N2O6S: C, 58.59; H, 5.15; N, 6.51; found: C, 58.63; H, 5.17; N, 6.55. 
Ethyl 5-amino-3-(4-trifluoromethyl-benzoylamino)-benzo[b]thiophene-2-
carboxylate (8e). Yield 80%. Mp 198-199 _C. IR nmax: 3612, 3356 (NH2), 3293 (NH), 
1688, 1664 (CO) cm_1. 1H NMR (DMSO-d6) d: 1.18 (t, 3H, J = 8.0 Hz, CH3), 4.22 (q, 
2H, J = 8.0 Hz, CH2), 5.34 (br s, 2H, NH2) 6.89 (d, 1H, J = 2.0 Hz, H-4), 6.93 (dd, 1H, J 
= 2.0, 8.0 Hz, H-6), 7.66 (d, 1H, J = 8.0 Hz, H-7), 7.98 (d, 2H, J = 8.8 Hz, H-3’, H-5’), 
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8.25 (d, 2H, J = 8.8 Hz, H-2’, H-6’), 10.54 (s, 1H, NH). 13C NMR (DMSO-d6) d: 14.0 
(q), 60.9 (t), 119.1 (s), 118.3 (d), 120.8 (s), 123.1 (d), 123.7 (s), 125.5 (d), 126.9 (s), 
128.6 (d), 129.1 (d), 134.4 (s), 137.1 (s), 146.6 (s), 147.9 (s), 161.7 (s), 164.3 (s). Anal. 
Calcd. (%) for C19H15F3N2O3S: C, 55.88; H, 3.70; N, 6.86; found: C, 55.84; H, 3.73; 
N, 6.82. 
Ethyl 5-amino-3-(3-chloro-4-fluoro-benzoylamino)-benzo[b]thiophene-2-
carboxylate (8f). Yield 52%. Mp 226-227 _C. IR nmax: 3615, 3360 (NH2), 3290 (NH), 
1689, 1667 (CO) cm_1. 1H NMR (CDCl3) d: 1.18 (t, 3H, J = 8.0 Hz, CH3), 4.23 (q, 2H, 
J = 8.0 Hz, CH2), 5.35 (br s, 2H, NH2), 6.87 (d, 1H, J = 2.0 Hz, H-4), 6.93 (dd, 1H, J = 
2.0, 10.0Hz,H-2’), 7.65 (d, 1H, J = 8.0Hz,H-7), 7.66 (t, 1H, J = 10.0Hz,H-5’), 8.08 (dq, 
1H, J = 2.0, 10.0 Hz, H-6’), 8.29 (dd, 1H, J = 2.0, 8.0 Hz, H-6), 10.34 (s, 1H, NH). 13C 
NMR (DMSO-d6) d: 14.0 (q), 61.1 (t), 99.5 (s), 117.3 (d), 118.5 (s), 120.0 (d), 122.6 (s), 
123.2 (s), 125.8 (d), 128.9 (d), 131.5 (s), 134.3 (d), 137.0 (s), 141.1 (s), 146.6 (s), 161.6 
(d), 163.2 (s), 164.3 (s). Anal. Calcd. (%) for C18H14ClFN2O3S: C, 55.03; H, 3.59; N, 
7.13; found: C, 55.04; H, 3.60; N, 7.22. 
General procedure for the synthesis of ethyl 3-benzoylamino- 5-[(1H-imidazol-4-yl-
methyl)-amino]-benzo[b]thiophene-2- carboxylates 10 a-l 
To a suspension of the 8 a-f (1.25 mmol) and the appropriate aldehyde (1.6 mmol) in dry 
ethanol (10 mL) was added acetic acid up to pH 4. The mixture was stirred for 30 min, 
and then NaCNBH3 (1.6 mmol) was added by stirring at room temperature for further 6-
24 h. The reaction solvent was removed under reduced pressure and the crude product 
was purified by chromatography column using dichloromethane/methanol 98:2 as eluent. 
Recrystallized from ethanol. 
Ethyl 3-benzoylamino-5-[(1H-imidazol-4-yl-methyl)-amino]- benzo[b]thiophene-2-
carboxylate (10a). Yield 76%. Mp 184-185 _C. IR nmax: 3301, 3245 (NH), 1684, 1668 
(CO) cm_1. 1H NMR (DMSO-d6) d: 1.19 (t, 3H, J = 8.0 Hz, CH3), 4.24 (q, 2H, J = 8.0 
Hz, CH2), 4.52-4.54 (m, 3H, NH, NCH2) 6.89 (s, 1H, H-5’’), 7.19 (s, 1H, H-2’’), 7.29 
(dd, 1H, J =  2.0, 8.0 Hz, H-6), 7.56-7.65 (m, 5H, C6H5), 7.73 (d, 2H, J = 8.0 Hz, H-7), 
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8.04 (d, 1H, J = 2.0 Hz, H-4) 10.39 (s, 1H, NH), 12.10 (br s, 1H, NH). 13C NMR 
(DMSO-d6) d: 13.5 (q), 46.1 (t), 60.4 (t), 100.3 (d), 119.7 (s), 122.8 (s), 122.9 (d), 125.9 
(s), 128.4 (d), 129.5 (d), 131.1 (s), 132.5 (s), 134.4 (d), 135.1 (d), 135.7 (d), 137.0 (d), 
146.2 (s), 149.5 (s), 161.6 (s), 165.9 (s). Anal. Calcd. (%) for C22H20N4O3S: C, 62.84; 
H, 4.79; N, 13.32; found: C, 62.86; H, 4.80; N, 13.35. 
Ethyl5-[(1H-imidazol-4-yl-methyl)-amino]-3-(4-methoxy-benzoylamino)-
benzo[b]thiophene-2-carboxylate (10b). Yield 62%. Mp 124-125 _ C. IR nmax: 3306, 
3243 (NH), 1682, 1667 (CO) cm_1. 1H NMR (DMSO-d6) d: 1.15 (t, 3H, J = 8.0 Hz, 
CH3), 3.86 (s, 3H, OCH3), 4.20 (q, 2H, J = 8.0 Hz, CH2), 4.28 (d, 2H, J = 2.0 Hz, 
NCH2) 5.34 (t, 1H, J = 2.0 Hz, NH), 6.91 (s, 1H, H-5’’ ), 7.04-7.16 (m, 4H, H-3’ , H-5’ , 
H-2’’ , H-6), 7.54 (d, 1H, J = 8.0 Hz, H-7), 7.58 (d, 1H, J = 2.0 Hz, H-4), 8.06 (d, 2H, J = 
8.0 Hz, H-2’, H-6’) 10.06 (s, 1H, NH), 11.96 (br s, 1H, NH). 13C NMR (DMSO-d6) d: 
14.0 (q), 40.1 (t), 55.4 (q), 60.8 (t), 99.5 (s), 103.5 (d), 113.6 (d), 113.7 (s), 117.7 (d), 
122.0 (s), 122.5 (s), 122.9 (d), 126.2 (d), 129.7 (d), 134.8 (d), 135.6 (s), 137.0 (s), 146.6 
(s), 161.9 (s), 162.0 (s), 164.9 (s). Anal. Calcd. (%) for C23H22N4O4S: C, 61.32; H, 
4.92; N, 12.44; found: C, 61.31; H, 4.94; N, 12.48. 
Ethyl5-[(1H-imidazol-4-yl-methyl)-amino]-3-(4-methyl-benzoylamino)-
benzo[b]thiophene-2-carboxylate (10c). Yield 58%. Mp 138-139 _ C. IR nmax: 3307, 
3253 (NH), 1680, 1669 (CO) cm_1. 1H NMR (DMSO-d6) d: 1.18 (t, 3H, J 1⁄4 8.0 Hz, 
CH3), 2.42 (s, 3H, CH3), 4.14 (d, 2H, J = 2.0 Hz, NCH2), 4.23 (q, 2H, J = 8.0 Hz, CH2), 
6.11 (t, 1H, J = 2.0 Hz, NH), 6.91-6.93 (m, 2H, H-4, H-5’’), 7.06 (dd, 1H, J = 2.0, 8.0 
Hz, H-6), 7.38 (d, 2H, J = 8.0 Hz, H-3’ , H-5’ ), 7.56 (s, 1H, H-2’’ ), 7.68 (d, 1H, J = 8.0 
Hz, H-7), 7.97 (d, 2H, J = 8.0 Hz, H-2’, H-6’), 10.23 (s, 1H, NH), 11.93 (br s, 1H, NH). 
13C NMR (DMSO-d6) d: 14.0 (q), 21.0 (q), 40.4 (t), 60.8 (t), 103.4 (d), 117.4 (d), 117.7 
(d), 122.7 (s), 122.9 (d), 126.1 (s), 127.8 (d), 129.0 (d), 131.3 (s), 134.8 (d), 135.3 (s), 
137.0 (s), 141.8 (s), 146.6 (s), 161.9 (s), 165.3 (s), 172.0 (s). Anal. Calcd. (%) for 
C23H22N4O3S: C, 63.58; H, 5.10; N, 12.89; found: C, 63.60; H, 5.12; N, 12.85. 
Ethyl5-[(1H-imidazol-4-yl-methyl)-amino]-3-(3,4,5-trimethoxy-benzoylamino)-
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benzo[b]thiophene-2-carboxylate (10d). Yield 94%. Mp 165-166 _C. IR: 3301, 3245 
(NH), 1684, 1668 (CO) cm_1. 1H NMR (DMSO-d6) d: 1.20 (t, 3H, J = 7.0 Hz, CH3), 
3.76 (s, 3H, OCH3), 3.89 (s, 6H, 2 OCH3), 4.34 (d, 2H, J = 1.8 Hz, NCH2), 4.24 (q, 2H, 
J 1⁄4 7.0 Hz, CH2), 6.14 (t,1H, J = 1.8 Hz, NH), 6.89 (d,1H, J = 1.8 Hz, H-4) 6.95 (s, 1H, 
H-5’’ ), 7.07 (dd, 1H, J = 1.8, 8.8 Hz, H-6), 7.40 (s, 2H, H-2’, H-6’), 7.58 (s, 1H, H-2’’), 
7.70 (d, 1H, J = 8.8 Hz, H-7), 10.25 (s, 1H, NH), 12.22 (br s, 1H, NH). 13C NMR 
(DMSO-d6) d: 14.0 (q), 40.2 (t), 56.0 (q), 60.1 (q), 60.2 (t), 99.5 (s), 103.3 (s), 105.3 (d), 
117.7 (d), 122.9 (d), 126.1 (d), 129.1 (s), 129.5(s), 134.8 (s), 135.2 (d), 137.0 (s), 140.4 
(s), 146.6 (s), 152.6 (d), 156.9 (s), 161.8 (s), 164.9 (s). Anal. Calcd. (%) for 
C25H26N4O6S: C, 58.81; H, 5.13; N, 10.97; found: C, 58.83; H, 5.14; N, 10.95. 
Ethyl5-[(1H-imidazol-4-yl-methyl)-amino]-3-(4-trifluoromethyl-benzoylamino)-
benzo[b]thiophene-2-carboxylate (10e). Yield 84%. Mp 192-193 _C. IR nmax: 3298, 
3233 (NH), 1679, 1665 (CO) cm_1. 1H NMR (DMSO-d6) d: 1.21 (t, 3H, J = 6.0 Hz, 
CH3), 4.25 (q, 2H, J = 6.0 Hz, CH2), 4.53-4.56 (m, 3H, NCH2, NH), 6.90 (1, 1H, H-5’’ 
), 7.19 (d, 1H, J = 2.0 Hz, H-4), 7.57 (s, 1H, H-2’’ ), 7.74 (d, 1H, J = 8.0 Hz, H-7), 7.99 
(d, 2H, J = 10.0 Hz, H-3’, H-5’), 8.22 (d, 2H, J = 10.0 Hz, H-2’, H-6’), 10.56 (s, 1H, 
NH), 11.93 (br s, 1H, NH). 13C NMR (DMSO-d6) d: 14.0 (q), 40.0 (t), 60.9 (t), 99.5 (s), 
113.0 (d), 117.9 (d), 121.1 (d), 125.4 (s), 125.5 (s), 126.2 (d), 128.6 (d), 129.0 (s), 130.6 
(d), 134.4 (d), 134.8 (s), 136.9 (s), 137.8 (s), 146.7 (s), 161.7 (s), 164.5 (s), 166.3 (s). 
Anal. Calcd. (%) for C23H19F3N4O3S: C, 56.55; H, 3.92; N, 11.47; found: C, 56.53; H, 
3.91; N, 11.49. 
Ethyl 5-[(1H-imidazol-4-yl-methyl)-amino]-3-(3-chloro-4- fluoro-benzoylamino)-
benzo[b]thiophene-2-carboxylate (10f). Yield 43%. Mp 162-163 _C. IR nmax: 3306, 
3253 (NH), 1690, 1669 (CO) cm_1. 1H NMR (CDCl3) d: 1.34 (t, 3H, J = 8.0 Hz, CH3), 
4.26-4.30 (m, 3H, NH, NCH2), 4.32 (q, 2H, J = 8.0 Hz, CH2), 6.82 (dd, 1H, J = 2.0, 8.0 
Hz, H-6), 6.96 (s, 1H, H-5’’), 7.24 (t, 1H, J = 8.0 Hz, H-5’), 7.43 (d, 1H, J = 8.0 Hz, H-
7), 7.47 (s, 1H, H-2’’), 7.73 (d, 1H, J = 2.0 Hz, H-4), 7.89 (dq, 1H, J = 2.0, 8.0 Hz, H-6’ 
), 8.07 (dd, 1H, J = 2.0, 8.0 Hz, H-2’ ), 9.73 (s, 1H, NH), 10.45 (br s, 1H, NH). 13C 
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NMR (DMSO-d6) d: 14.0 (q), 40.6 (t), 60.9 (t), 103.0 (d), 117.0 (d), 117.9 (d), 119.6 (s), 
120.0 (s), 123.0 (d), 123.4 (s), 126.1 (s), 129.0 (d), 129.1 (d), 130.3 (d), 131.7 (s), 134.4 
(s), 134.8 (d), 136.9 (s), 146.8 (s), 161.7 (s), 163.3 (s), 172.2 (s). Anal. Calcd. (%) for 
C22H18ClFN4O3S: C, 55.87; H, 3.84; N, 11.85; found: C, 55.91; H, 3.81; N, 11.88. 
Ethyl 3-benzoylamino-5-[(5-methyl-1H-imidazol-4-yl- methyl)-amino]-
benzo[b]thiophene-2-carboxylate (10g). Yield 49%. Mp 169-171 _ C. IR nmax: 3607, 
3336 (NH), 1671, 1543 (CO) cm_1. 1H NMR (DMSO-d6) d: 1.22 (t, 3H, J = 6.0 Hz, 
CH3), 2.24 (s, 3H, CH3), 4.22-4.33 (m, 4H, OCH2, NCH2), 5.27 (t, 1H, J = 4.0 Hz, NH), 
7.27 (d, 1H, J = 8.0 Hz, H-7), 7.52 (s, 1H, H-2’’ ), 7.60-7.66 (m, 5H, C6H5), 8.12 (d, 1H, 
J = 2.0 Hz, H-4), 8.15 (dd, 1H, J = 2.0, 8.0 Hz, H-6), 10.25 (s, 1H, NH), 11.96 (br s, 1H, 
NH). 13C NMR (DMSO-d6) d: 10.0 (q), 14.0 (q), 39.0 (t), 60.8 (t), 102.8 (d), 117.9 (d), 
122.9 (s), 123.5 (d), 125.0 (s), 125.9 (s), 127.8 (d), 128.4 (d), 129.2 (d), 131.0 (s), 132.3 
(s), 132.7 (d), 146.5 (s), 147.5 (s), 160.8 (s), 165.4 (s), 171.9 (s). Anal. Calcd. (%) for 
C23H22N4O3S: C, 63.58; H, 5.10; N, 12.89; found: C, 63.54; H, 5.06; N, 12,86. 
Ethyl 5-[(5-methyl-1H-imidazol-4-yl-methyl)-amino]-3-(4- methoxy-benzoylamino)-
benzo[b]thiophene-2-carboxylate (10h). Yield 34%. Mp 165-1667 °C. IR nmax: 3603, 
3328 (NH), 1670, 1611 (CO) cm_1. 1H NMR (DMSO-d6) d: 1.18 (t, 3H, J = 6.2 Hz, 
CH3), 2.09 (s, 3H, CH3), 3.87 (s, 3H, OCH3), 4.06 (br s, 2H, CH2), 4.22 (q, 2H, J = 6.2 
Hz, CH2), 6.07 (br s, 1H, NH), 6.87 (s, 1H, H-4), 7.00-7.18 (m, 3H, H-6, H-3’, H-5’), 
7.51 (s, 1H, H-2’’), 7.67 (d, 1H, J = 8.2 Hz, H-7), 8.06 (d, 2H, J = 8.0 Hz, H-2’ , H-6’ ), 
10.17 (s, 1H, NH), 11.36 (s, 1H, NH). 13C NMR (DMSO-d6) d: 10.0 (q), 14.0 (q), 40.1 
(t), 55.4 (q), 60.7 (t), 99.5 (s), 102.9 (d), 110.5 (s), 113.6 (s), 117.9 (d), 121.3 (s), 122.5 
(d), 122.8 (s), 126.1 (d), 129.5 (s), 129.7 (d), 133.1 (d), 135.6 (s), 137.0 (s), 146.5 (s), 
162.0 (s), 164.8 (s). Anal. Calcd. (%) for C24H24N4O4S: C, 62.05; H, 5.21; N, 12.06; 
found: C, 62.09; H, 5.24; N, 12.10. 
Ethyl 5-[(5-methyl-1H-imidazol-4-yl-methyl)-amino]-3-(4- methyl-benzoylamino)-
benzo[b]thiophene-2-carboxylate (10i). Yield 32%. Mp 164-166 °C. IR nmax: 3615, 
3360 (NH), 1689, 1667 (CO) cm_1. 1H NMR (DMSO-d6) d: 1.18 (t, 3H, J = 6.2 Hz, 
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CH3), 2.09 (s; 3H, CH3), 2.42 (s, 3H, CH3), 4.06 (br, s, 2H, CH2), 4.22 (q, 2H, J = 6.2 
Hz, CH2), 6.05 (br s, 1H, NH), 6.88 (d, 1H, J = 2.0 Hz, H-4), 7.06 (dd, 1H, J = 2.0, 8.6 
Hz, H-6), 7.38 (d, 2H, J = 8.0 Hz, H-3’, H-5’), 7.44 (s, 1H, H-2’’), 7.67 (d, 1H, J = 8.6 
Hz, H-7), 8.98 (d, 2H, J = 8.0 Hz, H- 2’, H-6’), 10.23 (s, 1H, NH), 11.84 (br s, 1H, NH). 
13C NMR (DMSO-d6) d: 10.1 (q), 14.0 (q), 21.0 (q), 39.0 (t), 60.8 (t), 102.8 (d), 117.9 
(d), 122.8 (d), 126.1 (s), 127.8 (d), 128.9 (d), 129.6 (s), 131.2 (s), 133.1 (d), 135.4 (s), 
137.0 (s), 141.8 (s), 146.6 (s), 161.9 (s), 165.3 (s), 171.1 (s), 172.1 (s). Anal. Calcd. (%) 
for C24H24N4O3S: C, 64.27; H, 5.39; N, 12.49; found: C, 64.31; H, 5.36; N, 12.51. 
Ethyl 5-[(5-methyl-1H-imidazol-4-yl-methyl)-amino]-3- (3,4,5-trimethoxy-
benzoylamino)-benzo[b]thiophene-2-carboxylate (10j). Yield 56%. Mp 167-168 °C. 
IR nmax: 3617, 3363 (NH), 1690, 1665 (CO) cm_1. 1H NMR (DMSO-d6) d: 1.25 (t, 
3H, J = 6.2 Hz, CH3), 2.16 (s; 3H, CH3), 3.81 (s, 3H, OCH3), 3.94 (s, 6H, OCH3x2), 
4.35 (d, 2H, J = 1.6 Hz, CH2), 4.29 (q, 2H, J = 7.0 Hz, CH2), 6.23 (t, 1H, J = 1.6Hz, 
NH), 6.85 (d, 1H, J = 1.6Hz, H-4), 7.11 (dd, 1H, J = 2.0, 8.8 Hz, H-6), 7.46 (s, 2H, H-2’, 
H-6’), 7.62 (s, 1H, H-2’’), 7.74 (d. 1H, J = 8.8 Hz, H-7), 10.27 (s, 1H, NH), 12.09 (br s, 
1H, NH). 13C NMR (DMSO-d6) d: 14.0 (q), 21.0 (q), 40.1 (t), 56.0 (q), 60.1 (q), 60.8 
(t), 99.5 (s), 102.7 (s), 105.3 (d), 117.9 (s), 123.0 (d), 126.1 (s), 129.1 (s), 133.2 (d), 
135.2 (s), 137.0 (s), 140.3 (s), 140.4 (s), 146.6 (s), 152.6 (d), 161.8 (s), 164.8 (s), 172.0 
(s). Anal. Calcd. (%) for C26H28N4O6S: C, 59.53; H, 5.38; N, 10.68; found: 59.56; H, 
5.40; N, 10.66. 
Ethyl5-[(5-methyl-1H-imidazol-4-yl-methyl)-amino]-3-(4-trifluoromethyl-
benzoylamino)-benzo[b]thiophene-2-carboxylate (10k). Yield 34%. Mp 171-173 °C. 
IR nmax: 3612, 3294 (NH), 1691, 1644 (CO) cm_1. 1H NMR (DMSO-d6) d: 1.18 (t, 
3H, J = 7.0 Hz, CH3), 2.08 (s, 3H, CH3), 4.05 (br s, 2H, CH2), 4.22 (q, 2H, J = 7.0 Hz, 
CH2), 6.03 (br s, 1H, NH), 6.88 (d, 1H, J = 2.0 Hz, H-4), 7.06 (dd, 1H, J = 2.0, 8.6 Hz, 
H-6), 7.44 (s, 1H, H-2’’), 7.68 (d, 1H, J = 8.6 Hz, H-7), 7.97 (d, 2H, J = 8.2 Hz, H-3’, H-
5’), 8.20 (d, 2H, J = 8.2 Hz, H-2’, H-6’), 10.53 (s, 1H, NH), 11.67 (br s, 1H, NH). 13C 
NMR (DMSO-d6): d 10.3 (q), 14.0 (q), 39.1 (t), 60.9 (t), 99.5 (s), 102.4 (d), 118.1 (d), 
122.9 (d), 123.6 (s), 125.4 (s), 125.5 (d), 126.1 (s), 128.7 (d), 131.9 (s), 133.1 (d), 134.5 
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(s), 137.0 (s), 137.9 (s), 146.8 (s), 161.7 (s), 164.5 (s), 172.0 (s). Anal. Calcd. (%) for 
C24H21F3N4O3S: C, 57.36; H, 4.21; N, 12.15; found: C, 57.46; H, 4.31; N, 12.25. 
Ethyl5-[(5-methyl-1H-imidazol-4-yl-methyl)-amino]-3-(3-chloro-4-fluoro-
benzoylamino)-benzo[b]thiophene-2-carboxylate (10l). Yield 35%. Mp 184.7-186 °C. 
IR nmax: 3607, 3332 (NH), 1701, 1655 (CO) cm_1. 1H NMR (DMSO-d6) d: 1.24 (t, 
3H, J = 7.1 Hz, CH3), 2.15 (s, 3H, CH3), 4.11 (br s, 2H, CH2), 4.28 (q, 2H, J = 7.1 Hz, 
CH2), 6.10 (br s, 1H, NH), 6.92 (d, 1H, J = 1.7 Hz, H-4), 7.12 (dd, 1H, J = 8.8 Hz, H-6), 
7.47 (s, 1H, H-2’’ ), 7.66-7.75 (m, 2H, H-7, H-2’ ), 8.13 (dd, 1H, J = 2.1, 13.3 Hz, H-6’), 
8.34 (dd, 1H, J = 2.0, 7.1 Hz, H-5’), 10.50 (s, 1H, NH) 11.96 (br s, 1H, NH). 13C NMR 
(DMSO-d6) d: 10.5 (q), 14.0 (q), 39.1 (t), 60.9 (t), 99.5 (s), 102.4 (d), 116.9 (d), 117.4 
(d), 118.1 (d), 119.6 (s), 119.9 (s), 123.0 (d), 123.5 (s), 126.1 (s), 129.2 (d), 130.3 (d), 
131.7 (s), 134. 5 (s), 137.0 (s), 146.8 (s), 161.7 (s), 163.3 (s), 172.2 (s). Anal. Calcd. (%) 
for C23H20ClFN4O3S: C, 56.73; H, 4.14; N, 11.50; found: C, 56.77; H, 4.10; N, 11.54. 
Biology 
Chemicals and reagents 
Propidium iodide, ribonuclease A (RNAse A), 3-(4,5-dimethyl-2- thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT), and DMSO were obtained from Sigma Aldrich 
(St. Louis, MO, USA). RPMI, fetal bovine serum (FBS), phosphate buffered saline 
(PBS), L-glutamine solution (200 mM), trypsin-EDTA solution (170.000 U/l trypsin and 
0.2 g/l EDTA) and penicillin-streptomycin solution (10.000 U/ml penicillin and 10 
mg/ml streptomycin) were purchased from Lonza (Verviers, Belgium). 
Cell culture 
The cancer cell line HeLa (Human epithelial cervical cancer) was obtained from 
American Type Culture Collection (ATCC) (Rockville, MD, USA). The cells were 
cultured in RPMI supplemented with 5% FBS, 2 mM L-glutamine, 50 IU/ml penicillin, 
and 50 mg/ml streptomycin and maintained in a humidified atmosphere with 5% CO2 at 
37 °C. The cells were routinely cultured in 75 cm2 culture flasks and were trypsinized 
using trypsin-EDTA when the cells reached approximately 80% confluence. 
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Exponentially growing cells were used for experiments. 
Antiproliferative evaluation assay  
3-benzoylamino-benzo[b]thiophene derivatives 10 a-l and 8 a-f were submitted to the 
MTT assay to assess the growth inhibition activity against HeLa cells. The MTT assay is 
a measurement of cell metabolic activity, quite effective in estimating cell proliferation, 
which is based on the protocol first described by Mossmann (104). The assay was 
performed as previously described (105). The cells were seeded into a series of standard 
96-well plates in 100 ml of complete culture medium at 1.0 104 cells/cm2. Cells were 
incubated for 24 h under 5% CO2 at 37 °C and the medium was then replaced with 100 
ml of fresh medium supplemented by 5% (v/ v) FBS containing the treatments. 
Benzothiophene derivatives were previously dissolved in DMSO to obtain 20 mM stock 
solutions. Working solutions were freshly prepared on the day of testing by dilutions of 
the stock solutions in the complete culture medium. For the experiments a concentration 
range from 50 to 0.05 mM was used. 24 h after seeding aliquots of 100 ml of different 
solutions at the appropriate concentrations were added to the appropriate wells and the 
cells were incubated for 48 h without renewal of the medium. In each experiment, 
DMSO concentration never exceeded 0.25% and culture medium with 0.25% DMSO 
was used as control. After the incubation time, cells were washed and 100 mL FBS-free 
medium containing 0.5 mg/mL of MTT was added. The medium was discarded after a 4 
h incubation at 37 °C and formazan blue formed in the cells was dissolved in DMSO. 
The absorbance (optical density, OD) at 570 nm of MTT-formazan was measured in a 
microplate reader. As the absorbance is directly proportional to the number of living, 
metabolically active cells, the percentage of growth (PG) to with respect to untreated cell 
control for each drug concentrations was calculated according to one of the following 
two expressions: 
if  (ODtest – Odtzero) > 0; then  
PG = 100 x (ODtest – Odtzero)/(ODctr – Odtzero) 
if  (ODtest _ ODtzero) < 0; then  
PG = 100 (ODtest – Odtzero)/ODtzero 
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where ODtzero is the average of optical density measurements before exposure of cells to 
the test compound, ODtest is the average of optical density measurements after the desired 
period of time, and ODctr is the average of optical density measurements after the desired 
period of time with no exposure of cells to the test compound. The concentration 
necessary for 50% of growth inhibition (GI50) for each derivative was calculated from 
concentration-response curves using linear regression analysis by fitting the test 
concentrations that give PG values above and below the reference value (50%). Each 
result was the mean value of three separate experiments performed in quadruplicate. 
Cell-cycle analysis 
Effects of 3-benzoylamino-benzo[b]thiophene derivatives 8d, 10j, and 10l exposure on 
cell-cycle were performed by DNA staining with propidium iodide (PI) and flow 
cytometry analysis. HeLa cells were seeded on 12 well plates at a density of 2.0 104 
cells/cm2, and treated 24 h after seeding without or with indicated concentrations of the 
test compound for 24 h. Following the treatments, cells were collected, washed in PBS 
and stained with staining solution (20 mg/ml propidium iodide, 200 mg/ml RNAse A and 
0.1% Triton X-100 in PBS), for 30 min at 37 °C. The DNA contents of more than 10,000 
cells were subjected to fluorescence-activated cell sorting (FACS) analysis (Coulter® 
Epics® XLTM, Beckman) and the percentage of cells belonging to the different 
compartments of the cell cycle was determined. All experiments were performed in 
duplicate and reproduced two times. 
Statistical analysis 
All data are expressed as mean ± SD. Statistical difference was calculated using unpaired 
Student's t-test. Bonferroni least significance difference test was used to examine 
difference between group means. Values of p lower than 0.05 were considered 
significant. 
Computational details 
The compounds of the Anti-Cancer Agents Mechanism Database (NCI ACAM 
Database) (96)(97)(98), were drawn and optimized in vacuo by Ligprep software of 
MAESTRO SUITE (106). The NCI ACAM Database entries containing cations or 
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consisting of a mix of two structures were excluded. Thus the starting database was 
constituted from 114 compounds classified in six mechanism of action: 30, Alkylating 
Agents; 13, Antimitotic Agents; 24, Topoisomerase I Inhibitors; 15, Topoisom- erase II 
Inhibitors; 16, RNA/DNA Antimetabolites; 16, DNA Anti- metabolites (Table 2). 2D 
and 3D molecular descriptors were calculated for all structures to achieve all the 
structural information useful for building a lock model database. Each descriptor value 
range is delimited by µDj(MA) ± sDj(MA), where (MA) is a specific mechanism of 
action, mDj(MA) is the molecular descriptor j average value and sDj(MA) is the standard 
deviation of descriptor j. When the molecular descriptor value Dj of a tested structure X 
falls within the defined range (mDj ± sDj) a = 1 (i.e. D1, D3, and Dj), otherwise a = 0. 
Therefore, after processing descriptor values as mentioned above, every training set 
database structure is converted into a binary sequence. Then all of the binary values are 
summed, so the higher is the number of fitted pins (descriptors with a = 1), the higher 
will be the affinity of the investigated compound to a specific class with potential 
anticancer mechanism. Thus, the percentage of affinity A% (Eq. (1)) for each compound 
belonging to training set database has been defined for each class (MA) as: 
A% = Sai; j(MA) Dtot*100     Equation (1) 
where Sai, j (MA) is the sum of all fitted molecular descriptors for the MA class and Dtot 
is the total of the molecular descriptors used in the VLAK protocol. 
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Benzo[b]furan series 
Synthesis of ethyl 3-amino-5-nitro-benzo[b]furan-2-carboxylate (16) 
To a solution of 2-fluoro-5-nitrobenzonitrile (4) (0.3 g, 1.8 mmol) in dry DMF (5 mL), 
ethyl glycolate (0.3 mL, 3.2 mmol) and potassium carbonate (0.95 g, 6.8 mmol) were 
added at room temperature, and the mixture was heated at 100°C for 12h. After the 
reaction was completed, the reaction mixture was cooled and poured in water/ice. The 
precipitate was collected by filtration and dried to give orange-red needles of 16. Yield 
63%. Mp 195-196 °C. IR νmax: 3453, 3450 (NH2), 1675 (CO) cm-1. 1H NMR (CDCl3) δ: 
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1.46 (t, J= 6.0 Hz, 3H, CH3), 4.47 (q, J= 6.0 Hz, 2H, CH2), 5.14 (br s, 2H, NH2), 7.56 (d, 
J= 9.6 Hz, 1H, H-7), 8.37 (dd, J= 2.0, 9.6 Hz, 1H, H-6), 8.59 (d, 1H, J= 2.0Hz, H-4); 13C 
NMR (CDCl3) δ: 14.6, 61.0, 113.2, 116.9, 122.0, 123.9, 131.6, 141.6, 143.4, 156.3, 
161.4. Anal. Calcd. (%) for C11H10N2O5: C, 52.80; H, 4.03; N, 11.23; found: C, 52.85; H, 
4.07; N, 11.26. 
General procedure for the synthesis of ethyl 3-benzoylamino-5-nitro-
benzo[b]furan-2-carboxylates 17a-f 
To a suspension of amine 16 (0.37 mmol) and pyridine (0.56 mmol) was added the 
appropriate benzoyl chloride 6 (0.56 mmol). The reaction mixture was stirred at room 
temperature for about 12h, and then poured onto stirred water/ice. The precipitate was 
collected by filtration, dried over night. The crude was recrystallized from ethylacetate. 
Ethyl 3-benzoylamino-5-nitro-benzo[b]furan-2-carboxylate (17a) 
Yield 84%. Mp 172-174 °C. IR νmax: 3607 (NH), 1695, 1672 (CO), 1529, 1343 (NO2) 
cm-1. 1H NMR (CDCl3) δ: 1.50 (t, J= 6.0 Hz, 3H, CH3), 4.44 (q, J= 6.0 Hz, 2H, CH2), 
7.50 (d, J= 8.0 Hz, 1H, H-7), 7.56-7.64 (m, 5H, C6H5), 8.06 (dd, J= 2.0, 8.0 Hz, 1H, H-
6), 8.65 (d, J= 2.0 Hz, 1H, H-4), 10.69 (s, 1H, NH). 13C NMR (CDCl3) δ: 14.3, 62.3, 
112.8, 121.5, 124.1, 124.7, 127.7, 129.1, 132.1, 132.4, 132.7, 132.9, 144.0, 156.5, 161.4, 
164.7. Anal. Calcd. (%) for C18H14N2O6: C, 61.02; H, 3.98; N, 7.91; found: C, 61.13; H, 
3.88; N, 7.87. 
Ethyl3-(4-methoxy-benzoylamino)-5-nitro-benzo[b]furan-2-
carboxylate (17b). Yield 81%. Mp 218-219 °C. IR νm a x: 3610 (NH), 
1697, 1675 (CO), 1546, 1345 (NO2) cm- 1. 1H NMR (DMSO-d6) δ:  1.30 (t,  
J= 6.0 Hz, 3H, CH3), 3.88 (s, 3H, OCH3), 4.38 (q, J= 6.0 Hz, 2H, CH2), 
7.15 (d, J= 8.0 Hz, 2H, H-3’,H-5’), 8.00 (d, J= 8.0 Hz, 1H, H-7), 8.07 (d, 
J= 8.0 Hz, 2H, H-2’, H-6’), 8.43 (dd, J=2.0, 8.0 Hz, 1H, H-6), 8.98 (d, J= 
2.6 Hz, 1H, H-4), 10.50 (s, 1H, NH). 1 3C NMR (DMSO-d6) δ:  14.0, 55.7, 
61.5, 113.7, 114.6, 120.1, 123.2, 124.9, 127.9, 129.9, 131.3, 132.6, 143.6, 
155.6, 162.1, 164.5, 167.0. Anal. Calcd. (%) for C1 9H1 6N2O7: C, 59.38; H, 
4.20; N, 7.29; found: C, 59.42; H, 4.31; N, 7.19.  
Ethyl 3-(4-methyl-benzoylamino)-5-nitro-benzo[b]furan-2-carboxylate 
(17c) Yield 62%. Mp 219-220 °C. IR νm a x: 3606 (NH), 1697, 1674 (CO), 
1528, 1345 (NO2) cm- 1. 1H NMR (DMSO-d6) δ:  1.30 (t,  J= 6.9 Hz, 3H, 
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CH3), 2.44 (s, 3H, CH3), 4.38 (q, J= 6.9 Hz, 2H, CH2), 7.43 (d, J= 8.0 Hz, 
2H, H-3’,H-5’), 7.99 (d, J= 8.0 Hz, 2H, H-2’, H-6’), 8.02 (d, J= 7.8 Hz, 
1H, H-7), 8.44 (dd, J= 2.0, 7.8 Hz, 1H, H-6), 8.98 (d, J= 2.0 Hz, 1H, H-
4), 10.54 (s, 1H, NH). 1 3C NMR (DMSO-d6) δ:  14.2, 21.1, 62.3, 112.7, 
121.4, 128.0, 129.1, 129.3, 129.9, 130.4, 132.1, 132.7, 143.0, 144.6, 
145.7, 164.2, 165.3. Anal. Calcd. (%) for C1 9H1 6N2O6: C, 61.95; H, 4.38; 
N, 7.61; found: C, 61.83; H, 4.42; N, 7.67.  
Ethyl 3-(3,4,5-trimethoxy-benzoylamino)-5-nitro-benzo[b]furan-2-
carboxylate (17d). Yield 82%. Mp 215-216 °C. IR νm a x: 3603 (NH), 
1680, 1668 (CO), 1550, 1333 (NO2) cm- 1. 1H NMR (DMSO-d6) δ:  1.32 (t,  
J= 6.0 Hz, 3H, CH3), 3.78 (s, 3H, OCH3), 3.91 (s, 6H, 2xOCH3), 4.35 (q, 
J= 6.0 Hz, 2H, CH2), 7.24 (s, 2H, H-2’,H-6’), 8.03 (d, J= 8.9 Hz, 1H, H-
7), 8.44 (dd, J=2.0, 8.9 Hz, 1H, H-6), 8.86 (d, J= 2.0 Hz, 1H, H-4), 10.52 
(s, 1H, NH). 1 3C NMR (DMSO-d6) δ:  14.2, 55.8, 60.1, 60.2, 106.2, 113.4, 
115.7, 123.6, 124.2, 125.8, 127.9, 132.4, 141.2, 144.2, 144.9, 152.6, 
162.1, 166.9. Anal. Calcd. (%) for C2 1H2 0N2O9: C, 56.76; H, 4.54; N, 
6.30; found: 56.82; H, 4.57; N, 6.39.  
Ethyl 3-(4-trifluoromethyl-benzoylamino)-5-nitro-benzo[b]furan-2-
carboxylate (17e). Yield 81%. Mp 236-237 °C. IR νm a x: 3616 (NH), 1695, 
1684 (CO), 1493, 1339 (NO2) cm- 1. 1H NMR (CDCl3) δ:  1.42 (t,  J= 6.0 
Hz, 3H, CH3), 4.47 (q, J= 6.0 Hz, 2H, CH2), 7.56 (d, J= 8.6 Hz, 2H, H-3’, 
H-5’), 7.76 (d, J= 8.0 Hz, 1H, H-7), 8.10 (d, J= 8.6 Hz, 2H, H-2’, H-6’), 
8.36 (dd, J=2.0, 8.0 Hz, 1H, H-6), 9.55 (d, J= 2.0 Hz, 1H, H-4), 10.44 (s, 
1H, NH).1 3C NMR (DMSO-d6) δ:  14.0, 61.6, 113.7, 120.4, 123.6, 125.6, 
125.7, 126.5, 126.6, 128.8, 136.8, 137.7, 143.8, 155.5, 158.5, 163.9, 
167.9. Anal. Calcd. (%) for C1 9H1 3F3N2O6: C, 54.04; H, 3.10; N, 6.63; 
found: C, 54.14; H, 3.17; N, 6.59.  
Ethyl 3-(3-chloro-4-fluoro-benzoylamino)-5-nitro-benzo[b]furan-2-
carboxylate (17f). Yield 86%. Mp 212-213 °C. IR νm a x: 3606 (NH), 1700, 
1674 (CO) 1497, 1335 (NO2) cm- 1. 1H NMR (CDCl3) δ:  1.43 (t,  J= 6.7 Hz, 
3H, CH3), 4.48 (q, J= 6.7 Hz, 2H, CH2), 7.25 (t,  J= 9.8 Hz, 1H, H-5’), 
7.56 (d, J= 9.6 Hz, 1H, H-7), 7.87 (dq, J= 2.0, 3.9, 9.6 Hz, 1H, H-6’), 
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8.08 (dd, J=3.9, 8.0 Hz, 1H, H-2’), 8.34 (dd, J= 2.0, 9.6 Hz, 1H, H-6), 
9.50 (d, J= 2.0 Hz, 1H, H-4), 10.30 (s, 1H, NH). 1 3C NMR (CDCl3) δ:  
14.6, 61.0, 113.2, 115.0, 117.0, 120.9, 122.0, 123.9, 128.8, 130.0, 131.5, 
131.7, 138.2, 143.4, 156.3, 160.0, 161.0, 165.3. Anal. Calcd. (%) for 
C1 8H1 2ClFN2O6: C, 53.15; H, 2.97; N, 6.89; found: C, C, 53.21; H, 2.92; 
N, 6.94.  
General procedure for the synthesis of ethyl 5-amino-3-benzoylamino-
benzo[b]furan-2-carboxylates 11a-f 
A suspension of 5-nitro compound 17a-f (1 mmol), 10% Pd/C (0.05 g) in ethanol was 
subjected to hydrogenation using a Parr Hydrogenation apparatus at 500 psi for 2h. After 
then, the catalyst was removed by filtration and the filtrate was concentrated under 
reduced pressure. The crude was crystallized from ethanol. 
Ethyl 5-amino-3-benzoylamino-benzo[b]furan-2-carboxylate (11a) 
Yield 84%. Mp 173-174 °C. IR νmax:3411, 3368 (NH2), 3293 (NH), 1688, 1667 (CO) 
cm-1. 1H NMR (CDCl3): δ 1.46 (t, J= 6.3 Hz, 3H, CH3), 3.30 (br s, 2H, NH2), 4.45 (q, J= 
6.3 Hz, 2H, CH2), 6.91 (dd, J= 2.0, 8.7 Hz, 1H, H-6), 7.32 (d, J= 8.7 Hz, 1H, H-7), 7.49-
7.65 (m, 3H, H-3’, H-4’, H-5’), 7.81 (d, J=2.0 Hz, 1H, H-4), 8.03 (dd, J= 1.6, 8.4 Hz, 
2H, H-2’, H-6’), 10.31 (s, 1H, NH).13C NMR (DMSO-d6) δ: 14.0, 60.7, 104.3, 112.2, 
117.8, 124.5, 126.9, 127.6, 128.6, 132.1, 133.4, 135.2, 145.1, 146.7, 159.2, 164.6. Anal. 
Calcd. (%) for C18H16N2O4: C, 66.66; H, 4.97; N, 8.64; found: C, 66.57; H, 4.87; N, 8.69. 
Ethyl 5-amino-3-(4-methoxy-benzoylamino)-benzo[b]furan-2-
carboxylate (11b). Yield 57%. Mp 146-147 °C. IR νm a x: 3613, 3357 
(NH2), 3296 (NH), 1718, 1667 (CO) cm- 1. 1H NMR (CDCl3): δ  1.46 (t,  J= 
6.7 Hz, 3H, CH3), 2.83 (br s,  2H, NH2), 3.89 (s, 3H, OCH3), 4.49 (q, J= 
6.7 Hz, 2H, CH2), 6.91 (dd, J= 2.0, 8.0 Hz, 1H, H-6), 7.02 (d, J= 8.0 Hz, 
2H, H-3’, H-5’), 7.31 (d, J= 8.0 Hz, 1H, H-7), 7.82 (d, J= 2.0 Hz, 1H, H-
4), 8.01 (d, J= 8.0 Hz, 2H, H-2’, H-6’), 10.24 (s, 1H, NH). 1 3C NMR 
(DMSO-d6) δ:  14.1, 55.5, 60.8, 104.5, 112.1, 113.9, 115.4, 117.8, 120.5, 
129.6, 132.6, 135.7, 143.3, 145.0, 146.7, 159.3, 162.3. Anal. Calcd. (%) 
for C1 9H1 8N2O5: C, 64.40; H, 5.12; N, 7.91;found.: C, 64.47; H, 5.09; N, 
7.98.  
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Ethyl 5-amino-3-(4-methyl-benzoylamino)-benzo[b]furan-2-
carboxylate (11c). Yield 93%. Mp 208-209 °C. IR νm a x: 3607, 3370 
(NH2), 3307 (NH), 1692, 1662 (CO) cm- 1. 1H NMR (DMSO-d6) δ:  1.27 (t,  
J= 6.0 Hz, 3H, CH3), 2.42 (s, 3H, CH3), 4.31 (q, J= 6.0 Hz, 2H, CH2), 
5.25 (br s,  2H, NH2), 6.84-6.93 (m, 2H, H-6, H-7), 7.37 (d, J= 2.0 Hz, 1H, 
H-4), 7.39 (d, J= 8.0 Hz, 2H, H-3’, H-5’), 7.96 (d, J= 8.0 Hz, 2H, H-2’, 
H-6’), 10.17 (s, 1H, NH). 1 3C NMR (DMSO-d6) δ:  14.0, 21.0, 60.8, 104.6, 
112.1, 117.8, 124.5, 127.1, 127.7, 129.2, 130.6, 134.9, 142.2, 144.7, 
146.7, 159.3, 164.3. Anal. Calcd. (%) for C1 9H1 8N2O4: C, 67.44; H, 5.36; 
N, 8.28; found: C, 67.53; H, 5.42; N, 8.23.  
Ethyl 5-amino-3-(3,4,5-trimethoxy-benzoylamino)-benzo[b]furan-2-
carboxylate (11d) Yield 36%. Mp 176-177 °C. IR νm a x: 3404, 3316 
(NH2), 3213 (NH), 1691, 1654 (CO) cm- 1. 1H NMR (DMSO-d6): δ  1.27 (t,  
J= 6.0 Hz, 3H, CH3), 3.76 (s, 3H, OCH3), 3.88 (s, 6H, 2xOCH3), 4.31 (q, 
J= 6.0 Hz, 2H, CH2), 5.35 (br s,  2H, NH2), 6.81-6.88 (m, 2H, H-6, H-7), 
7.36-7.41 (m, 3H, H-4, H-2’, H-6’), 10.18 (s, 1H, NH). 1 3C NMR (DMSO-
d6) δ:  14.0, 56.0, 60.1, 60.8, 104.1, 105.2, 106.4, 112.2, 117.8, 124.7, 
128.5, 135.6, 140.5, 144.9, 146.7, 152.7, 164.2, 166.9. Anal. Calcd. (%) 
for C2 1H2 2N2O7: C, 60.86; H, 5.35; N, 6.76; found: C, 60.86; H, 5.35; N, 
6.76.  
Ethyl 5-amino-3-(4-trifluoromethyl-benzoylamino)-benzo[b]furan-2-
carboxylate (11e). Yield 60%. Mp 198-199 °C. IR νm a x: 3612, 3356 
(NH2), 3293 (NH), 1688, 1664 (CO) cm- 1. 1H NMR (CDCl3): δ  1.39 (t,  J= 
6.0 Hz, 3H, CH3), 2.72 (br s,  2H, NH2), 4.42 (q, J= 6.0 Hz, 2H, CH2), 
6.85 (dd, J= 2.0, 8.0 Hz, 1H, H-6), 7.25 (d, J= 8.0 Hz, 1H, H-7), 7.72 (d, 
J= 2.0 Hz, 1H, H-4), 7.73 (d, J= 8.0 Hz, 2H, H-3’, H-5’), 8.07 (d, J= 8.0 
Hz, 2H, H-2’, H-6’), 10.34 (s, 1H, NH). 1 3C NMR (DMSO-d6) δ:  14.0, 
60.8, 112.3, 117.8, 124.6, 125.6, 126.0, 128.6, 130.1, 131.5, 132,1, 135.9, 
137.3, 145.2, 146.7, 159.0, 163.7. Anal. Calcd. (%) for C1 9H1 5F3N2O4: C, 
58.17; H, 3.85; N 7.14; found: C, 58.23; H, 3.81; N 7.07.  
Ethyl 5-amino-3-(3-chloro-4-fluoro-benzoylamino)-benzo[b]furan-2-
carboxylate (11f). Yield 81%. Mp 193-195 °C. IR νm a x: 3615, 3360 
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(NH2), 3342 (NH), 1672, 1623 (CO) cm- 1. 1H NMR (DMSO-d6) δ:  1.29 (t,  
J= 6.0 Hz, 3H, CH3), 3.59 (br s,  2H, NH2), 4.36 (q, J= 6.0 Hz, 2H, CH2), 
7.42-7.51 (m, 2H, H-2’, H-5’), 7.76 (d, J= 2.0 Hz, 1H, H-4), 7.78 (d, J= 
6.8 Hz, 1H, H-7), 8.12-8.22 (m, 2H, H-6, H-6’), 10.54 (s, 1H, NH). 1 3C 
NMR (DMSO-d6) δ:  14.1, 61.0, 104.3, 112.3, 115.0, 117.9, 120.9, 123.6, 
128.8, 130.0, 131.7, 137.2, 142.9, 146.3, 149.0, 160.0, 162.6, 165.8. 
Anal. Calcd. (%) for C1 8H1 4ClFN2O4: C, 57.38; H, 3.75; N, 7.44; found: 
C, 57.43; H, 3.84; N, 7.37.  
General procedure for the synthesis of ethyl 3-benzoylamino-5-[(1H-
imidazol-4-yl-methyl)-amino]-benzo[b]furan-2-carboxylates 12a-f and 
13a-f 
To a suspension of the 11a-f (1.25 mmol) and the appropriate aldehyde (1.6 mmol) in dry 
ethanol (10 mL) was added acetic acid up to pH 4. The mixture was stirred for 30 min, 
and then NaCNBH3 (1.6 mmol) was added continuing the stirring at room temperature 
for further 6-24h. The reaction solvent was removed under reduced pressure and the 
crude product was purified by chromatography column using dichloromethane/methanol 
98:2 as eluent. Recrystallization from ethanol. When is employed the carbaldehyde 9b 
from the crude it was also possible to isolate the methyl-imidazole side-chain derivative 
18 in variable yields (10-23%). 
Ethyl 5-[(5-methyl-1H-imidazol-4-yl-methyl)-amino]-3-amino-
benzo[b]furan-2-carboxylate (18). Mp 140-141 °C. IR νm a x: 3311, 3234 
(NH), 1683, (CO) cm- 1. 1H NMR (DMSO-d6) δ :  1.30 (t,  J= 6.7 Hz, 3H, 
CH3), 2.17 (s, 3H, CH3), 4.05 (s, 2H, CH2), 4.26 (q, J=6.7 Hz, 2H, CH2), 
5.54 (br s,  1H, NH), 6.11 (s, 2H, NH2), 6.94 (dd, J=2.0, 8.0 Hz, 1H, H-6), 
7.03 (d, J=2.0 Hz, 1H, H-4), 7.20 ( d, J=8.0 Hz, 1H, H-7), 7.48 (s, 1H, H-
2’). 1 3C NMR (DMSO-d6) δ:  9.7, 14.1, 40.7, 60.8, 101.5, 112.9, 117.4, 
121.3, 124.7, 125.2, 126.0, 135.8, 139.6, 142.1, 159.5, 164.7. Anal. 
Calcd. (%) for C1 6H1 8N4O3: C, 61.14; H, 5.77; N, 17.82; found: C, 61.17; 
H, 5.79; N, 17.86.  
Ethyl 3-benzoylamino-5-[(1H-imidazol-4-yl-methyl)-amino]-
benzo[b]furan-2-carboxylate (12a). Yield 50%. Mp 184-185 °C. IR νm a x: 
3301, 3245 (NH), 1684, 1668 (CO) cm- 1. 1H NMR (DMSO-d6) δ:  1.25 (t,  
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J= 6.7 Hz, 3H, CH3), 4.14 (br s,  2H, CH2), 4.30 (q, J= 6.7 Hz, 2H, CH2), 
5.92 (t,  J= 4.0 Hz, 1H, NH), 6.86-7.08 (m, 3H, H-4, H-6, H-5”), 7.44 (d, 
J= 7.8 Hz, 1H, H-7), 7.53-7.69 (m, 4H, H-3’, H-4’, H-5’, H-2”), 8.05 (d, 
J= 8.0 Hz, 2H, H-2’, H-6’), 10.29 (s, 1H, NH), 12.03 (br s,  1H, NH). 1 3C 
NMR (DMSO-d6) δ:  14.0, 40.7, 60.8, 101.5, 112.3, 116.5, 117.5, 124.4, 
126.8, 127.3, 127.7, 128.6, 132.1, 133.5, 134.8, 135.3, 145.3, 146.8, 
159.2, 164.9. Anal. Calcd. (%) for C2 2H2 0N4O4: C, 65.34; H, 4.98; N, 
13.85; found: C, 65.39; H, 4.45; N, 13.79.  
Ethyl 5-[(1H-imidazol-4-yl-methyl)-amino]-3-(4-methoxy-
benzoylamino)-benzo[b]furan-2-carboxylate (12b). Yield 24%. Mp 124-
125 °C. IR νm a x: 3306, 3243 (NH),1682, 1667 (CO) cm- 1. 1H NMR 
(DMSO-d6): δ  1.26 (t,  J= 6.0 Hz, 3H, CH3), 3.87 (s, 3H, OCH3), 4.14 (d, 
J= 2.0 Hz, 2H, CH2), 4.30 (q, J= 6.0 Hz, 2H, CH2), 5.91 (t,  J= 2.0 Hz, 1H, 
NH), 6.92-7.04 (m, 3H, H-4, H-6, H-5”), 7.12 (d, J= 8.0 Hz, 2H, H-3’, H-
5’), 7.43 (d, J=8.0 Hz, 1H, H-7), 7.58 (s, 1H, H-2”), 8.04 (d, J= 8.0 Hz, 
2H, H-2’, H-6’) 10.13 (s, 1H, NH), 11.93 (br s,  1H, NH). 1 3C NMR 
(DMSO-d6) δ:  14.0, 40.3, 55.4, 60.8, 101.9, 107.2, 112.3, 113.9, 116.6, 
117.5, 124.3, 125.5, 127.1, 129.7, 134.8, 134.9, 145.0, 146.9, 159.3, 
162.3, 164.4. Anal. Calcd. (%) for C2 3H2 2N4O5: C, 63.59; H, 5.10; N, 
12.90; found: C, 63.66; H, 5.18; N, 12.88.  
Ethyl 5-[(1H-imidazol-4-yl-methyl)-amino]-3-(4-methyl-
benzoylamino)-benzo[b]furan-2-carboxylate (12c). Yield 65%. Mp 138-
139 °C. IR νm a x: 3307, 3253 (NH), 1680, 1669 (CO) cm- 1. 1H NMR 
(DMSO-d6) δ:  1.26 (t,  J= 6.3 Hz, 3H, CH3), 2.42 (s, 3H, CH3), 4.14 (s, 
2H, CH2), 4.30 (q, J= 6.3 Hz, 2H, CH2), 5.92 (br t ,  J= 3.7 Hz, 1H, NH), 
6.92-7.04 (m, 3H, H-4, H-6, H-5”), 7.37-7.45 (m, 3H, H-7, H-3’, H-5’), 
7.58 (s, 1H, H-2”), 7.92 (d, J= 8.1 Hz, 2H, H-2’, H-6’) 10.20 (s, 1H, NH), 
12.02 (br s,  1H, NH). 1 3C NMR (DMSO-d6) δ:  14.0, 21.0, 40.4, 60.8, 
101.7, 112.3, 117.5, 124.3, 124.5, 126.9, 127.7, 129.2, 130.6, 135.1, 
138.2, 142.3, 145.2, 146.9, 159.3, 162.2, 164.7. Anal. Calcd. (%) for 
C2 3H2 2N4O4: C, 66.02; H, 5.30; N, 13.39; found: C, 66.13; H, 5.27; N, 
13.31.  
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Ethyl 5-[(1H-imidazol-4-yl-methyl)-amino]-3-(3,4,5-trimethoxy-
benzoylamino)-benzo[b]furan-2-carboxylate (12d). Yield 30%. Mp 137-
139 °C. IR νm a x: 3307, 3250 (NH), 1687, 1670 (CO) cm- 1. 1H NMR 
(DMSO-d6) δ:  1.32 (t,  J= 6.0 Hz, 3H, CH3), 3.73 (s,  3H, OCH3), 3.83 (s, 
3H, 2xOCH3), 4.28 (d, J= 2.0 Hz, 2H, CH2), 4.35 (q, J= 6.0 Hz, 2H, CH2), 
6.64 (br s,  1H, NH), 7.24 (s, 2H, H-2’, H-6’), 7.41 (s, 1H, H-5”), 7.62 (s, 
1H, H-2”), 8.02 (d, J= 9.7 Hz, 1H, H-7), 8.44 (dd, J= 3.0, 9.7 Hz, 1H, H-
6), 8.87 (d, J= 3.0 Hz, 1H, H-4) 10.37 (s, 1H, H-2”), 10.52 (s, 1H, NH), 
12.94 (br s,  1H, NH). 1 3C NMR (DMSO-d6) δ:  14.2, 40.5, 55.8, 60.1, 
60.8, 105.5, 106.3, 113.7, 117.7, 123.6, 124.9, 125.9, 127.4, 128.0, 137.2, 
140.2, 141.2, 143.7, 152.6, 155.6, 158.6, 165.3, 166.9, 172.0. Anal. 
Calcd. (%) for C2 5H2 6N4O7: C, 60.72; H, 5.30; N, 11.33; found: C, 60.77; 
H, 5.36; N, 11.25.  
Ethyl 5-[(1H-imidazol-4-yl-methyl)-amino]-3-(4-trifluoromethyl-
benzoylamino)-benzo[b]furan-2-carboxylate (12e). Yield 23%. Mp 169-
171 °C. IR νm a x: 3293, 3229 (NH), 1674, 1668 (CO) cm- 1. 1H NMR 
(DMSO-d6) δ:  1.24 (t,  J= 6.3 Hz, 3H, CH3), 4.14 (s, 2H, CH2), 4.30 (q, J= 
6.3 Hz, 2H, CH2), 5.96 (br s,  1H, NH), 6.84 (s, 1H, H-5”), 6.94-7.07 (m, 
2H, H-4, H-6), 7.45 (d, J= 7.8 Hz, 1H, H-7), 7.62 (s, 1H, H-2”), 7.98 (d, 
J= 8.2 Hz, 2H, H-3’, H-5’), 8.24 (d, J= 8.2 Hz, 2H, H-2’, H-6’) 10.54 (s, 
1H, NH), 12.04 (br s,  1H, NH). 1 3C NMR (DMSO-d6) δ :  14.0, 60.7, 100.8, 
112.4, 117.6, 124.6, 125.6, 126.0, 128.7, 130.0, 134.8, 135.8, 135.0, 
135.5, 135.9, 137.4, 145.5, 146.7, 158.9, 163.8, 166.3. Anal. Calcd. (%) 
for C2 3H1 9F3N4O4: C, 58.48; H, 4.05; N, 11.86; found: C, 58.56; H, 4.13; 
N, 11.79.  
Ethyl 5-[(1H-imidazol-4-yl-methyl)-amino]-3-(3-chloro-4-fluoro-
benzoylamino)-benzo[b]furan-2-carboxylate (12f). Yield 57%. Mp 162-
163 °C. IR νm a x: 3306, 3253 (NH), 1690, 1669 (CO) cm- 1. 1H NMR 
(CDCl3) δ:  1.26 (t,  3H, J= 6.6 Hz, CH3), 4.16 (s, 2H, CH2), 4.31 (q, J= 6.6 
Hz, 2H, CH2), 5.93 (br s,  1H, NH), 6.82 (dd, J= 2.0, 8.0 Hz, 1H, H-6), 
6.96 (s, 1H, H-5”), 7.25 (t,  1H, J= 8.0 Hz, H-5’), 7.46 (d, J= 8.0Hz, 1H, 
H-7), 7.47 (s, 1H, H-2”), 7.73 (d, J= 2.0 Hz, 1H, H-4), 7.89 (dq, J= 2.0, 
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8.0 Hz, 1H, H-6’), 8.07 (dd, J= 2.0, 8.0 Hz, 1H, H-2’), 10.35 (s, 1H, NH). 
1 3C NMR (DMSO-d6) δ:  14.0, 40.6, 60.9, 103.0, 117.0, 117.9, 119.6 (s),  
120.0, 123.0, 123.4, 126.1, 129.0, 129.1, 130.3, 131.7, 134.4, 134.8, 
136.9, 146.8, 161.7, 163.3, 172.2. Anal. Calcd. (%) for C2 2H1 8ClFN4O4: 
C, 57.84; H, 3.97; N, 12.26; found: C, 57.87; H, 3.93; N, 12.23.  
Ethyl 3-benzoylamino-5-[(5-methyl-1H-imidazol-4-yl-methyl)-amino]-
benzo[b]furan-2-carboxylate (13a). Yield 30%. Mp 183-184 °C. IR νm a x: 
3311, 3248 (NH), 1687, 1664 (CO) cm- 1. 1H NMR (DMSO-d6) δ :  1.26 (t,  
J= 6.0 Hz, 3H, CH3), 2.19 (s, 3H, CH3), 4.14 (br s,  2H, CH2), 4.31 (q, J= 
6.0 Hz, 2H, CH2), 5.98 (br s,  1H, NH), 6.82 (d, J= 2.0 Hz, 1H, H-4), 6.99 
(dd, J= 2.0, 8.0 Hz, 1H, H-6), 7.54-7.72 (m, 3H, H-3’, H-4’, H-5’), 8.00-
8.13 (m, 3H, H-2’, H-6’, H-2”), 10.28 (s, 1H, NH), 13.12 (br s,  1H, NH). 
1 3C NMR (DMSO-d6) δ:  9.1, 14.0, 54.9, 60.8, 101.7, 112.5, 117.6, 124.3, 
125.7, 126.5, 127.0, 127.3, 127.7, 128.7, 132.9, 133.4, 135.2, 144.7, 
147.1, 159.2, 164.9. Anal. Calcd. (%) for C2 3H2 2N4O4: C, 66.02; H, 5.30; 
N, 13.39; found: C, 66.06; H, 5.34; N, 13.35.  
Ethyl 5-[(5-methyl-1H-imidazol-4-yl-methyl)-amino]-3-(4-methoxy-
benzoylamino)-benzo[b]furan-2-carboxylate (13b). Yield 34%. Mp 154-
155 °C. IR νm a x: 3310, 3247 (NH), 1691, 1665 (CO) cm- 1. 1H NMR 
(DMSO-d6): δ  1.26 (t,  J= 6.0 Hz, 3H, CH3), 2.14 (s, 3H, CH3), 3.87 (s, 
3H, OCH3), 4.05 (br s,  2H, CH2), 4.29 (q, J= 6.0 Hz, 2H, CH2), 5.83 (br s,  
1H, NH), 6.85 (d, J= 2.0 Hz, 1H, H-4), 7.00 (dd, J= 2.0, 9.7 Hz, 1H, H-6), 
7.12 (d, J= 8.0 Hz, 2H, H-2’, H-6’), 7.43 (d, J= 9.7 Hz, 1H, H-7), 7.53 (s, 
1H, H-2”), 8.04 (d, J= 8.0 Hz, 2H, H-3’, H-5’), 10.13 (s, 1H, NH). 1 3C 
NMR (DMSO-d6) δ:  10.1, 14.0, 39.4, 55.5, 60.7, 101.4, 105.8, 112.2, 
113.8, 124.4, 125.7, 127.3, 129.7, 133.1, 135.0, 144.1, 145.3, 146.8, 
159.3, 162.2, 164.1, 172.0. Anal. Calcd. (%) for C2 4H2 4N4O5: C, 64.28; H, 
5.39; N, 12.49; found: C, 64.24; H, 5.35; N, 12.47.  
Ethyl 5-[(5-methyl-1H-imidazol-4-yl-methyl)-amino]-3-(4-methyl-
benzoylamino)-benzo[b]furan-2-carboxylate (13c). Yield 15%. Mp 168-
169 °C. IR νm a x: 3311, 3258 (NH), 1681, 1670 (CO) cm- 1. 1H NMR 
(DMSO-d6) δ:  1.26 (t,  J= 6.0 Hz, 3H, CH3), 1.82 (s, 3H, CH3), 1.92 (s, 
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1H, CH3), 4.15 (s, 2H, CH2), 4.30 (q, J= 6.0 Hz, 2H, CH2), 6.12 (br s,  1H, 
NH), 6.85 (d, J= 2.0 Hz, H-4), 7.00 (dd, J= 2.0, 8.0 Hz, 1H, H-6), 7.40 (d, 
J= 8.0 Hz, 1H, H-7), 7.45 (d, J= 8.0 Hz, 2H, H-3’, H-5’), 7.97 (d, J= 8.0 
Hz, 2H, H-2’, H-6’), 8.08 (s, 1H, H-2”), 10.21 (s, 1H, NH). 1 3C NMR 
(DMSO-d6) δ:  9.5, 14.1, 21.0, 38.4, 60.8, 101.7, 112.4, 117.6, 124.3, 
125.7, 127.2, 127.7, 129.2, 130.6, 133.0, 135.0, 142.2, 144.9, 147.0, 
159.3, 164.5, 172.1. Anal. Calcd. (%) for C2 4H2 4N4O4: C, 66.65; H, 5.59; 
N, 12.96; found: C, 66.67; H, 5.54; N, 12.98.  
Ethyl 5-[(5-methyl-1H-imidazol-4-yl-methyl)-amino]-3-(3,4,5-
trimethoxy-benzoylamino)-benzo[b]furan-2-carboxylate (13d). Yield 
27%. Mp 162-163 °C. IR νm a x: 3307, 3239 (NH), 1686, 1665 (CO) cm- 1. 
1H NMR (DMSO-d6) δ:  1.27 (t,  J= 6.0 Hz, 3H, CH3), 2.21 (s, 3H, CH3), 
3.77 (s, 3H, OCH3), 3.89 (s, 3H, 2xOCH3), 4.17 (s, 2H, CH2), 4.28 (q, J= 
6.0 Hz, 2H, CH2), 6.02 (br s,  1H, NH), 6.24 (d, J= 2.0 Hz, 1H, H-4), 6.99 
(dd, J= 2.0, 8.0 Hz, 1H, H-6), 7.40 (s, 2H, H-2’, H-6’), 7.47 (d, J= 8.0 
Hz, 1H, H-7), 8.23 (s, 1H, H-2”), 10.21 (s, 1H, NH).1 3C NMR (DMSO-d6) 
δ :  10.0, 14.1, 39.7, 55.7, 60.1, 60.8, 105.3, 113.4, 117.6, 123.3, 124.8, 
125.8, 127.3, 128.7, 131.9, 135.0, 140.2, 141.2, 143.7, 152.6, 155.3, 
158.3, 165.0, 166.7, 172.0. Anal. Calcd. (%) for C2 6H2 8N4O7: C, 61.41; H, 
5.55; N, 11.02; found: C, 61.43; H, 5.57; N, 11.05.  
Ethyl 5-[(5-methyl-1H-imidazol-4-yl-methyl)-amino]-3-(4-
trifluoromethyl-benzoylamino)-benzo[b]furan-2-carboxylate (13e). 
Yield 90%. Mp 183-184 °C. IR νm a x: 3287, 3230 (NH), 1670, 1661 (CO) 
cm- 1. 1H NMR (DMSO-d6) δ:  1.25 (t,  J= 6.0 Hz, 3H, CH3), 2.10 (s, 3H, 
CH3), 4.32 (s, 2H, CH2), 4.49 (q, J= 6.0 Hz, 2H, CH2), 6.83 (br s,  1H, 
NH), 7.07 (dd, J= 2.0, 8.0 Hz, 1H, H-6), 7.41-7.51 (m, 2H, H-4, H-7), 
7.99-8.02 (m 3H, H-3’, H-5’ H-2”), 8.24 (d, J= 8.6 Hz, 2H, H-2’, H-6’) 
10.54 (s, 1H, NH). 1 3C NMR (DMSO-d6) δ:  11.1, 14.1, 40.2, 60.8, 112.3, 
117.5, 124.4, 124.9, 125.3, 126.2, 128.7, 130.1, 134.7, 135.3, 135.7, 
135.9, 137.2, 145.7, 146.2, 158.6, 163.9, 167.5. Anal. Calcd. (%) for 
C2 4H2 1F3N4O4: C, 59.26; H, 4.35; N, 11.52; found: C, 59.28; H, 4.33; N, 
11.57.  
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Ethyl 5-[(5-methyl-1H-imidazol-4-yl-methyl)-amino]-3-(3-chloro-4-
fluoro-benzoylamino)-benzo[b]furan-2-carboxylate (13f). Yield 54%. 
Mp 139-141 °C. IR νm a x: 3307, 3232 (NH), 1693, 1655 (CO) cm- 1. 1H 
NMR (DMSO-d6) δ:  1.25 (t,  J= 6.7 Hz, 3H, CH3), 2.13 (s, 3H, CH3), 4.05 
(s, 2H, CH2), 4.29 (q, J=6.7 Hz, 2H, CH2), 5.84 (br s,  1H, NH), 6.75 (d, 
J=2.0 Hz, 1H, H-4), 7.01 (dd, J=2.0, 8.0 Hz, 1H, H-6), 7.44 ( d, J=8.0 Hz, 
1H, H-7), 7.47 (s, 1H, H-2”), 7.67 (t,  J=9.0 Hz, 1H, H-5’), 8.07 (dq, 
J=2.0, 9.0 Hz, 1H, H-6’), 8.29 (dd, J=2.0, 8.0 Hz, 1H, H-2’), 10.44 (s, 
1H, NH). 1 3C NMR (DMSO-d6) δ:  10.1, 14.0, 39.7, 60.7, 99.5, 102.5, 
112.3, 113.5, 115.9, 117.5, 119.7, 120.6, 124.7, 125.9, 129.0, 130.3, 
131.2, 133.1, 136.0, 145.6, 146.7, 158.8, 162.7. Anal. Calcd. (%) for 
C2 3H2 0ClFN4O4: C, 58.67; H, 4.28; N, 11.90; found: C, 58.65; H, 4.26; N, 
11.95.  
Biology 
Propidium iodide, ribonuclease A (RNAse A), 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT), and DMSO were obtained from Sigma Aldrich 
(St. Louis, MO, USA). RPMI, fetal bovine serum (FBS), phosphate buffered saline 
(PBS), L-glutamine solution (200 mM), trypsin-EDTA solution (170.000 U/l trypsin and 
0.2 g/l EDTA) and penicillin-streptomycin solution (10.000 U/ml penicillin and 10 
mg/ml streptomycin) were purchased from Lonza (Verviers, Belgium). 
Cell culture 
The tumor cell lines HeLa (human epithelial cervical cancer) and MCF-7 (human 
epithelial breast cancer), were obtained from American Type Culture Collection (ATCC) 
(Rockville, MD, USA). The cells were cultured as monolayers and maintained in a 
humidified atmosphere with 5% CO2 at 37 °C. MCF-7 cells were grown in DMEM while 
HeLa cells in RPMI. Both medium were supplemented with 5% FBS, 2 mM L-
glutamine, 50 IU/ml penicillin, and 50 µg/ml streptomycin. The cells were routinely 
cultured in 75 cm2 culture flasks and were trypsinized using trypsin-EDTA when the 
cells reached approximately 80% confluence. Exponentially growing cells were used for 
experiments. 
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Antiproliferative Evaluation Assay 
3-benzoylamino-benzo[b]furan derivatives 11a-f, 12a-f and 13a-f were submitted to the 
MTT assay to assess the growth inhibition activity against HeLa and MCF-7 tumor cell 
lines. The MTT assay is based on the protocol first described by Mosmann (107). It is a 
measurement of cell metabolic activity, and correlates quite well with cell proliferation. 
The assay was performed as previously described.15 The cells were seeded into a series 
of standard 96-well microtiter plates in 100 µl of complete culture medium, at a plating 
density depending on the doubling times of individual cell line. MCF-7 cells were seeded 
at 1.5 × 104 cells/cm2, while HeLa cells were seeded at 1.0 × 104 cells/cm2. Cells were 
incubated for 24 h under 5% CO2 at 37 °C and the medium was then replaced with 100 
µl of fresh medium containing the treatments. Benzo[b]furan derivatives were previously 
dissolved in DMSO to obtain 20 mM stock solutions. Working solutions were freshly 
prepared on the day of testing by dilutions of the stock solutions in the complete culture 
medium and the synthetized derivatives were tested in the 50–0.1 µM concentration 
range. 24 h after seeding aliquots of 100 µl of different solutions at the appropriate 
concentrations were added to the appropriate microtiter wells and the cells were 
incubated for 48 h, without renewal of the medium. In each experiment DMSO 
concentration never exceeded 0.25%. and culture medium with 0.25% DMSO was used 
as control. After the incubation time, cells were washed, and 50 µL FBS-free medium 
containing 0.5 mg/mL of methyl thiazolyl tetrazolium (MTT) reagent was added. The 
medium was discarded after to 3h incubation at 37 °C, and formazan blue formed in the 
cells was dissolved in DMSO. The absorbance (OD, optical density) at 570 nm of MTT-
formazan was measured in a microplate reader. The absorbance is directly proportional 
to the number of living, metabolically active cells. 
The percentage of growth (PG) to respect untreated cell control for each drug 
concentrations was calculated according to one of the following two expressions: 
if (ODtest – ODtzero) ≥ 0, then  
PG = 100 × (ODtest – ODtzero)/(ODctrl− ODtzero);  
if (ODtest −  ODtzero) < 0,  then 
 PG = 100 × (ODtest − ODtzero)/ODtzero,  
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where ODtzero is the average of optical density measurements before exposure of cells to 
the test compound, ODtest is the average of optical density measurements after the desired 
period of time, and ODctrl is the average of optical density measurements after the desired 
period of time with no exposure of cells to the test compound. 
The concentration necessary for 50% of growth inhibition (GI50) for each compound 
were calculated from concentration−response curves using linear regression analysis by 
fitting the test concentrations that give PG values above and below the reference value 
(i.e., 50%). If, however, for a given cell line all of the tested concentrations produce PGs 
exceeding the respective reference level of, then the highest tested concentration is 
assigned as the default value, which is preceded by a “>” sign. Each result is a mean 
value of three separate experiments. 
Cell-cycle analysis 
Effects of the 3-benzoylamino-benzo[b]furan derivatives 13a-f exposure on cell-cycle 
were evaluated by DNA staining with propidium iodide and flow cytometry analysis. 
HeLa cells were seeded on 6 well plates at a density of 2.5 104 cells/cm2, and treated 24 
hours after seeding with or without various concentrations of test compounds. Following 
the treatments, cells were collected, washed in PBS, fixed in ice-cold 70% ethanol and 
kept at -20 °C. Fixed cells were centrifuged, resuspended in PBS and stained with 
staining solution (20 µg/ml propidium iodide, 200 µg/ml RNAse A and Triton X-100 in 
PBS), for 30 min at 37°C. The DNA contents of more than 10000 cells were subjected to 
fluorescence-activated cell sorting (FACS) analysis (Coulter® Epics® XLTM, Beckman) 
and the percentage of cells belonging to the different compartments of the cell cycle was 
determined. All experiments were performed in duplicate and reproduced at least two 
times. 
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Experimental part (G4-binders) 
General. All reaction solvents were purified in accordance with Purification of 
Laboratory Chemicals (Fourth Edition) prior to use. All reagents were used as 
purchased without further purification. The solvents were removed under reduced 
pressure using standard rotary evaporators. 
All of the reactions were monitored by TLC using Merck’s silica gel 60 F254-
precoated aluminum sheets. Visualization was accomplished with UV light (254 or 
365 nm). Solvent mixtures used for chromatography are always given in a vol/vol ratio. 
Flash column chromatography was generally performed using Silica Gel 60 (Merck, 
spherical, 40-63 µm). 
Melting points were determined on a Büchi-540 capillary melting point apparatus and 
are uncorrected. 
The high-resolution accurate masses (HRMS) were determined with an Agilent 6230 
time-of-flight mass spectrometer. Samples were introduced by the Agilent 1260 Infinity 
LC system. The mass spectrometer was operated in conjunction with a Jet Stream 
electrospray ion source in positive ion mode. Reference masses of m/z 121.050873 and 
922.009798 were used to calibrate the mass axis during analysis. Mass spectra were 
processed using Agilent MassHunter B.02.00 software. 
High-performance liquid chromatography (HPLC) was performed on a Jasco 2080 Plus 
isocratic binary pump, using a Jasco 2075 Plus variable wavelength absorbance detector 
and Jasco ChromPass v.1.8.6.1 software. 
Elemental analyses were performed on an Elementar VarioEL III apparatus. MW 
irradiation experiments were carried out in a monomode CEM-Discover MW reactor, 
using the standard configuration as delivered, including proprietary software. The 
experiments were executed in 10 or 80 mL MW process vials with control of the 
temperature by infrared detection. After completion of the reaction, the vial was cooled 
to 50 °C by air jet cooling. 
1H and 13C nuclear magnetic resonance (NMR) spectra were recorded at ambient 
temperature (if not indicated otherwise), in the solvent indicated, on a Varian 
Mercury Plus 400 spectrometer at frequency of 400 and 100 MHz or on a Bruker Avance 
III 500 spectrometer at frequency of 500 and 125 MHz respectively. Chemical shifts are 
given using the δ-scale (in ppm) relative to tetramethylsilane or the residual solvent 
signal as an internal reference. Coupling constants are indicated in Hertz (Hz). The 
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following abbreviations are used for spin multiplicity: s=singlet, d=doublet, t=triplet, 
q=quartet, m=multiplet, ovl. m=overlapping multiplet, br=broad, dd = doublet doublet, 
dm = doublet multiplet and tm = triplet multiplet. The signification of the one star (*) in 
the 13C NMR means tentative assignments. 
 
Biology 
Chemicals and reagents 
Propidium iodide, ribonuclease A (RNAse A), 3-(4,5-dimethyl-2- thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT), and DMSO were obtained from Sigma Aldrich 
(St. Louis, MO, USA). RPMI, fetal bovine serum (FBS), phosphate buffered saline 
(PBS), L-glutamine solution (200 mM), trypsin-EDTA solution (170.000 U/l trypsin and 
0.2 g/l EDTA) and penicillin-streptomycin solution (10.000 U/ml penicillin and 10 
mg/ml streptomycin) were purchased from Lonza (Verviers, Belgium). 
Cell culture 
The cancer cell line HeLa (Human epithelial cervical cancer) was obtained from 
American Type Culture Collection (ATCC) (Rockville, MD, USA). The cells were 
cultured in RPMI supplemented with 5% FBS, 2 mM L-glutamine, 50 IU/ml penicillin, 
and 50 mg/ml streptomycin and maintained in a humidified atmosphere with 5% CO2 at 
37 °C. The cells were routinely cultured in 75 cm2 culture flasks and were trypsinized 
using trypsin-EDTA when the cells reached approximately 80% confluence. 
Exponentially growing cells were used for experiments. 
Antiproliferative evaluation assay  
Compounds were submitted to the MTT assay to assess the growth inhibition activity 
against HeLa cells. The MTT assay is a measurement of cell metabolic activity, quite 
effective in estimating cell proliferation, which is based on the protocol first described by 
Mossmann (104). The assay was performed as previously described (105). The cells were 
seeded into a series of standard 96-well plates in 100 ml of complete culture medium at 
1.0 104 cells/cm2. Cells were incubated for 24 h under 5% CO2 at 37 °C and the medium 
was then replaced with 100 ml of fresh medium supplemented by 5% (v/ v) FBS 
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containing the treatments. The derivatives were previously dissolved in DMSO to obtain 
20 mM stock solutions. Working solutions were freshly prepared on the day of testing by 
dilutions of the stock solutions in the complete culture medium. For the experiments a 
concentration range from 50 to 0.05 mM was used. 24 h after seeding aliquots of 100 ml 
of different solutions at the appropriate concentrations were added to the appropriate 
wells and the cells were incubated for 48 h without renewal of the medium. In each 
experiment, DMSO concentration never exceeded 0.25% and culture medium with 
0.25% DMSO was used as control. After the incubation time, cells were washed and 100 
mL FBS-free medium containing 0.5 mg/mL of MTT was added. The medium was 
discarded after a 4 h incubation at 37 °C and formazan blue formed in the cells was 
dissolved in DMSO. The absorbance (optical density, OD) at 570 nm of MTT-formazan 
was measured in a microplate reader. As the absorbance is directly proportional to the 
number of living, metabolically active cells, the percentage of growth (PG) to with 
respect to untreated cell control for each drug concentrations was calculated according to 
one of the following two expressions: 
if  (ODtest – Odtzero) > 0; then  
PG = 100 x (ODtest – Odtzero)/(ODctr – Odtzero) 
if  (ODtest _ ODtzero) < 0; then  
PG = 100 (ODtest – Odtzero)/ODtzero 
where ODtzero is the average of optical density measurements before exposure of cells to 
the test compound, ODtest is the average of optical density measurements after the desired 
period of time, and ODctr is the average of optical density measurements after the desired 
period of time with no exposure of cells to the test compound. The concentration 
necessary for 50% of growth inhibition (GI50) for each derivative was calculated from 
concentration-response curves using linear regression analysis by fitting the test 
concentrations that give PG values above and below the reference value (50%). Each 
result was the mean value of three separate experiments performed in quadruplicate. 
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General procedure for the synthesis of bis isoquinoline derivatives 
22a-b To	a	solution	of	20a-b	(2.5	mmol)	in	acetonitrile,	1,3-dichloro-2-propanol	(1.25)	was	added.	The	mixture	was	stirred	within	a	Shlenk	flask	over	10-20	hours	at	140	°C.	The	reaction	solvent	was	removed	by	filtration	under	reduced	pressure.		
(22a). Yield 95%. Mp 279-283 °C. 1H NMR (CDCl3) δ: 10.23 (s, J= 1.5 Hz, 1H, CH), 
8.62 (t, J= 7.5 Hz, 1H, CH), 8.55 (m, 1H, CH), 8.42 (m, 1H, CH), 8.10 (m, 1H, CH), 4.85 
(s, J= 7.0 Hz, 2H, CH2), 8.89 (d, J= 7.5 Hz, H), 3.2 (q, J= 7.0 Hz, 1H), 3.58 (s, OH). 13C 
NMR (CDCl3) δ: 23.53, 45.82, 70.75, 119.07, 125.92, 126.58, 128.81, 127, 74, 130.80, 
136.74, 151.46, 174.90. Anal. Calcd. (%) for C21H20N2O2+: C, 79.72; H, 6.37; N, 8.85; O, 
5.06; found: C, 79.75; H, 6.31; N, 8.82; O, 5.08. 
(22b). Yield 90%. Mp 271-278 °C. 1H NMR (DMSO-d6) δ: 10.31 (s, J= 1.5 Hz, 1H, 
CH), 8.04 (t, J= 1.5 Hz, 1H, CH), 8.55 (m, 1H, CH), 8.42 (m, 1H, CH), 8.10 (m, 1H, 
CH), 4.85 (s, J= 7.0 Hz, 2H, CH2), 2.91 (s, 3H, CH3 ), 3.2 (q, J= 7.0 Hz, 1H), 3.58 (s, 
OH). 13C NMR (CDCl3) δ: 20.8, 58.1, 64.7, 124.8, 127.2, 127.3, 128.4, 140.3, 143.2, 
155.1. Anal. Calcd. (%) for C23H24N2O2+: C, 80.20; H, 7.02; N, 8.13; O, 4.64 found: C, 
80.22; H, 7.07; N, 8.16; O, 4.60. 
Synthesis of compound (24) Under	inert	atmosphere,	to	a	suspension	of	23	in	DCM	pyridine	was	added	at	0	°C.	Then,	trifluoromethansulfonic	anhydride	was	added	dropwise.	The	mixture	was	reacted	overnight,	at	room	temperature.	A	satured	solution	of	NaHCO3	was	added	until	neutralization.	The	mixture	was	extracted	(3x20ml)	with	DCM	and	the	collected	fraction	dried	over	Na2SO4,	then	filtered	and	concentrated	under	reduced	pressure.	The	crude	was	purified	by	column	chromatography	(PE/EtOAc	95:5)	to	afford	a	white	solid.	Recrystallization	from	ethanol.	
(24). Yield 60%. Mp 58.9-60.2 °C. 1H-NMR (DMSO-d6) δ: 7.91 (d, J= 7.5 Hz, 1H, CH), 
7.26 (s, J= 1.5 Hz, 1H, CH), 7.05 (d, J= 1.5 Hz, 1H, CH). 13C NMR (CDCl3) δ: 107.8, 
115.2, 117.8, 124.4, 129.6, 137.5, 153.7. Anal. Calcd. (%) for C12H6F6O6S2: C, 33.97; H, 
1.43; F, 26.87; O, 22.63; S, 15.11 found: C, 33.95; H, 1.41; F, 26.89; O, 22.65; S, 15.18.  
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Synthesis of 2,7-bis(4-bromobut-1-yn-1-yl)naphthalene (25) 
To a solution of 24 (2.36 mmol) and Pd(PPh3)Cl2 (0.35 mmol) in DMF was added under 
N2, at room temperature a mixture of 4-bromo-1-butyne (4.72 mmol) in THF (8ml), 
DIPEA (2.5 ml) , CuI (0.3 mmol) and dry DMF (8 ml). The mixture was reacted over 30 
min. After that time, the mixture was diluted with DCM and the organic phase extracted 
with a satured solution of NH4Cl (1X) followed by extraction with distilled water (2X). 
The collected organic phases were dried over Na2SO4, filtered and dried under reduced 
pressure to afford a brownish oil. Purification by column cromatography (PE). 
(25). Yield 40%. Mp 58.9-60.2 °C. 1H-NMR (DMSO-d6) δ: 8.29 (s, 1H, CH), 7.78 (d, J= 
1.5 Hz, 1H, CH), 7.53 (d, J= 7.5 Hz, 1H, CH), 3.47 (t, J= 7.5 Hz, 2H, CH2), 2.53 (t, J= 
7.5 Hz, 2H, CH2). 13C NMR (CDCl3) δ: 24.1, 29.4, 81.9, 102.6, 119.7, 127.7, 129.5, 
131.8, 133.2, 135.0. Anal. Calcd. (%) for C18H14Br2: C, 55.42; H, 3.62; Br, 40.96 found: 
C, 55.40; H, 3.65; Br, 40.97. 
Synthesis of 2,7-bis(4-morpholinobut-1-yn-1-yl)naphthalene (26) 
To a solution of 25 (5.12 mmol) in dry DCM is added a solution of morpholine (1.12) in 
dry DCM at room temperature, dropwise. The mixture was reacted refluxing over 3 
hours. After cooling, the solvent reaction was removed under reduced pressure and the 
crude was purified on silica gel (PE/EtOAc 7:3) to give a white solid. 
(26). Yield 30%. Mp 80.9-91.5 °C. 1H-NMR (DMSO-d6) δ: 8.29 (s, 1H, CH), 7.78 (d, J= 
1.5 Hz, 1H, CH), 7.53 (d, J= 7.5 Hz, 1H, CH), 2.53 (t, J= 7.1 Hz, 2H, CH2), 2.13 (t, J= 
7.5 Hz, 2H, CH2), 2.36 (d, J= 7.1 Hz, 2H, CH2), 3.65 (d, J= 7.5 Hz, 2H, CH2). 13C NMR 
(DMSO-d6) δ: 17.1, 55.2, 58.9, 66.7, 81.9, 102.6, 119.7, 127.7, 129.5, 131.8, 133.2, 
135.0. Anal. Calcd. (%) for C26H30N2O2: C, 77.58; H, 7.51; N, 6.96; O, 7.95 found: C, 
77.6; H, 7.53; N, 6.93; O, 7.94. 
Synthesis of 5,5'-(naphthalene-2,7-diylbis(oxy))bis(2-benzyl-4-bromopyridazin-
3(2H)-one) (28) 
2,7-Dihydroxynaphthalene (0.31 mmol) was dissolved in DMF and K+(CH3)CO-  (0.94 
mmol) was added. After 30min, 27 (0.62 mmol) was added to the mixture and it was 
refluxed for 3 hours. The solvent was removed under reduced pressure. Distilled water 
was added to the mixture that was extracted with DCM (5X30 ml). The collected organic 
phases were subsequently dried over Na2SO4 and concentrated. The solvent was 
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evaporated under reduced pressure and the compounds were purified by column 
chromatography (Hexane/EtOAc 7:3). Recrystallization from diethyl ether. 
28. Yield 95%. Mp 115.1-120.3 oC. 1H-NMR (DMSO-d6) δ: 7.91 (d, J= 7.5 Hz 1H, CH), 
7.68 (m, 1H, CH), 7.50 (s, 1H, CH), 7.33 (m, 1H, CH), 7.26 (m, 1H, CH), 7.26 (s, J= 1.5 
Hz, 1H, CH), 6.10 (d, J= 7.5 Hz, 2H, CH2). 13C NMR (DMSO-d6) δ: 34.7, 107.8, 115.2, 
124.4, 126.4, 126.7, 126.9, 128.5, 129.6, 133.2, 134.5, 137.5, 148.8, 153.9, 155.4. Anal. 
Calcd. (%) for C32H22Br2N4O4: C, 56.00; H, 3.23; Br, 23.28; N, 8.16; O, 9.32 found: C, 
56.04; H, 3.26; Br, 23.31; N, 8.18; O, 9.37. 
Synthesis compound (33). 
A mixture of 28 (0.06 mmol), Pd(PPh3)2Cl2 (20%mol), and NaOAcx3H2O (0.15 mmol)in 
DMA was stirred at 110 °C under Ar atmosphere over 3 hours. The mixture was 
evaporated to dryness in vacuo. Distilled water was added and the mixture was 
subsequently extracted with chloroform. The combined organic phases were dried over 
Na2SO4. The solvent was evaporated under reduced pressure to afford a grey powder.  
(33) Yield 100%. Mp 269.1-273.5 oC. 1H-NMR (DMSO-d6) δ: 7.80 (s, J= 1.5 Hz, 1H, 
CH), 7.73 (s, 1H, CH), 7.68 (m, 1H, CH), 7.69 (m, 1H, CH), 7.66 (d, J= 7.5 Hz, 1H, 
CH), 7.59 (d, J= 7.5 Hz 1H, CH), 7.50 (s, 1H, CH), 7.51 (s, 1H, CH), 6.10 (s, 2H, CH2). 
13C NMR (DMSO-d6) δ: 51.5, 111.5, 113.4, 120.4, 121.2, 123.1, 126.7, 126.9, 128.3, 
128.5, 130.6, 134.5, 138.5, 143.0, 154.7, 158.4, 158.5. Anal. Calcd. (%) for C32H20N4O4: 
C, 73.27; H, 3.84; N, 10.68; O, 12.20 found: C, 73.29; H, 3.82; N, 10.66; O, 12.23. 
Synthesis of 5,5'-((3,6-dibromonaphthalene-2,7-diyl)bis(oxy))bis(2-benzylpyridazin-
3(2H)-one) (31). 
3,6-Dibromo-2,7-dihydroxynaphthalene (0.63 mmol) was dissolved in dry CH3CN and 
K2CO3 (3.15 mmol) was added. After 30min, 30 (1.26 mmol) was added to the mixture 
and it was refluxed for 3 hours in a microwave reactor. The solvent was removed under 
reduced pressure. Distilled water was added to the mixture that was extracted with DCM 
(5X30 ml). The collected organic phases were subsequently dried over Na2SO4 and 
concentrated. The solvent was evaporated under reduced pressure and the compound was 
purified by column chromatography (Hexane/EtOAc 7:3). Recrystallization from diethyl 
ether. 
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(31) Yield 60%. Mp 141.7-143.9 oC. 1H-NMR (DMSO-d6) δ: 8.13 (s, J= 1.5 Hz, 1H, 
CH), 7.68 (m, 1H, CH), 7.50 (s, 1H, CH), 7.33 (m, 1H, CH), 7.26 (m, 1H, CH), 7.09 (s, 
1H, CH) 6.10 (s, 2H, CH2), 5.12 (s, 1H, CH). 13C NMR (DMSO-d6) δ: 35.4, 109.0, 
110.8, 113.5, 126.7, 126.9, 127.1, 128.5, 130.3, 130.5, 134.5, 138.9, 157.0, 159.4, 161.5. 
Anal. Calcd. (%) for C32H22Br2N4O4: C, 56.00; H, 3.23; Br, 23.28; N, 8.16; O, 9.32 
found: C, 56.04; H, 3.21; Br, 23.29; N, 8.19; O, 9.36. 
Synthesis compound (32) 
A mixture of 31 (0.7 mmol), Pd(PPh3)2Cl2 (20%mol), and NaOAcx3H2O (1.75 mmol) in 
DMA was stirred at 130 °C under N2 atmosphere over 3 hours. The mixture was 
evaporated to dryness in vacuo. Distilled water was added and the mixture was 
subsequently extracted with chloroform. The combined organic phases were dried over 
Na2SO4. The solvent was evaporated under reduced pressure to afford a yellow powder.  
(32) Yield 40%. Mp 159.7-163.5 oC. 1H-NMR (DMSO-d6) δ: 7.80 (s, J= 1.5 Hz, 1H, 
CH), 7.73 (s, J= 1.5 Hz, 1H, CH), 7.68 (m, 1H, CH), 7.50 (s, 1H, CH), 7.33 (m, 1H, CH), 
7.26 (m, 1H, CH), 6.10 (s, 2H, CH2). 13C NMR (DMSO-d6) δ: 51.5, 120.4, 121.2, 123.1, 
126.7, 126.9, 128.5, 128.3, 128.7, 129.7, 134.5, 143.0, 154.7, 158.4, 158.5, Anal. Calcd. 
(%) for C32H20N4O4: C, 73.27; H, 3.84; N, 10.68; O, 12.20 found: C, 73.24; H, 3.82; N, 
10.67; O, 12.19. 
Synthesis of 5,5'-(1,2-phenylenebis(oxy))bis(2-benzyl-4-bromopyridazin-3(2H)-one) 
(37) 
1,2-Dihydroxybenzene (9.1 mmol) was dissolved in dry CH3CN and dry K2CO3 (73 
mmol) was added. After 30min, 27 (18.2 mmol) was added to the mixture and it was 
refluxed for 3 hours, at 85 °C, 200 PSI, 50 watt in a microwave reactor. The solvent was 
removed under reduced pressure. Distilled water was added to the mixture that was 
extracted with DCM (5X30 ml). The collected organic phases were subsequently dried 
over Na2SO4 and concentrated. The solvent was evaporated under reduced pressure and 
the compound was purified by column chromatography (Hexane/EtOAc 7:3). 
Recrystallization from diethyl ether. 
(37) Yield 50%. Mp 189.1-189.6 oC. 1H-NMR (DMSO-d6) δ: 7.68 (m, 1H, CH), 7.50 (s, 
1H, CH), 7.50 (s, 1H, CH), 7.33 (m, 1H, CH), 7.26 (m, 1H, CH), 6.84 (d, J= 7.5 Hz, 1H, 
CH), 6.78 (d, J= 7.5 Hz, 1H, CH), 6.10 (s, 2H, CH2). 13C NMR (DMSO-d6) δ: 34.7, 
116.3, 123.6, 126.4, 126.7, 126.9, 128.5, 133.2, 134.5, 142.8, 148.8, 155.4, Anal. Calcd. 
	 90	
(%) for C28H20Br2N4O4: C, 52.85; H, 3.17; Br, 25.12; N, 8.81; O, 10.06 found: C, 52.83; 
H, 3.11; Br, 25.15; N, 8.80; O, 10.04. 
Synthesis of 5,5'-(naphthalene-1,8-diylbis(oxy))bis(2-benzyl-4-bromopyridazin-
3(2H)-one) (38) 
1,8-Dihydroxynaphthalene (3.75 mmol) was dissolved in dry CH3CN and dry K2CO3 
(18.75 mmol) was added. After 30min, 27 (1.26 mmol) was added to the mixture and it 
was refluxed for 4 hours, at 100 °C, 200 PSI, 50 watt in a microwave reactor. The solvent 
was removed under reduced pressure. Distilled water was added to the mixture that was 
extracted with DCM (5X30 ml). The collected organic phases were subsequently dried 
over Na2SO4 and concentrated. The solvent was evaporated under reduced pressure and 
the compound was purified by column chromatography (Hexane/EtOAc 7:3). 
Recrystallization from diethyl ether. 
(38) Yield 50%. Mp 246.9-247.4 oC. 1H-NMR (DMSO-d6) δ: 7.73 (d, 1H, CH), 7.68 (m, 
1H, CH), 7.50 (s, 1H, CH), 7.43 (t, 1H, CH), 7.33 (m, 1H, CH), 7.26 (m, 1H, CH), 6.71 
(d, J= 7.5 Hz, 1H, CH), 6.78  (m, 1H, CH), 6.10 (s, 2H, CH2). 13C NMR (DMSO-d6) δ: 
34.7, 109.7, 110.6, 114.9, 126.4, 126.7, 126.9, 128.5, 133.2, 134.5, 134.6, 146.2, 148.8, 
155.4.  Anal. Calcd. (%) for C28H20Br2N4O4: C, 52.85; H, 3.17; Br, 25.12; N, 8.81; O, 
10.06 found: C, 52.83; H, 3.11; Br, 25.15; N, 8.80; O, 10.04. 
Synthesis of 5,5'-(naphthalene-2,7-diylbis(oxy))bis(4-bromo-2-methylpyridazin-
3(2H)-one) (40) 
2,7-Dihydroxybenzene (1.25 mmol) was dissolved in dry CH3CN and dry K2CO3 (6.25 
mmol) was added. After 30min, 39 (2.50 mmol) was added to the mixture and it was 
refluxed for 19 hours. The solvent was removed under reduced pressure. Distilled water 
was added to the mixture that was extracted with DCM (5X30 ml). The collected organic 
phases were subsequently dried over Na2SO4 and concentrated. The solvent was 
evaporated under reduced pressure and the compound was purified by column 
chromatography (Hexane/EtOAc 7:3). Recrystallization from diethyl ether. 
(40) Yield 30%. Mp 170.9-172.4 oC. 1H-NMR (DMSO-d6) δ: 7.91 (d, 1H, CH), 7.50 (s, 
1H, CH), 7.26 (s, 1H, CH), 7.05 (d, 1H, CH), 2.74 (s, 1H, NH). 13C NMR (DMSO-d6) δ: 
39.9, 107.8, 115.2, 124.4, 126.4, 133.2, 137.5, 148.8, 153.9, 155.4.  Anal. Calcd. (%) for 
C28H20Br2N4O4: C, 52.85; H, 3.17; Br, 25.12; N, 8.81; O, 10.06 found: C, 52.83; H, 3.11; 
Br, 25.15; N, 8.80; O, 10.04. 
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